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Abstract 
 
CXCR4b, CXCR7b and their ligand, CXCL12a, are essential for the migration of the 
posterior lateral line primordium (pLLP) and primordial germ cells (PGCs) in zebrafish 
(Dambly-Chaudière et al. 2007, Boldajipour et al. 2008). A number of tetraspanins have 
been shown to affect CXCR4-mediated processes through regulating CXCR4 trafficking 
or downstream signalling (Yoshida et al. 2008, Li et al. 2011, Leung et al. 2011). Based 
upon these results we set out to identify candidate tetraspanins that may play a similar 
role in CXCR4b signalling during pLLP and PGC migration. CD9b, one of the zebrafish 
homologs of human CD9, was identified as a good candidate gene. Morpholino knock 
down of cd9b, using either a translation-blocking or splice-site blocking morpholino, 
resulted in reduced neuromast deposition and abnormal structure of the posterior 
lateral line. However, morpholinos often have nonspecific effects and so two CD9b 
knockout lines were created using TALENs. Surprisingly CD9b homozygous mutants 
showed normal lateral line structure.  Preliminary results suggest that the phenotype 
differences between CD9b morphants and mutants may be due to residual 
functionality in the wildtype N-terminal of CD9b, upstream of the mutation site, in 
CD9b mutants.  
As well as assessment of PGC and pLLP migration, CD9b mutants were also assessed 
for fertility defects. Significantly reduced numbers of pups are born to CD9 knockout 
mice. This is due to a requirement of CD9 on the egg membrane for efficient sperm-
egg fusion in the CD9-/- female mice (Kaji et al. 2000, Le Naour et al. 2000, Miyado et 
al. 2000). CD9b -/- zebrafish also appear to have fertility defects. Fewer eggs were laid 
by CD9b -/- zebrafish pairs and of the eggs laid, a lower percentage were fertilised.    
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Chapter 1: Introduction 
1.1 CXCR4 
CXCR4 (chemokine CXC motif receptor 4) was originally cloned from human monocytes 
and named LESTR (leukocyte derived seven transmembrane domain receptor) by 
Loetscher et al. in 1994. The 352 amino acid protein was found to have considerable 
sequence identity with the bovine neuropeptide Y receptor boLCR1 (96%) and 
interleukin-8 (IL-8) receptors (34%) which were known G-protein coupled receptors 
and chemokine receptors at the time (Rimland et al. 1991, Loetscher et al. 1994). It 
was noted by Loetscher et al., that the predicted structure had many typical G-protein 
coupled receptor (GPCR) domains, including seven transmembrane domains, a binding 
site for the Gi-subtype of G-proteins, potential N-glycosylation sites in the N-terminus 
and putative intracellular substrate motifs for protein kinase C. The high abundance of 
CXCR4 mRNA in human leukocytes led Loetscher et al., to speculate that CXCR4 
functions in the activation of leukocytes, though the relevant ligand could not be 
identified.  
 A function for CXCR4 was soon found by Yu et al. 1996, as a co-receptor for T-cell-
tropic, but not macrophage-tropic, HIV-1 (human immunodeficiency virus-type 1) in 
CD4+ cells. Expression of CXCR4 in CD4+, human or non-human cells allowed HIV-1 
envelope glycoprotein (Env) mediated fusion, syncitium formation and HIV-1 infection 
in normally non-permissive cells.  CD4- cells were also rendered susceptible to T-cell-
tropic Env mediated cell fusion by co-expression of human CD4 and CXCR4, even in 
non-human cell lines. Sole expression of either CD4 or CXCR4 did not permit Env-
mediated fusion in normally non-permissive cells (Yu et al. 1996, Berson et al. 1996).  
Soon after the discovery of CXCR4’s function in HIV-1 infection its ligand, CXCL12 
(chemokine CXC motif ligand 12), was found.  Previously known as SDF-1 (stromal cell 
derived factor 1), CXCL12, was shown to inhibit T-cell tropic HIV-1 infection in CXCR4+ 
and CD4+ cells. CXCL12 was also shown to act as a highly efficient chemoattractant, 
inducing Ca2+ release from and internal actin polymerization in CXCR4-transfected cells 
and leukocytes, supporting the hypothesis made by Loetscher et al., in 1994 (Bleul et 
al. 1996a, 1996b, Oberlin et al. 1996).   
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Cloning of the murine CXCR4 homolog revealed high amino acid identity with human 
CXCR4 (91%) and identical responses of CXCR4+ cells to murine CXCL12. It was also 
noted that CXCR4 was expressed in embryos at embryonic day 7.5-17.5 (E7.5-E17.5) as 
well as in a number of adult tissues such as the spleen, thymus, brain and kidney 
(Nagasawa et al. 1996b, Heesen et al. 1996). To investigate the potential role of CXCR4 
in these tissues and others, CXCR4 homozygous knockout mice were made by a 
number of groups. CXCR4-/- embryos were viable until E15.5 after which the majority 
of the embryos died. Only 50% of the expected number of pups were seen at E17.5 
and the few pups that survived to full term died within a few hours of being born.  The 
viable CXCR4-/- embryos were observed to have a number of defects including 
reduced body size, defective B-cell lymphopoiesis and bone-marrow myelopoiesis as 
well as a cardiac ventricular septal defect, all of which mirrored the defects seen in 
CXCL12-/- mice previously (Nagasawa et al. 1996a, Tachibana et al. 1998, Zou et al. 
1998, Ma et al. 1998).  
Lack of CXCR4 also affected the migration or positioning of many neuronal cells and 
neural progenitors. CXCR4 deficient embryos showed an ectopic granule cell layer in 
the cerebellum, an underdeveloped hippocamal dentate gyrus due to defective 
progenitor cell migration and premature differentiation as well as ectopic migration of 
interneurons in the neocortex (Zou et al. 1998, Ma et al. 1998, Lu et al. 2002, Stumm et 
al. 2003). Migratory defects were not only seen in neuronal cells, but also in progenitor 
muscle cells and germ cells where CXCR4 appears to also regulate survival of these cell 
types (Molyneaux et al. 2003, Vasyutina et al. 2005). It was also noted by Tachibana et 
al. 1998 that CXCR4-/- embryos often displayed multiple haemorrhages or vascular 
congestions in the small intestines. It was found that CXCR4 was required for correct 
vascularization of the small intestines after E11.5, with CXCR4 mutants showing 
decreased vascular branching and re-modelling after this time point. While a reduced 
number of large vessels were seen in the small intestine, they were completely absent 
in the stomach of CXCR4-/- embryos, a phenotype which was also attributed to 
defective branching and re-modelling (Tachibana et al. 1998).  
Since the creation of CXCR4-/- mice, CXCR4 and CXCL12 signaling has been found to 
guide or regulate the migration of numerous cell types, with similar functions found in 
multiple other models including human cell culture and zebrafish.  
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1.1.1 CXCR4 and WHIM  
With the embryonic lethality of CXCR4-/- it is unsurprising that no human homozygous 
CXCR4 mutations have been reported, however, heterozygous C-terminal CXCR4 
mutations have been reported to cause the disorder WHIM (warts, 
hypogammaglobulinemia, infection, and myelokathexis) (Hernandez et al. 2003). 
WHIM syndrome was first described in 1990, and is caused by a gain of function 
mutation in CXCR4 which results in neutrophil retention and apoptosis in the bone 
marrow and consequently increased infection rates (Wetzler et al. 1990, Hernandez et 
al. 2003, Busillo and Benovic 2007, Pawig et al. 2015). 
This syndrome appears to result from the dysregulation of CXCR4 signaling upon 
CXCL12 stimulation. In WHIM syndrome patients, the C-terminal truncated CXCR4 
displays heightened and prolonged G-protein activation due to the inability to 
uncouple from its G-protein and internalize upon CXCL12 binding (Balabanian et al. 
2005b, Busillo and Benovic 2007). This lack of internalization has been suggested to be 
due to the loss of phosphorylation sites in the C-terminus of CXCR4, which then results 
in the impaired ability of GRK3 (GPCR kinase-3) to bind and induce the internalization 
of CXCR4 (Balabanian et al. 2008). As well as increased G-protein signaling, enhanced 
β-arrestin2 signaling via ERK1/2 has been suggested to contribute to the augmented 
chemotactic response to CXCL12 by WHIM leukocytes (Lagane et al. 2008).  
1.1.2 CXCR4 and cancer 
Many cell types have been reported to require CXCR4 for correct migration and so it is 
also unsurprising that CXCR4 has become associated with metastasis for many 
different cancers including breast, prostate, ovarian, pancreatic, colon cancers, T-cell 
hybridoma, and melanoma (Zeelenberg et al. 2001, 2003, Murakami et al. 2002, Singh 
et al. 2004, Saur et al. 2005, Gladson and Welch 2008, Barbolina et al. 2010, Chatterjee 
et al. 2014). Originally it was found that breast cancer cells require CXCR4/CXCL12 
signalling for metastasis (Müller et al. 2001). Breast cancer cells exhibit significantly up 
regulated CXCR4 expression compared to healthy mammary gland tissue and 
commonly metastasise to organs which express high levels of CXCL12, such as lymph 
nodes, lungs, liver and bone marrow. Neutralisation of CXCR4 signalling using an anti-
CXCR4 antibody resulted in a significant reduction of metastasis in vivo (Müller et al. 
2001). CXCR4 overexpression has been reported in >23 human cancers, with 
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implications not only in metastasis and invasion but also in tumour survival through 
growth, angiogenesis and treatment resistance (Chatterjee et al. 2014). The effects 
mediated by CXCR4 on cancer cell behaviours are diverse, often depending on the 
cancer type and the partner proteins or downstream signalling activated. For example, 
CXCR4 mediates migration and invasion of many different cancer cell types. In breast 
cancer, CXCR4 interaction with CXCL12 leads to the transactivation of the receptor 
HER-2/neu (human epidermal growth factor receptor 2/ receptor tyrosine-protein 
kinase erbB-2), which is essential for HER-2-mediated metastasis (Balkwill 2004, 
Cabioglu et al. 2005). In multiple myeloma CXCR4 mediates migration and homing 
through G-protein signalling to activate the PI3K and ERK/MAPK pathways (Alsayed et 
al. 2007). While ovarian cancers also use MAPK and PI3K to promote invasion, these 
pathways are activated via αvβ6 integrin expression, which is upregulated by CXCR4 
(Xue et al. 2013).  
As well as promoting migration, CXCR4 is often important for tumour cell survival 
(Chatterjee et al. 2014). In leukaemia CXCR4 and CXCL12 interaction helps to protect 
cancerous cells from chemotherapy-induced apoptosis through the phosphorylation of 
PI3K/AKT, MAPK and ERK. Similarly, MEK/ERK signalling is activated by CXCR4 in 
prostate cancer cell, however, this then leads to the activation of NF-κB which was 
suggested to be important for tumour cell survival (Chatterjee et al. 2014). The 
activation of MAPK is also used by small cell lung cancer to inhibit chemotherapy-
induced cell death. However, the mechanism is slightly different. CXCR4 activates actin 
polymerisation and MAPK signalling which leads to adhesion of small cell lung cancer 
cells to the surrounding extracellular matrix (Sethi et al. 1999, Burger et al. 2003). This 
adhesion results in increased β1, α3, α6 and αv integrin expression and increased 
tyrosine-kinase activity therefore preventing caspase activation and inhibiting 
chemotherapy-induced cell death (Sethi et al. 1999, Chatterjee et al. 2014). 
1.1.3 CXCR4 and alternative ligands 
Although CXCL12 was originally thought to be the sole ligand for CXCR4, a number of 
other ligands have since been identified. Migration inhibitory factor (MIF), Ubiquitin 
and gp120 have all been shown to bind and activate CXCR4. MIF was shown to 
stimulate T-cell chemotaxis through CXCR4 as well as activating G-protein signaling and 
adhesion of partner proteins such as VCAM-1 (vascular cell adhesion molecule-1) 
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(Bernhagen et al. 2007, Pawig et al. 2015). Extracellular ubiquitin has also been shown 
to activate G-protein signaling upon binding to CXCR4 in monocyte and macrophage 
cell lines, resulting in a Ca2+ release as seen with CXCL12 binding (Saini et al. 2010). 
Lastly the HIV-1 envelope glycoprotein gp120 has been shown to induce rapid CXCR4 
internalization upon binding, in both CD4+ and CD4- cells (Tarasova et al. 1998). 
1.2 CXCL12  
Originally cloned in 1993 murine CXCL12, formerly named SDF-1 or TPAR1 (TPA 
repressed gene 1), was found to produce two different isoforms as a result of 
alternative splicing. The 89 and 93 amino acid sequence forms (where the first 89 
amino acids are identical), CXCL12-α and CXCL12-β respectively, were found to be part 
of the CXC subfamily of the cytokine family, having high similarity with the cytokine IL-
8 and the characteristic CXC motif (Tashiro et al. 1993, Jiang et al. 1994, Shirozu et al. 
1995). The human homologs of CXCL12-α and CXCL12-β were cloned in 1995 and were 
found to have >92% identity with their murine counterparts.  
Additional isoforms, CXCL12-γ, CXCL12-δ, CXCL12-ε and CXCL12-ϕ, resulting from 
alternative splicing events were found in 2006. All six isoforms appear to produce 
functional proteins, which are expressed in different tissues and appear to have 
different functions. For example CXCL12-α appears most widely expressed, however, it 
is broken down rapidly in the bloodstream unlike CXCL12- β which is consequently 
more highly expressed in highly vascularised organs and functions in angiogenesis (Yu 
et al. 2006, Janowski 2009). CXCL12- α has been the most widely studied and is the 
isoform of interest for this work, so any reference to CXCL12 in mammals refers to 
CXCL12-α unless otherwise stated. 
While mammals have a single cxcl12 gene zebrafish have two, cxcl12a and cxcl12b 
(David et al. 2002). Unlike the mammalian homolog, multiple isoforms of these genes 
have yet to be identified.  
1.2.1 CXCL12 and CXCR4 signalling 
Upon ligand binding, freely diffusing CXCR4 is immobilised in the plasma membrane. 
Immobilisation is dependent on and correlates with G-protein dependent signalling 
and occurs prior to subsequent receptor trafficking. Immobilisation of the receptor is 
suggested to be due to the formation of a supramolecular scaffold or signalosome 
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comprising of the G-protein dependent signalling pathways activated upon ligand 
binding (Beletkaia et al. 2016).  
The G-protein complex associated with CXCR4 comprises of three subunits, Gα, Gβ, 
and Gγ. Receptor activation leads to dissociation of GβGγ from Gα, allowing Gα to 
activate extracellular-signal-related-kinases (ERK1/2), the phosphatidylinositol-3-
kinase pathway (PI3K) and Rho leading to downstream effects such as chemotaxis, 
promotion of cell survival and transcription. The GβGγ subunit also activates PI3K, 
along with phospholipase C-β (PLC-β) and Rac leading to Ca2+ release and chemotaxis 
(Figure 1.1) (Ganju et al. 1998, Tan et al. 2006, Busillo and Benovic 2007, Teicher and 
Fricker 2010, Pawig et al. 2015).  
G-protein independent signalling has also been reported, with β-arrestin shown to 
promote ERK1/2 activation as well as p38 mitogen-activated protein kinase (p38MAPK) 
activation (Busillo and Benovic 2007, Pawig et al. 2015). The Janus kinase/Signal 
Transducer and Activator of Transcription protein (JAK/STAT) pathway has also been 
implicated in CXCR4 signalling. Vila-Coro et al. 1999 reported the association of 
activated JAK2 and JAK3 with CXCR4 after ligand binding and receptor dimerization, 
leading to the recruitment of several STAT proteins (Figure 1.1).  
Ligand binding not only induces downstream signalling but also ligand trafficking, with 
the endocytosis of up to 60% of surface CXCR4 (Tarasova et al. 1998, Förster et al. 
1998). The receptor is endocytosed by clathrin-coated pits, with β-arrestin acting as a 
mediator between CXCR4 and clathrin (Tarasova et al. 1998, Förster et al. 1998, Busillo 
and Benovic 2007, Pawig et al. 2015). The receptor is then targeted to the lysosomes 
for degradation following the ubiquitination of lysine residues in the C-terminal 
degradation motif SSLKILSKGK by the E3 ubiquitin ligase AIP4 (Marchese and Benovic 
2001, Marchese et al. 2003). Recycling of internalised CXCR4 after ligand binding was 
reported to occur, albeit inefficiently (Tarasova et al. 1998). Interestingly, CXCR4 
crosslinking using an anti-CXCR4 antibody did result in rapid and efficient receptor 
internalisation and recycling (Förster et al. 1998).  
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Figure 1.1 Diagram showing the signalling pathways of CXCR4.  
ERK (Extracellular signal-regulated kinases), Gαβγ (G-protein), JAK (Janus kinase), 
PI3K (phosphoinositide 3-kinase), PLC-β (Phospholipase C-β), STAT (signal transducer 
and activator of transcription), U (Ubiquitination)  
Figure 1.2 Diagram of ACKR3 signalling.  
ACKR3 (black) and CXCR4 (red) can heterodimerise to regulate G-protein and β-
Arrestin signalling. U (Ubiquitination), MAPK (Mitogen-activated protein kinases) 
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1.3 ACKR3 (Atypical chemokine receptor 3) 
A second CXCL12 receptor, ACKR3, was originally known as the orphan receptor RDC1 
or CXCR7. ACKR3 was initially grouped with GPCRs due to the presence of typical GPCR 
features such as 7 transmembrane domains, an extracellular N-terminus and 
intracellular C-terminus as well as characteristic conserved cysteines (Libert et al. 1989, 
Heesen et al. 1998).  
Adopted by CXCL12 in 2005 and CXCL11 in 2006, ACKR3 was shown to be expressed on 
T lymphocytes and tumour cell lines with the ability to bind CXCL12 with higher affinity 
than CXCR4  (Balabanian et al. 2005a, Burns et al. 2006). Despite the similarities in 
protein domains, ACKR3 has been reported to be unable to elicit G-protein signalling 
or bind to G-proteins on multiple occasions (Burns et al. 2006, Sierro et al. 2007, 
Rajagopal et al. 2010, Canals et al. 2012, Kumar et al. 2012, Hoffmann et al. 2012),  
although this has been challenged by Odemis et al. 2012 who demonstrated ACKR3 
signalling via G-proteins in rodent astrocytes and human glioma cells. This 
predominant lack of G-protein association is thought to be due to differences in the C-
terminal domain and second intracellular loop between CXCR4 and ACKR3. CXCR4 
contains a DRYLAIV motif in the second intracellular loop that is considered critical for 
G-protein association. In ACKR3 this motif is altered to DRYLSIT and substitution of the 
CXCR4 C-terminal with ACKR3 C-terminal renders CXCR4 unable to bind G-proteins 
(Sierro et al. 2007, Naumann et al. 2010, Hoffmann et al. 2012). However, replacement 
of either or both of these domains with the equivalent CXCR4 domain is not sufficient 
to render ACKR3 the ability to bind G-proteins (Naumann et al. 2010, Hoffmann et al. 
2012). 
Despite this apparent lack of signalling via G-proteins, ACKR3 has been shown to have 
a wide variety of functions and is highly conserved between species with 92% similarity 
between humans and mice (Heesen et al. 1998, Sierro et al. 2007). ACKR3-/- mice died 
at birth, displaying ventricular septal defects and decreased expression of factors 
important in endothelial cell growth and survival, angiogenesis and vessel protection; 
however, haematopoiesis appeared unaffected unlike CXCR4-/- and CXCL12-/- 
embryos (Sierro et al. 2007). Roles for ACKR3 in cell chemotaxis, growth, survival, 
positioning and adhesion have been reported in multiple cell types including T 
lymphocytes, breast cancer cells, lung cancer cells, renal progenitor cells, interneurons, 
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marginal zone B-cells and melanoma cells (Balabanian et al. 2005a, Burns et al. 2006, 
Miao et al. 2007, Mazzinghi et al. 2008, Wang et al. 2011b, 2012, Kumar et al. 2012, 
Liedtke et al. 2014).  
The functionality of ACKR3 has been shown to use multiple different pathways 
including acting as a ligand sink for CXCL12, signalling through β-arrestin upon CXCL12 
binding or forming heterodimers with CXCR4 to down regulate G-protein signalling and 
up regulate β-arrestin signalling pathways (Figure 1.2). The rapid recycling of ACKR3 
and high affinity for CXCL12 renders the receptor well suited as a ligand scavenger, 
efficiently binding, internalising and degrading CXCL12 before recycling back to the cell 
membrane (Naumann et al. 2010, Canals et al. 2012, Hoffmann et al. 2012). This allows 
ACKR3 to regulate chemotaxis by moderating chemokine gradients, as well as 
regulating CXCR4 function and cell reactivity to CXCL12 (Boldajipour et al. 2008, 
Naumann et al. 2010, Sánchez-Alcañiz et al. 2011, Canals et al. 2012, Hoffmann et al. 
2012).  
Whilst scavenging roles for ACKR3 do not report any subsequent signalling after ligand 
binding, many cell types have shown ligand induced ACKR3 signalling via β-arrestin to 
activate MAP kinases resulting in enhanced cell survival, proliferation, chemotaxis or 
trans-endothelial migration (Figure 1.2) (Zabel et al. 2009, Rajagopal et al. 2010, 
Odemis et al. 2010, Wang et al. 2011b, Kumar et al. 2012).  
Although monomeric signalling has been shown by ACKR3, it has also been shown to 
hetero-dimerise with CXCR4 upon CXCL12 binding which causes conformational 
changes in the pre-formed CXCR4-G-protein complex. These changes lead to the 
inhibition of G-protein and CXCR4 coupling, subsequently downregulating G-protein 
signalling pathways and upregulating β-arrestin signalling pathways via MAP kinases 
(Levoye et al. 2009, Décaillot et al. 2011). This switch in cell signalling allows ACKR3 to 
regulate and enhance cell survival, proliferation or migration (Décaillot et al. 2011). 
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1.4 CXCR4 in zebrafish 
Due to a fish specific genome duplication, many mammalian genes have two 
homologous genes in teleost fish (Meyer and Van de Peer 2005, Brunet et al. 2006). 
This is true for cxcr4, cxcl12 and ackr3 in zebrafish, with homologous genes labelled a 
or b (Chong et al. 2001, David et al. 2002, Miyasaka et al. 2007) (Table 1.1).  
Human 
gene 
Mouse 
gene 
% Identity to human Zebrafish gene % Identity to human 
CXCR4 Cxcr4 88 cxcr4a 66 
cxcr4b 62 
ACKR3 Ackr3 93 ackr3a 47 
ackr3b 54 
CXCL12 Cxcl12 71 cxcl12a 42 
cxcl12b 42 
 
 
The expression of cxcr4a and cxcr4b are predominantly mutually exclusive in the 
developing zebrafish embryo, with the genes only being co-expressed in the lateral 
mesoderm and posterior midbrain (Chong et al. 2001). Together cxcr4a and cxcr4b are 
expressed in the majority of cell types that have been reported to express cxcr4 in 
mammals, leading to Chong et al. 2001 hypothesising that the functions of mammalian 
CXCR4 may be split between CXCR4a and CXCR4b in zebrafish.  
This appears to be true, with CXCR4a and CXCR4b regulating different biological 
processes during development reminiscent of those controlled by CXCR4 in mammals, 
for example CXCR4a is required for vasculogenesis and angiogenesis whereas CXCR4b 
controls neutrophil chemotaxis and germ cell migration (Table 1.2) (Doitsidou et al. 
2002, Siekmann et al. 2009, Walters et al. 2010, Harrison et al. 2015). These functions 
require the activation of CXCR4a and CXCR4b through the specific binding of either 
CXCL12a or CXCL12b. Whilst some functions have been shown to use CXCR4a and 
CXCL12a, predominantly it has been shown that CXCR4a and CXCL12b or CXCR4b and 
CXCL12a interact to elicit specific functions (Dufourcq and Vriz 2006, Boldajipour et al. 
Table 1.1 Percentage identity of the mouse and zebrafish homologs to human CXCR4, 
ACKR3 and CXCL12. Data from ensembl.org (Herrero et al. 2016). 
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2011). This preference has been shown to be due to a single amino acid in the CXCL12 
ligands which confers higher affinity with one of the CXCR4 receptors (Boldajipour et 
al. 2011). However, due to the high identity between CXCL12a and CXCL12b at the 
amino acid level (82%), these ligands have been shown to be partially functionally 
redundant for posterior lateral line primordium migration (Li et al. 2004).  
 
CXCR4a function Reference CXCR4b function Reference 
Angiogenesis Harrison et 
al. 2015 
Cardiomyocyte migration Itou et al. 
2012 
Endodermal cell 
migration 
Mizoguchi et 
al. 2008 
Germ cell migration Doitsidou et 
al. 2002 
Epidermal cell 
proliferation 
Dufourcq & 
Vriz 2006 
GnRH3 (Hypothalamic 
gonadotropin-releasing hormone) 
neuron migration 
Palevitch et 
al. 2010 
Neural crest cell 
migration 
Boer et al. 
2015 
Neutrophil chemotaxis/ WHIM-
syndrome 
Walters et al. 
2010 
Fast muscle 
formation 
Chong et al. 
2007 
Olfactory neuron precursor 
migration 
Miyasaka et 
al. 2007 
Slow muscle 
migration 
Chong et al. 
2007 
Posterior lateral line primordium 
migration 
 
David et al. 
2002 
Vasculogenesis Siekmann et 
al. 2009 
Retinal ganglion cell axon 
migration 
Li et al. 2005 
  Trigeminal sensory neuron 
migration 
Lewellis et al. 
2013 
 
 
 
 
 
Table 1.2 Reported functions of CXCR4a and CXCR4b in zebrafish. 
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1.4.1 Primordial germ cell migration 
One of the most well characterised functions of CXCR4 in zebrafish is the regulation of 
primordial germ cell (PGC) migration by CXCR4b and CXCL12a. PGCs are specified early 
on during embryogenesis, at 3-4hpf, by the segregation of germ plasm RNAs into 
future PGCs (Yoon et al. 1997, Weidinger et al. 1999, 2003). PGCs cluster at four 
locations, which are dependent on the orientation of the earlier cleavage planes, 
although these planes are random in respect to the future dorsoventral body axis 
(Yoon et al. 1997, Weidinger et al. 1999). Immediately after specification PGCs are 
indistinguishable from their somatic neighbours as both cell types present a round 
non-motile morphology (Blaser et al. 2005). Following this, PGCs start to extend 
multiple protrusions in multiple directions, although remain immotile and appear 
unable to respond to CXCL12a (Blaser et al. 2005, Raz and Reichman-Fried 2006). 
Transition to motile cell behaviour is acquired in co-ordination with the expression of 
CXCL12a, a process which is regulated by Rgs14a (regulator of G-protein signalling 14a 
protein), E-cadherin levels and function of the RNA-binding protein Dead end 
(Weidinger et al. 2003, Blaser et al. 2005, Goudarzi et al. 2012, Hartwig et al. 2014, 
Paksa and Raz 2015).  
Directed cell migration is mediated by CXCR4b-expressing PGCs actively and 
individually migrating towards CXCL12a expressing tissues (Doitsidou et al. 2002, Knaut 
et al. 2003). The expression pattern of CXCL12a is dynamic and changes throughout 
development, leading the PGCs to initially cluster bilaterally at somites 1-3 before 
migrating posteriorly to the region where the gonads will later develop (Figure 1.3) 
(Weidinger et al. 1999, 2002, Doitsidou et al. 2002, Knaut et al. 2003). This dynamic 
chemoattractant pattern is fine tuned into an effective chemotactic gradient at the 
protein level by ACKR3 and at the mRNA level by miR-430 (Boldajipour et al. 2008, 
Staton et al. 2011). ACKR3 is expressed by somatic cells and acts as a ligand sink, 
binding, internalising and degrading CXCL12a before recycling back to the cell surface. 
The degradation of CXCL12a generates sharp gradients of diffusible chemokine, 
allowing PGCs to follow the dynamic pattern of cxcl12a transcription and migrate to 
the new source of transcription  (Mahabaleshwar et al. 2008, 2012, Boldajipour et al. 
2008) (Figure 1.3). miR-430 aids this fine-tuning of gradients by removing cxcl12a 
transcripts from previous expression domains and regulating the levels of ackr3 
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(Staton et al. 2011, 2013). This function for miR-430 in PGC migration has been 
debated by Goudarzi et al. 2013 as they found the results reported by Staton et al., 
could not be reproduced. However, this mechanism of ligand clearance has been 
reported in a second CXCR4b-mediated process, the migration of trigeminal sensory 
neurons (Lewellis et al. 2013).  
When following the chemotactic gradient of CXCL12a PGCs perform a ‘run and tumble’ 
behaviour. During run phases polarised cells actively migrate in a single direction, 
whilst direction can be changed by entering a tumbling phase in which cells lose their 
polarity, extend filopodia around the cell surface, before re-polarising to correct the 
migration path and entering a new run phase (Reichman-Fried et al. 2004). Correct 
polarisation of cells, and therefore correct migration, relies on CXCR4b-CXCL12a 
signalling. PGC filopodia allow the cells to detect the chemokine gradient and polarise 
towards the source of the gradient (Meyen et al. 2015). CXCL12a binds to CXCR4b on 
the filopodia, activating the scaffold protein Irsp53 which promotes the formation of 
more actin-rich filopodia at the cell front, increasing CXCL12a binding potential and the 
resulting signal (Meyen et al. 2015). CXCL12a binding CXCR4b induces G-protein 
signalling, specifically signalling by the Gβγ subunits. This results in an elevated pH at 
the cell front, mediated by Carbonic Anhydrase 15b, that promotes polarised Rac1 
activity and actin polymerisation (Dumstrei et al. 2004, Kardash et al. 2010, Xu et al. 
2012, Meyen et al. 2015, Tarbashevich et al. 2015).  
Although actin polymerisation is upregulated at the cell front in response to the 
CXCL12a gradient, it does not power cell migration as it does cell polarisation (Blaser et 
al. 2005, Meyen et al. 2015). Migration of PGCs occurs by blebbing. At sites of high 
levels of free calcium, myosin contraction is activated. This contraction causes local 
separation of the acto-myosin cortex from the plasma membrane, allowing an influx of 
cytoplasm which creates a bleb (Blaser et al. 2006, Goudarzi et al. 2012). The local 
increase in free calcium which initiates bleb formation has been hypothesised to be 
due to activation of CXCR4b on CXCL12a binding (Blaser et al. 2006).  
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Figure 1.3 Illustration of PGC migration and cxcl12a expression. 
Four clusters of non-motile PGCs (a) become motile upon cxcl12a expression 
(yellow) (a I). The motile PGCs move dorsally but are repelled from the dorsal 
midline (a I). At the 1-somite stage, PGCs move laterally and anteriorly to position 
adjacent to developing somites (b).  PGCs continue to migrate towards and cluster 
at somites 1-3 (c) before migrating posteriorly to cluster adjacent to somites 8-10 
(d). This final cluster position is just above the anterior yolk extension, where the 
gonads will later develop (e). Based on Weidinger et al. 1999; Weidinger et al. 
2002; Doitsidou et al. 2002; Blaser et al. 2005. 
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1.4.2 Posterior lateral line migration 
The lateral line is a mechanosensory organ which allows fish to detect water 
movements, facilitating behaviours such as prey detection, predator avoidance and 
schooling (Dambly-Chaudière et al. 2003, Ghysen and Dambly-Chaudiere 2004, Suli et 
al. 2012). Water flow is detected by individual sense organs called neuromasts, which 
are comprised of central hair cells surrounded by support cells. Neuromasts on the 
head and neuromasts on the trunk make up the two different lateral line systems, the 
anterior lateral line (aLL) and the posterior lateral line (pLL) (Gompel et al. 2001). 
The adult zebrafish posterior lateral line consists of more than 1000 neuromasts, which 
are loosely arranged in dorso-ventral rows called stitches (Ledent 2002, Sapede et al. 
2002). The embryonic posterior lateral line structure is much simpler, comprising of 7-
8 neuromasts on both sides of the embryo along the horizontal myoseptum (Metcalfe 
et al. 1985, Metcalfe 1985, Gompel et al. 2001). The development of the posterior 
lateral line from the simple embryonic to the complex adult organ requires the 
migration of multiple primordia, the formation of intercalary neuromasts from 
interneuromast cells deposited by these primordia and budding of new neuromasts 
from primary neuromasts (Ledent 2002, Sapede et al. 2002, Grant et al. 2005, López-
Schier and Hudspeth 2005, Nuñez et al. 2009, Sarrazin et al. 2010).  
The development of the embryonic posterior lateral line has been extensively studied 
and become a popular model for collective cell migration and tissue morphogenesis, 
with implications for cancer metastasis (Ma and Raible 2009, Friedl and Gilmour 2009, 
Sarrazin et al. 2010, Aman et al. 2011). The 7-8 embryonic neuromasts are deposited 
by a single primordium of ~100 cells, the primary posterior lateral line primordium 
(Prim I/ pLLP), which migrates along the horizontal myoseptum between ~20-42hpf, 
depositing clusters of cells which later develop into neuromasts (Metcalfe 1985, 
Kimmel et al. 1995, Gompel et al. 2001). As in PGC migration, CXCL12a acts as a 
chemoattractant for the pLLP cells expressing CXCR4b (Gompel et al. 2001, David et al. 
2002, Haas and Gilmour 2006). Just prior to pLLP migration, at ~20hpf, CXCL12a starts 
to be expressed by cells in the horizontal myoseptum (David et al. 2002, Li et al. 2004). 
The expression of CXCL12a provides the pathway for the pLLP to migrate along; 
however it does not provide the directionality as the pathway contains no chemokine 
gradient (Haas and Gilmour 2006). Directionality is imparted by the CXCL12a receptors, 
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ACKR3a and ACKR3b, which are expressed in the anterior-most third of the 
primordium, complimentary to CXCR4b (David et al. 2002, Dambly-Chaudière et al. 
2007, Valentin et al. 2007, Venkiteswaran et al. 2013, Donà et al. 2013). Unlike CXCR4b 
which induces Gβ1 signalling and actin polymerisation, ACKR3 does not induce 
downstream signalling and cell migration upon ligand binding (Venkiteswaran et al. 
2013, Donà et al. 2013). ACKR3 functions as a ligand sink, allowing the formation of a 
local CXCL12a gradient around the primordium and preventing the more anteriorly 
expressed CXCR4b from binding CXCL12a. This results in directed migration of the 
primordium down the CXCL12a pathway towards the caudal fin (Dambly-Chaudière et 
al. 2007, Valentin et al. 2007, Venkiteswaran et al. 2013, Donà et al. 2013) (Figure 1.4).   
The expression pattern of the CXCL12a receptors is highly regulated and remains the 
same throughout the entire primordium cycle of pre-neuromast rosette formation, 
deposition, leading to cell proliferation and new rosette formation. Antagonistic 
interactions between the receptors have been reported. Dambly-Chaudière et al. 2007 
and Gamba, Cubedo, Ghysen, et al. 2010 have shown that knockdown of cxcr4b 
expression or activation results in an expansion of the ackr3 expression domain in the 
primordium. However, this antagonistic interaction has been disputed by Valentin et 
al. 2007, who found no expansion of the ackr3 expression domain in CXCR4b mutants. 
ackr3 expression has also been shown to be regulated by Wnt signalling through 
Hoxb8a, with this signalling also playing a role in maintaining cxcr4b expression at the 
leading edge (Aman and Piotrowski 2008, Matsuda and Chitnis 2010, Breau et al. 
2013). cxcr4b appears to be excluded from the anterior-most third of the primordium 
by the presence of oestrogen receptor ESR1, which acts independently of Wnt 
signalling (Gamba et al. 2010a) (Figure 1.4). 
Wnt signalling in the leading cells is important in a number of primordium functions 
other than regulating receptor expression, including leading cell proliferation, Fgf 
ligand production and regulating Fgf signalling in the trailing cells (Figure 1.4) 
(Nechiporuk and Raible 2008, Aman and Piotrowski 2008, 2011, Matsuda and Chitnis 
2010, Gamba et al. 2010b, Aman et al. 2011, McGraw et al. 2011, Valdivia et al. 2011, 
Matsuda et al. 2013). Fgf signalling in turn regulates Wnt signalling in the leading cells, 
as well as being essential for the formation of rosettes and correct neuromast 
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deposition (Nechiporuk and Raible 2008, Aman and Piotrowski 2008, Matsuda and 
Chitnis 2010, Harding and Nechiporuk 2012, Durdu et al. 2014) (Figure 1.4).  
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Figure 1.4 Illustration of the embryonic pLLP migration and signalling.  
The completed embryonic pLLP consists of 7-8 neuromasts by 42-48hpf (a). Prim 1 
migrates from the ear to the tail, along a pathway of cxcl12a (yellow), depositing 
neuromasts along the way (b). Directed migration is a result of the internal signalling 
within the primordium (c). CXCR4b and ACKR3 are restricted to the leading and trailing 
edge respectively. With ACKR3 acting as a ligand sink, this creates a CXCL12a gradient 
along the primordium (c). Proliferation, rosette formation and neuromast deposition are 
controlled by Wnt and Fgf signalling respectively (c I).  Wnt and Fgf signalling inhibit the 
expression of the other to maintain distinct domains, although the Wnt domain 
produces Fgf ligands which diffuse (dashed line) to the Fgf domain to active Fgfr1 (c I).  
Based on Dambly-Chaudière et al. 2007; Donà et al. 2013; Angers & Drapeau 2014; Huc-
Brandt et al. 2014; McGraw et al. 2014; Ariza-Cosano et al. 2015; He et al. 2015; Xing et 
al. 2015. 
42-48 hpf 
~36 hpf 
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1.5 Tetraspanins 
Tetraspanins are large family of small membrane proteins, which have been shown to 
be involved in a wide variety of cellular functions. Discovered in 1990, tetraspanins 
have since been found in a range of diverse organisms from the amoeba Entamoeba 
histolytica, fungus Coprinopsis cinerea  and ascidian C.intestinalis to mice, zebrafish 
and humans (Oren et al. 1990, Szala et al. 1990, Boucheix et al. 1991, Huang et al. 
2005, 2010, Garcia-España et al. 2008). In mice, humans and zebrafish there are 
currently 34, 33 and 50 known members of the tetraspanin family, respectively 
(Garcia-España et al. 2008, Huang et al. 2010).  
 
 
 
 
 
 
 
 
 
 
 
Tetraspanins are characterised by four transmembrane domains (TM1-4), a short 
intracellular loop and two extracellular domains, flanked by short intracellular N- and 
C-termini domains (Figure 1.5) (Oren et al. 1990, Szala et al. 1990, Boucheix et al. 1991, 
Wright and Tomlinson 1994). The larger of the two extracellular domains, EC2, 
contains a highly conserved CCG motif with an additional 2-6 cysteine residues, which 
form disulphide bonds to stabilise the correct folding of the domain (Wright and 
Tomlinson 1994, Kitadokoro et al. 2001, Seigneuret et al. 2001). This structural model 
Figure 1.5 Diagram of Tetraspanin structure. 
Tetraspanins have a consistent structure of four transmembrane domains (grey), 
intracellular N- and C- termini, a small intracellular loop and two extracellular loops 
(EC1, EC2). The large extracellular loop (EC2) can be split into constant and variable 
(blue) domains. Within the variable domain are conserved cysteine residues and CCG 
motif which form structural di-sulphide bonds. Most tetraspanins also contain 
palmitoylated juxta-membrane cysteines (green). 
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of the tetraspanin EC2 is based on the crystal structure of the EC2 of tetraspanin CD81  
reported by Kitadokoro et al. in 2001. The structure and sub-domains of other 
tetraspanin EC2 domains have been inferred from the CD81 EC2 crystal structure using 
homology modelling (Seigneuret et al. 2001).   
The EC2 also contains two sub-domains: a conserved region and a variable region 
(Seigneuret et al. 2001). The variable region has been shown to contain critical protein-
protein interaction sites, which allows tetraspanins to interact with their respective 
direct partner proteins (Higginbottom et al. 2000, Berditchevski et al. 2001, Zhu et al. 
2002, Stipp et al. 2003, Shoham et al. 2006). The conserved region, in contrast has 
been suggested to allow homo-dimerization and hetero-dimerization of tetraspanins, a 
function which has been shown to be conducted by the transmembrane domains 
through chemical cross-linking and FRET (Förster resonance energy transfer) 
experiments (Kitadokoro et al. 2001, Stipp et al. 2003, Kovalenko et al. 2004, Barreiro 
et al. 2008). The four transmembrane domains have been shown to not only be sites of 
inter- molecular interactions but also intra-molecular interactions, with interactions 
between TM1 and TM2 required for the tetraspanins correct folding and transport  
(Cannon and Cresswell 2001, Stipp et al. 2003, Kovalenko et al. 2005, Shoham et al. 
2006). The intracellular N- and C-termini can also contribute to tetraspanin functions in 
numerous ways. Some tetraspanins, such as CD63 contain tyrosine-based 
internalisation motifs in their C-termini which allow them to mediate the endocytosis 
and trafficking of their partner proteins to late endosomes via interactions with 
adaptor protein complexes (Berditchevski and Odintsova 2007, Pols and Klumperman 
2009). CD63 also contains a PDZ-binding motif in its C-terminus which allows binding of 
the protein syntenin, which has been suggested to negatively regulate CD63 
endocytosis (Latysheva et al. 2006). Other tetraspanins also display PDZ-domains, 
suggesting the ability to bind syntenin or other PDZ-domain containing proteins 
intracellularly (Berditchevski and Odintsova 2007, Charrin et al. 2014). The N- and C- 
termini have also been shown to be directly involved in signal transduction. For 
example, upon ligation CD37 becomes tyrosine phosphorylated at both termini, 
leading to the recruitment and activation of other enzymes and signalling molecules 
such as SHP1 or PI3K. This directly triggers the activation of two cell survival signalling 
pathways (Lapalombella et al. 2012). A link between tetraspanins and the cytoskeleton 
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has also been suggested to occur via the C-terminus as the tetraspanins CD81 and CD9 
have been shown to interact with proteins such as RAC1 and ezrin (Sala-Valdes et al. 
2006, Tejera et al. 2013, Arnaud et al. 2015). 
The tetraspanin structure allows them  to interact with a variety of membrane and 
intracellular proteins, including immunoglobulin superfamily members, integrins, 
GPCRs, growth factors, growth factor receptors, Rac1 and phosphatidylinositol 3-
kinase (Boucheix and Rubinstein 2001, Yáñez-Mó et al. 2009, Lapalombella et al. 2012, 
Arnaud et al. 2015).  
 Interactions with partner proteins and other tetraspanins allow the formation of 
multi-molecular complexes named TEMs (tetraspanin enriched microdomains). TEMs 
are constructed from  by individual tetraspanins recruiting one or more of their 
partner proteins and then forming larger complexes via tetraspanin-tetraspanin 
interactions. Formation of these complexes is supported by the palmitoylation of 
juxtamembrane cysteines in tetraspanins (Yang et al. 2002, Stipp et al. 2003, Delandre 
et al. 2009). Within TEMs there are three different types of protein interactions: direct, 
indirect and tetraspanin-tetraspanin interactions. Direct interactions between 
tetraspanins and partner protein were originally found by co-immunoprecipitation 
following the use of harsh detergents such as 1% NP-40. Similarly indirect tetraspanin-
protein interactions were discovered using co-immunoprecipitation following cell lysis, 
however, these interactions were only seen when mild detergents, that preserve 
tetraspanin-tetraspanin interactions, were used (Charrin et al. 2014). These 
interactions suggested that tetraspanins were able to form larger membrane 
complexes and may play a role in membrane compartmentalization, a hypothesis 
which was supported by the discovery that tetraspanins act in a similar manner to 
components of lipid raft micro-domains in sucrose gradients after cell lysis, signifying 
that tetraspanins are associated with detergent-resistant membranes (Claas et al. 
2001, Berditchevski et al. 2002, Charrin et al. 2014).  
Originally it was thought that TEMs were highly diverse, containing a variety of partner 
proteins and tetraspanins depending on the cell type and tetraspanins included 
(Rubinstein et al. 1996a, Boucheix and Rubinstein 2001, Yáñez-Mó et al. 2009). 
However, recent work has suggested that tetraspanins form individual adjacent 
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tetraspanin clusters, with little overlap between different tetraspanin clusters which 
challenges the prior view of diverse tetraspanin-containing regions (Zuidscherwoude et 
al. 2015).  
The ability to form TEMs, whether composed of individual tetraspanins or several, is 
hypothesised to facilitate the spatial organisation of membrane proteins by 
tetraspanins. In addition to this, tetraspanins have been shown to regulate their 
partner proteins through multiple other mechanisms (Charrin et al. 2014). This 
includes the ability to regulate the degradation, secretion, expression, multimerization 
and intracellular signalling of many different membrane proteins (Berditchevski and 
Odintsova 2007, Charrin et al. 2009, 2014, Yáñez-Mó et al. 2009).  
Trafficking of membrane proteins by tetraspanins has been demonstrated for both 
endocytic and secretory pathways. Many proteins, including CXCR4,  synaptotagmin 7 
and H+/K+ ATPases, have been shown to be internalised and/or trafficked to the 
lysosomes by CD63 (Pols and Klumperman 2009, Flannery et al. 2010). For some 
tetraspanins, such as CD63, internalisation and trafficking of partner proteins appears 
to be their primary function. Other tetraspanins, like CD81, are required for the 
secretion of their partner proteins. A mutation in CD81 results in an impaired humoral 
immune response due to a lack of surface CD19, which is an important B-cell receptor 
co-stimulatory molecule (Charrin et al. 2014). CD81 associates with CD19 early in 
biosynthesis at the endoplasmic reticulum and supports the entire process from 
exiting the endoplasmic reticulum to functioning on the plasma membrane (Shoham et 
al. 2006).  
Another method used by tetraspanins to affect partner function is to regulate their 
multimerization but not the trafficking of the partner protein (Charrin et al. 2014). The 
elevation of Norrin/β-Catenin signalling by TSPAN12 is one example of this.  TSPAN12 
is a component of the Norrin receptor complex, which also contains Frizzled-4 and 
lipoprotein-related protein 5, and promotes the oligomerization of the receptor 
complex to enhance the signalling response to Norrin binding (Junge et al. 2009). 
Lastly, several tetraspanins have displayed the ability to modulate the downstream 
signalling of their partner proteins.  Both indirect and direct partner proteins have 
been shown to be affected in this way. The signalling of tyrosine kinase receptors, such 
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as epithelial growth factor receptor and vascular endothelial growth factor receptor-3, 
has been shown to be modulated by the expression or deletion of CD9 or CD82, 
although no direct interactions have been found between the tetraspanins and the 
receptors so far (Odintsova et al. 2000, Murayama et al. 2008, Iwasaki et al. 2012, 
Charrin et al. 2014). In contrast, CD151 has been shown to directly interact with 
several laminin-binding integrins and appears to moderate the activation of several of 
their downstream signalling molecules, including Akt, Src and focal adhesion kinase 
(Yauch et al. 1998, Serru et al. 1999, Takeda et al. 2007, Yang et al. 2008, Yamada et al. 
2008, Charrin et al. 2014).  
This diverse range of functions, partner proteins and their expression in all cell types 
means that the tetraspanin family have been found to be involved in a variety of 
processes including proliferation, cell motility, angiogenesis, host-pathogen 
interactions, antigen presentation, tumour development and metastasis (Miyazaki et 
al. 1997; Boucheix & Rubinstein 2001; Zhang et al. 2009; Monk & Partridge 2012; 
Detchokul et al. 2014; Jiang et al. 2015; Rocha-Perugini et al. 2015; Y.-G. Yang et al. 
2016). 
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1.6 Tetraspanins in zebrafish 
Not only are tetraspanins found in evolutionarily diverse organisms but they are also 
fairly highly conserved between organisms. Zebrafish tetraspanin genes show between 
~45- 80% identity with their human orthologs (Table 1.3). However, protein identity 
between zebrafish and human orthologs differs dramatically within the tetraspanin 
structure (Stipp et al. 2003). Stipp et al analysed the identity of different domains of 
four tetraspanins, CD9, CD81, CD151 and Tspan7 in human and zebrafish. They found 
the transmembrane domains and intracellular structures to be the most highly 
conserved between orthologs, with 83% and 72-78% identity. Polar residues within the 
transmembrane domains and membrane-proximal cysteines were 100% conserved 
between humans and zebrafish. These high identities are consistent with these regions 
or residues having important conserved functions. This is in contrast to the EC1 and 
EC2 which displayed 43-58% identity, suggesting some potential diversification in 
function or protein partners (Stipp et al. 2003).  
Though tetraspanins are fairly highly conserved between humans and zebrafish there 
is not much known about the function or expression pattern of tetraspanins in 
zebrafish. As shown in Table 1.4, only 18 of the 50 zebrafish tetraspanins have had 
their expression patterns described in any detail.   
Tetraspanins have been reported in a number of gene expression screens, suggesting 
roles in various systems including the immune response, posterior lateral line 
development, hair cell regeneration, photoreceptor function and hypertrophic muscle 
growth (Pujic et al. 2006, Johnston et al. 2009, Gallardo et al. 2010, Yang et al. 2012, 
Steiner et al. 2014). However, few studies have focused on tetraspanin functions in 
zebrafish.  
Research looking at the functions of tetraspanins in zebrafish has so far only described 
functions for Tspan 18, Tspan 36, CD63 and Upk3a-l. Tspan 18 was described in a PhD 
thesis by Li  in 2011, to play a role in angiogenesis through the regulation of Vegfr2 and 
notch pathways (Li 2011).  A Tspan 36 mutant, deli, displayed abnormal skin pigment 
pattern formation which was shown to be due to defective melanophore migration 
and irregular interactions between melanophores and xanthophores (Inoue et al. 
2014).  Knock-down of CD63 using morpholinos rendered zebrafish embryos unable to 
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Table 1.3. Percentage identity of the mouse and zebrafish homologs to a number of 
human tetraspanins. Data from ensemble.org (Herrero et al. 2016) 
hatch from their chorion, a phenotype which appeared to result from an absence of 
secreted proteolytic enzymes which are required for chorion softening (Trikić et al. 
2011). Lastly, knockdown of Upk3a-l caused reduced pronephros function due to 
defective epithelial cell polarisation and morphogenesis (Mitra et al. 2012).  
Human 
gene 
Mouse 
gene 
% Identity to 
human 
Zebrafish 
gene 
% Identity to 
human 
Tspan 7 Tspan 7 98 tspan 7b 84 
CD9 Cd9 90 cd9a 60 
cd9b 59 
CD63 Cd63 79 cd63 45 
CD81 Cd81 92 cd81a 65 
cd81b 60 
CD151 Cd151 94 cd151 65 
cd151-L 71 
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Tetraspanin  hpf Expression Reference 
Tspan 1 96 Anterior neuromast mantle cells  Steiner et al. 2014 
Tspan 2a 19-60 Olfactory placode, brain, retina  Thisse et al. 2001 
Tspan 3a Adult Brain, eye, heart, skin, melanocyte, 
ovary, testis, xanthophore 
Inoue et al. 2014 
Tspan 3b Adult Brain, eye, ovary, testis Inoue et al. 2014 
Tspan 5a 10-60 CNS, olfactory placode Thisse & Thisse 2004 
Tspan 7b 16-60 Notochord, brain, spinal cord, 
pancreatic bud 
Thisse & Thisse 2004 
Tspan 18 24-60 Yolk vessel, intersegmental vessels, 
post cardinal vein, caudal vein, heart  
Li 2011 
Tspan 35 16-60 Pronephric duct, olfactory organ Thisse & Thisse 2004 
Tspan 36  16-
Adult 
Retina, neural crest, melanocyte, 
xanthophore, ovary, testis, skin, 
heart, brain 
Thisse et al. 2001; 
Pujic et al. 2006; 
Inoue et al. 2014 
CD9a 19-60 Heart, liver, retina, telencephalon Thisse & Thisse 2004 
CD9b 16-60 Otic placode, pronephric duct, skin, 
olfactory organ, lateral line 
primordium, neuromasts, pharynx 
Thisse & Thisse 2004; 
Gallardo et al. 2010 
CD63 19-120 Hatching gland, pronephric duct, 
dorsal fin, notochord, pharynx 
Rauch et al. 2003; 
Thisse & Thisse 2004; 
Trikić et al. 2011 
CD81b 19-60 Cephlic floor plate, cerebellum, 
hindbrain, cleithrum 
Thisse & Thisse 2004 
CD82a 19-60 CNS, brain, pectoral fin, otic vesicles Kudoh et al. 2001; 
Thisse & Thisse 2004 
CD151 10-60 Skin, slow muscle, heart, pectoral fin, 
swim bladder bud, 
Thisse & Thisse 2004 
CD151-L 10-60 Notochord, pronephric ducts, skin, 
pharynx, forebrain 
Thisse & Thisse 2004 
Upk3a-L 48 Retina, ganglia, pronephric tubules Mitra et al. 2012 
 Table 1.4 Known expression patterns of zebrafish tetraspanins. Data from zfin.org   
(D. Howe et al. 2013) 
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1.7 Tetraspanins and CXCR4 
A link between CXCR4 and tetraspanins was initially found in CD4+ human cell lines 
when a CD63 mutant prevented infection by CXCR4-using T-cell Tropic Human 
Immunodeficiency Virus Type 1 (HIV-1). Both mutant and wildtype CD63 was shown to 
inhibit CXCR4 surface expression, although the N-terminal deletion mutant was 
dramatically more efficient (Yoshida et al. 2008). CD63 binds CXCR4 at the Golgi 
apparatus via N-linked glycans in its EC2, allowing CD63 to regulate CXCR4 trafficking. 
It was found that the CD63 N-terminal deletion mutant exclusively trafficked CXCR4 to 
the late endosomes/lysosomes, whereas wildtype CD63 could also be found at the 
plasma membrane bound to CXCR4 (Yoshida et al. 2008, 2009). This role for CD63 in 
CXCR4 trafficking has also been replicated in activated B-cells, where CXCR4 cell 
surface expression was shown to be downregulated by CD63(Yoshida et al. 2011).  
Since CD63, three other tetraspanins, Tspan3, CD82 and CD9, have been functionally 
linked with CXCR4 (Li et al. 2011, Leung et al. 2011, Yang et al. 2016).  Most recently,  
loss of Tspan3 in leukemic cells was shown to reduce CXCR4 phosphorylation and 
impair the response to CXCL12 which resulted in the ectopic localisation of the 
leukemic cells (Yang et al. 2016).  
CD82 functions with CXCR4 in early human pregnancy to prevent the over invasion of 
embryonic trophoblasts into the maternal tissue. To prevent over-invasion CXCL12-
CXCR4 signalling on embryonic trophoblasts acts in both a paracrine and an autocrine 
manner. When acting in an autocrine manner, CXCL12 promotes invasion of the 
maternal tissue by the trophoblasts. However, when acting in a paracrine manner 
CXCL12 produced by the trophoblasts binds CXCR4 on the maternal decidual stromal 
cells which results in the upregulation of CD82 expression. CD82 upregulation 
promotes TIMP1 (tissue inhibitor of metalloproteinases) expression which in turn 
inhibits trophoblast invasion (Li et al. 2011, Meng et al. 2012). 
Lastly, Leung et al. 2011 found that CD9 was upregulated by CXCL12-CXCR4 signalling 
in hematopoietic stem cells (HSCs). A functional role for CD9 in CXCL12-mediated 
migration and in vivo homing of HSCs was suggested due to the inhibition of these 
functions in HSCs treated with an anti-CD9 antibody. 
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To investigate whether tetraspanins could play a role in CXCR4b signalling in the pLLP 
or PGC migration, the expression patterns of CD63, CD82 and CD9 zebrafish 
orthologues were assessed. As shown in Table 1 4, CD63 and CD82a are not expressed 
in the pLLP or the PGCs. With a lack of CD82b expression data, this left the CD9 
orthologues, CD9a and CD9b. Of the two orthologues, CD9b has been shown to be 
expressed in the pLLP and in the region to which PGCs migrate, making it a good 
candidate for playing a role in CXCR4b signalling (Figure 1.7) (Thisse and Thisse 2004, 
Gallardo et al. 2010).   
1.8 CD9  
First described in 1981 to be expressed on acute lymphoblastic leukaemia cells, CD9 
has since been found to have an almost ubiquitous expression pattern in normal 
human tissues (Kersey et al. 1981, Maecker et al. 1997, Sincock et al. 1997). Along with 
normal tissues, CD9 has been associated with multiple cancers including myeloma, 
breast cancer and small-cell lung cancer (reviewed in Xuan et al. 2014).  
 CD9 has been reported to modulate many different cellular functions in cancer 
pathogenesis, including adhesion, proliferation, apoptosis and stem cell properties 
(Ovalle et al. 2007, Yamazaki et al. 2011, He et al. 2013, Xuan et al. 2014). Most 
predominantly CD9 has been reported to affect the migration and metastasis of 
multiple cancer cell types. Initially it appeared that CD9 acted as a metastasis 
suppressor, with inverse correlations found between metastasis and CD9 expression in 
melanoma, breast, colon and ovarian cancers (Si and Hersey 1993, Miyake et al. 1995, 
Mori et al. 1998, Houle et al. 2002).  Experimental data appears to support these 
findings for a number of cancer types including: melanoma, fibrosarcoma, renal cell 
carcinoma, lung and prostate cancer (Ikeyama et al. 1993, Huang et al. 2004, Copeland 
et al. 2013, Garner et al. 2016). By contrast, lymphoblastic leukaemia, fibrosarcoma 
and esophageal squamous cell carcinoma displayed positive correlations between CD9 
expression and cancer cell migration or metastasis (Herr et al. 2013, Jian et al. 2015, 
Arnaud et al. 2015). Interestingly, conflicting reports have been described for breast 
cancer. Patient samples displayed an inverse correlation between CD9 and breast 
cancer metastasis, data supported by experimental evidence showing an increase in 
integrin α5β1-mediated migration of CD9-deficient breast cancer cells (Miyake et al. 
1995, Powner et al. 2011). However, more recent data has shown significant CD9 
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overexpression in breast cancer bone metastases from patients, as well as decreased 
migration of breast cancer cells in vivo upon CD9 knockdown (Kischel et al. 2012, 
Rappa et al. 2015). 
In non-cancerous cells, CD9 shows similar functions with roles in cell proliferation, 
adhesion and migration (Takemura et al. 1999, Shi et al. 2000, Cook et al. 2002, Leung 
et al. 2011, Yang et al. 2012, Jiang et al. 2013). CD9 has been shown to promote 
migration in a number of different cell types, including human cord blood cells, 
satellite cell-derived myoblasts, embryonic stem cells, megakaryocytes and endothelial 
cells (Deissler et al. 2007, Leung et al. 2011, Kamisasanuki et al. 2011, Iwasaki et al. 
2012, Brzoska et al. 2015, Desterke et al. 2015). A study by Iwasaki et al. in 2012 
showed that knockdown of CD9 resulted in a decrease in the migration of lymphatic 
endothelial cells. The authors also found that loss of CD9 reduced the creation of 
complexes between vascular endothelial growth factor receptor-3 and integrins α5 
and α9, which resulted in the inhibition of downstream ERK and p38 MAPK signalling 
upon vascular endothelial growth factor-C binding. Similar results were seen by 
Kamisasanuki et al. 2011, who also found that knockdown of CD9 reduced the vascular 
endothelial growth factor or hepatocyte growth factor stimulated endothelial cell 
migration during angiogenesis. Whilst they did not observe any difference in growth 
factor signalling, they did report the abnormal localisation of integrins and membrane 
type-1 matrix metalloproteinase upon CD9 knockdown (Kamisasanuki et al. 2011). CD9 
deficiency has been reported to cause altered signalling and reduced migration in 
megakaryocytes and re-epithelialization during wound healing, with the focal adhesion 
kinase and c-Jun NH2-terminal kinase/ matrix metalloproteinase-9 pathways affected 
respectively (Zhang et al. 2012, Desterke et al. 2015).  
CD9 has also been reported to function in cell proliferation and apoptosis (Shi et al. 
2000, Murayama et al. 2004, Iwasaki et al. 2012). By directly interacting with 
transforming growth factor-β (TGF-β), CD9 expression augments the activation of EGFR 
by TGF-β and increases proliferation in a juxtacrine manner. However, this co-
expression also resulted in decreased the autocrine proliferative activity (Shi et al. 
2000). Anti-CD9 antibodies have also been shown to give anti-proliferative effects, 
which Murayama et al. 2004 suggested was due to the inhibition of ERK1/2 activity. 
Interestingly, the same CD9 antibody was shown to induce apoptosis via the activation 
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of c-Jun NH2-terminal kinase/stress-activated protein kinase, p38 MAPK and caspase-3 
(Murayama et al. 2004). 
Lastly, cell adhesion to fibronectin has been shown to be repressed by CD9 in a 
number of studies (Cook et al. 2002, Leung et al. 2011, Wang et al. 2011a). This 
function was not observed in a C-terminal deletion mutant by Wang et al. 2011a, 
which would suggest involvement of the C-terminal. However, Cook et al. 2002 had 
previously shown that the EC2 of CD9 was important in the regulation of cell adhesion. 
Cook et al. also reported that CD9 co-localised with F-actin and integrin α5β1 at cell 
margins and affected the localisation of focal adhesion kinase and α-actinin. They 
suggested that CD9 could affect adhesion by regulating the formation of adhesion 
complexes.   
The co-ordination of these functions allows CD9 to mediate processes such as wound 
repair, lymphangiogenesis and angiogenesis (Deissler et al. 2007, Kamisasanuki et al. 
2011, Zhang et al. 2012, Iwasaki et al. 2012, Jiang et al. 2013). CD9 is also known to be 
important inhibitor of muscle cell, macrophage and HIV-1-induced cell fusion (Takeda 
et al. 2003, Gordón-Alonso et al. 2006, Charrin et al. 2013). Although a recent paper by 
Brzoska et al. 2015 did report a positive impact of CD9 expression on myoblast fusion, 
which could suggest contradictory functions for CD9 in cell fusion.  
 With the variety of cell functions regulated by CD9, it is surprising that cell fusion 
appeared to be the only CD9 function affected in CD9 knockout mice. Female 
homozygous CD9-/- mice were showed severely impaired fertility which resulted from 
defective gamete fusion (Le Naour et al. 2000, Miyado et al. 2000, Kaji et al. 2002). The 
apparent lack of widespread phenotypes in CD9-/- mice is most likely due to 
redundancy between tetraspanins. For example, the fertility phenotype can be rescued 
by injection of CD81 and lymphangiogenesis defects can only be seen in CD9/CD81-
double knock-out mice but not in single knock-out mice (Kaji et al. 2002, Iwasaki et al. 
2012).  
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1.9 CD9a and CD9b  
The zebrafish homologs of human CD9, CD9a and CD9b, show high amino acid identity 
to each other (63%) and to their human counterpart (60%, 59% respectively) (Table 1.3 
and Figure 1.6a). The highly similar hydrophobicity plots of the three homologs suggest 
many structural similarities although the second hydrophilic domain, the predicted 
EC2, appears the most diverse (Figure 1.6b). This correlates with a previous report 
which showed the EC2 is the least conserved domain between zebrafish and humans 
(Stipp et al. 2003). These differences may suggest divergent functions, even between 
the two zebrafish paralogs. This would not be unexpected as other zebrafish paralogs, 
such as CXCR4a and CXCR4b, show complimentary expression patterns and functions 
(Chong et al. 2001). As shown in Table 1.4 and Figure 1.7, CD9a and CD9b also appear 
to have distinct expression patterns. 
Neither CD9a nor CD9b have been studied extensively and so the functions of these 
proteins are not yet clear.  CD9a may play a role in the immune response as two 
reports have shown CD9a to be differentially regulated upon viral infection or vaccine 
immunisation (Encinas et al. 2010, Yang et al. 2012). While CD9b was not reported in 
either of those studies, it was shown to be upregulated in muscle fibres in the 
hypertrophic phenotype in comparison to muscle fibres in the hyperplastic phenotype, 
suggesting a role in muscle growth (Johnston et al. 2009). A role in the lateral line has 
also been suggested for CD9b. It is highly expressed in the lateral line primordium cells 
in comparison to surrounding cells and a brief proof-of-principle experiment by 
Gallardo et al. 2010 showed that knockdown of CD9b using a morpholino resulted in 
abnormal lateral line primordia structure in 50% of the injected embryos at 36hpf and 
reduced neuromast number at 48hpf. 
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Figure 1.6 Sequence alignment (a) and hydrophobicity plots (b) of human CD9 (a, b) 
and zebrafish CD9a (a, b I) and CD9b (a, b II).  
Sequences aligned using MUSCLE (Edgar 2004).  *,:, ., indicate fully conserved 
residues, strongly similar and weakly similar residues respectively. Kyte and Doolittle 
hydrophobicity plots where scores of >0 indicate hydrophobic regions  (Gasteiger et 
al. 2005).  
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a) 
b) 
Figure 1.7 cd9a (a) and cd9b (b) in 
situ hybridisation at stage Prim-15 
to Prim-25 by Thisse, B. and Thisse, 
C. 2004.  Reproduced with the 
authors’ permission. Black arrows 
indicate the two pLLP from either 
side of the embryo. 
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1.10 Aims and objectives 
This project aimed to investigate whether CD9b played a role in CXCR4b-mediated PGC 
and pLLP migration. To accomplish this, a reverse genetics approach was taken.  
Aims: 
1) To investigate whether CD9b knockdown causes abnormal PGC or pLLP 
migration.  
2) To investigate whether any of the PGC or pLL phenotypes seen in the CD9b 
morphants are replicated in CD9b homozygous mutants.  
3) To assess any novel PGC or pLL phenotypes seen in the CD9b mutants. 
4) To elucidate the mechanism in which the lack of CD9b is causing the 
phenotypes seen. 
5) To analyse and assess any other phenotypes observed in the CD9b mutants. 
Objectives: 
1) Use morpholinos to knockdown cd9b and visualise the completed migration of 
PGCs or the pLLP using in situ hybridisation. 
 Develop assays to accurately quantify differences observed in PGC migration 
and clustering in CD9b morphants. 
 Develop assays to accurately quantify differences observed in pLLP migration 
and pLL structure in CD9b morphants. 
2) Create homozygous CD9b mutants using TALENs. 
 Use same assays to analyse PGC and pLLP migration in CD9b mutants. 
3) Develop assays to accurately quantify novel PGC and pLL phenotypes in CD9b 
mutants. 
4) Analyse CXCR4b trafficking and internalisation in CD9b mutants using CXCR4b-
EGFP and CXCL12a-Venus. 
 Analyse whether CD9b is upregulated upon CXCR4b signalling. 
 Assess CXCR4b and CXCL12a expression in CD9b mutants. 
5) Develop assays to quantify any observed morphological differences in the CD9b 
mutants. 
 Develop assays to evaluate the fertility of CD9b mutants. 
Whilst the majority of these aims and objectives were met, the fourth aim was not 
fully investigated due to the CD9b mutants not replicating the pLL phenotypes seen in 
the CD9b morphants. In light of this a new aim was developed ‘To investigate why 
CD9b morphants and CD9b mutants show different pLL phenotypes’. To explore this 
aim, redundancy, morpholino off-target effects and residual CD9b function in the CD9b 
mutants were assessed. 
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Chapter 2: Materials and Methods 
2.1 Materials 
2.1.1 General laboratory reagents 
 
Water 
All unspecified water used was ultrapure (Type 1) water, often labelled MQH2O, which 
had been purified using Synergy Water Purification System from Merck Millipore. 
During RNA and DNA sensitive experiments, nuclease-free water from Ambion was 
used.  
Chemicals 
All chemicals used were analytical grade or equivalent and purchased from Sigma, 
Aldrich, VWR International or Fluka, unless stated otherwise. 
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2.1.2 General laboratory equipment 
 
 
 
 
 
 
 
 
Equipment Supplier 
Agarose gel documentation  Alrad Camera, UVP 2UV transilluminator 
Agarose gel electrophoresis Biorad gel box, Biorad PowerPac 300 
Balances Scientific Laboratory Supplies (SLS) Explorer 
Pro and Adventurer Pro 
Centrifuges Hettich Mikro 22, Sigma 1-14, Hermle Z 306 
Flaming/Brown Micropipette Puller Sutter Instrument Company 
Forceps Dumont 
Graticule Pyser-SGI Ltd.  
Incubators (fish) Sanyo, SLS LMS cooled incubator 
Incubator (microbiology) Neuberger 
Orbital Shaker Stuart 
Pasteur pipettes (glass) Volac 
Pasteur pipettes (plastic) SLS 
pH meter Mettler Toledo 
Pipettes (manual) Gilson 
PV800 Pneumatic PicoPump World Precision Instruments 
Spectrophotometers Eppendorf BioPhotometer, Nanodrop ND-
1000  
Thermal Cyclers Biorad S1000, Techne TC-412  
Water baths Grant- JB Nova 
Table 2.1 General Laboratory equipment 
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Microscopy related equipment Manufacturer 
AxioCam ERc 5s Camera Zeiss 
AxioCam MRm Camera Zeiss 
Axioskop 2 mot plus microscope Zeiss 
Axioskop microscope Zeiss 
AxioVision Software Zeiss 
Fluoview software Olympus 
FV1000 Confocal Olympus 
MS5 Dissecting microscope Leica 
Prog Res C14 camera  Jenoptik 
Prog Res Capture Pro Software Jenoptik 
Zoom.V16 microscope Zeiss 
 
 
2.1.3 General laboratory consumables 
Equipment Supplier 
1.5mL pestle, disposable Sigma 
1.5mL RNAse –free tubes TreffLab 
1.5mL tubes Eppendorf, TreffLab 
100mm petri dishes Thermo Scientific 
12-well plates Costar, Corning Inc.  
96 well PCR plates StarLab 
Borosilicate glass capillaries Harvard Apparatus 
Cover slips No.0 SLS 
Falcon tubes Becton Dickinson and Co. 
Glass slides VWR International or Fisherbrand 
Gloves Microflex 
PCR tubes StarLabs 
Pipette tips StarLabs 
 
 
Table 2.2 Microscopy equipment 
Table 2.3 General Laboratory Consumables 
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2.1.4 General laboratory buffers 
Buffer Preparation  
Phosphate Buffered Saline (PBS) 0.01M, 
pH7.4 
One tablet (Sigma) per 200 mL of 
deionized water    
PBS / 0.05% Tween 20 (PBST) 50mL 1x PBS, 25µL Tween 20 
Tris-Borate-EDTA  (TBE) (5X) 54g Tris base, 27.5g Boric Acid, 20mL 
0.5M EDTA in 1L water, pH to 8 
Tris-HCl (1M)  121 g Tris base in 1 L water. pH to 8.2 or 
9.5 depending on requirements 
20% Tween-20 10mL Tween-20 with 40mL MQH2O, kept 
in dark 
 
 
2.1.5 Solutions for microbiology 
Buffer/Solution Preparation 
LB  Re-suspend 25g LB broth powder (Sigma) 
in 1L water, then autoclave to sterilize 
SOC Outgrowth Medium Provided by New England Biolabs Inc. 
(NEB) with NEB 10- beta competent E.Coli. 
Contains 2% Vegetable Peptone, 0.5% 
Yeast Extract, 10 mM NaCl, 2.5 mM KCl, 
10 mM MgCl2, 10 mM MgSO4, 20 mM 
Glucose 
 
 
 
 
 
 
 
Table 2.4 General Laboratory Buffers 
Table 2.4 Solutions for microbiology 
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2.1.6 Solutions and reagents for zebrafish work 
Solution/Reagent Preparation 
E3 Methyl-Cellulose 3% Methyl cellulose dissolved in 1X E3 
1X E3 5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, 
0.33 mM MgSO4, 10
-5% Methylene Blue 
4% Paraformaldehyde (PFA) 4% PFA dissolved in PBS containing 1 mM 
NaOH 
20X Ringer’s buffer 2.3M NaCl, 58 mM KCl, 36 mM CaCl2, 100 
mM HEPES in water, pH 7.2. 
Tricaine (Ethyl 3-aminobenzoate 
methanesulfonate) 
 
400 mg Tricaine, 2.1 mL 1M Tris pH9 in 
97.9mL water to pH 7. Used at 4.2% 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.5 Solutions for zebrafish work 
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2.1.6.1 Solutions and reagents for in situ hybridisation 
Solution Preparation 
20X SSC In 800mL H2O, 140.2g 3M NaCl, 65.8g 
0.3M NaCitrate dihydrate to pH 7.0. 
Or taken from readymade 20X SSC(Sigma) 
BCIP 50mg 5-Bromo 4-Chloro3Indolyl 
Phosphate in 1mL anhydrous Dimethyl-
formamide 
Bleaching solution 0.5X SSC containing 10% H2O2 and 5% 
Formamide 
Blocking buffer 50mL PBST containing 1mL Sheep serum 
and 100mg BSA 
Hyb- 25mL Formamide, 12.5mL 20X SSC, 250µ 
20% Tween-20, 460µL 1M Citric Acid and 
H2O to 50mL 
Hyb+ 25mL Formamide, 25mg tRNA, 12.5mL 
20X SSC, 250µ 20% Tween-20, 50µL 
Heparin (50mg/mL), 460µL 1M Citric Acid 
and H2O to 50mL 
NBT  50mg Nitro Blue Tetrazolium and  0.7mL 
anhydrous Dimethyl-formamide added to 
0.3mL H2O 
PTU 0.089g PTU (N-Phenylthiourea) + 25ml 
MQH2O 
Staining buffer 5mL 1M Tris pH9.5, 2.5mL 1M 
MgCl2,1.66mL 4M NaCl, 250µL 20% 
Tween-20 to 50mL with H2O 
Staining solution 25mL Staining buffer with 112.5µL NBT 
and 87.5µL BCIP 
0.2 X SSCT or 2X SSCT Dilute 20X SSC by 1:10 or 1:100. To 50mL 
0.2 X or 2X SSC add 250µL 20% Tween-20 
 
Table 2.6 Solutions for ISH 
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2.1.7 Oligonucleotides for zebrafish work 
Primers 
All primers were purchased from IDT (Integrated DNA Technologies). Primers were re-
suspended in MQH2O to give 100µM primer concentration and stored at -20°C. 
Morpholinos 
Morpholinos (MOs) were purchased from Gene Tools LLC and re-suspended in MQH2O 
to give a stock concentration of 1mM. CD9b MOs were stored at room temperature in 
parafilm wrapped Eppendorf tubes as recommended by Gene Tools LLC. The mismatch 
MO was stored at -20°C and was incubated at 65°C for 20 minutes before use to 
ensure the MO was completely soluble. The mismatch MO is the same mismatch MO 
used  by Trikić et al. 2011, which had been stored at -20°C since purchase.  
MO name Activity Sequence 5’-3’ 
CD9b MO1 Translation blocker tttatgaggagaaacccaagactga 
CD9b i2e3 Splice-site blocker aacccctgaacacagagaaacaaca 
Mismatch MO None tttccctgctgcttatacagcgatg 
 
 
2.1.8 Analysis software 
Software Reference/Origin 
ApE v2.0.47 M. Wayne Davis 
http://biologylabs.utah.edu/jorgensen/wayned/ape/ 
Excel version 14.0.7166.5000, Microsoft 
GraphPad Prism version 6 GraphPad Software, La Jolla California USA, 
www.graphpad.com 
Image J/Fiji Schindelin et al. 2012; Schneider et al. 2012 
 
 
 
Table 2.7 Morpholino activity and sequence 
Table 2.8 Software used for data analysis 
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2.2 Methods 
2.2.1 Molecular techniques 
2.2.1.1 PCR 
PCR reactions were assembled on ice in PCR tubes or 96 well plates, depending on the 
number of reactions to be run. The reactions were set up as displayed below in Table 
2.9 and run in a PCR machine using the thermal cycle seen in Table 2.10. The annealing 
temperature shown in Table 2.10 is an example but would have depended on the 
primers used, with the annealing temperature generally being 5°C below the Tm of the 
primers. 
Upon completion of the reaction, 1-5µL of the PCR product was run on a 1-1.5% 
agarose (VWR) TBE gel containing 0.5 µg/mL ethidium bromide (VWR), at 80V for 15-
40 minutes depending on the length of the product and the band separation needed. A 
1kb or 100bp ladder (NEB) was run alongside the PCR products. 
 
 
 
 
 
 
 
 
 
Thermal Cycle Temperature (°C) Time  
Initial Denaturation 96 45 seconds 
35 Cycles 94 30 seconds 
55 (variable) 30 seconds 
72 1 minute per kb  
Final Extension 72 5 minutes 
 
 
 
Component Volume (µL) Concentration  
10x PCR Buffer 2.5 1x 
2.5mM NTPs 1 100 µM 
Taq polymerase 0.5 5 units 
10µM Forward 
Primer 
1 0.4 µM 
10µM Reverse 
Primer 
1 0.4 µM 
DNA 1 Variable 
MQH2O 18 - 
Table 2.9 PCR reaction 
Table 2.10 PCR thermal cycle 
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2.2.1.2 Genotyping 
2.2.1.2.1 Using gDNA sequencing for genotyping 
Genotyping was carried out either on fin clips from live adult fish or on the heads of 
fixed embryos. gDNA was extracted from the tissue sample using the method 
described by Meeker et al. 2007, which firstly used heated sodium hydroxide to lyse 
cells and denature the gDNA. The solution was then neutralised and centrifuged to 
pellet cell debris. The supernatant, which contains the gDNA, can then be used in PCR 
to amplify the relevant section of gDNA using the primers in Table 2.12.  The PCR 
products were checked on a gel before being cleaned using either ExoSAP or Sodium 
acetate/Ethanol (see below for method). Once cleaned, the PCR products were sent 
for sequencing with a sequencing primer (Table 2.13). Sequencing results were 
analysed using ApE v2.0.47 (a plasmid editor). 
Cleaning PCR products for sequencing 
Sodium Acetate/Ethanol  
To 18µL PCR product, 2µL 3M sodium acetate (Sigma) and 50µL 100% ethanol (Fisher 
scientific) were added before mixing then cooling at -20°C for 30 minutes. The 
products were then centrifuged for 30 minutes at maximum speed at 4°C. The pellet 
was washed once with 500µL PE buffer (QIAGEN) then re-suspended in 50µL EB buffer 
(QIAGEN). 1-4µL was then used for sequencing. 
ExoSAP 
ExoSAP clean-up of PCR products used SAP (Shrimp-Alkaline Phosphatase) (NEB) and 
Exonuclease 1 (Exo1) (NEB) to remove unused primers and NTPs from the finished 
reaction. SAP and Exo 1 were added to the PCR products, on ice, before immediately 
incubating the mix at 37°C for 45 minutes (Table 2.11). After 45 minutes, the enzymes 
were de-activated by incubating at 80°C for 15 minutes. 10µL of PCR product was then 
sent for sequencing with a relevant sequencing primer (IDT) (Table 2.13). 
Component Volume (µL) 
PCR 16 
SAP 
(1000units/mL) 
4 
Exonuclease 1 0.5 
Table 2.11 ExoSAP reaction 
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Genotyping and sequencing PCR primers 
Target Primer Sequence (5’-3) 
CD9b TALEN 1 cut site CD9b T1 F1 ggaaaggtacatttctcaggtgctcag 
CD9b TALEN 1 cut site CD9b T1 R1 atcctcacaacaacacaatcaagcct 
CD9b TALEN 2 cut site CD9b T2 F1 tgattgggatgtgcagttcagtttctg 
CD9b TALEN 2 cut site CD9b T2 R1 atttacaccgttcaaaacaaacagaa 
CD9b TALEN 1 cut site CD9b T1 F1 1.4.15 gcttgactaatccgcatttagactc 
CD9b TALEN 1 cut site CD9b T1 R1 1.4.15 ccagcctagatacaatcacacaaac 
 
 
Sequencing Primer Sequence (5’-3’) 
CD9b T1 F2 cgagtcaaaacccaaagagg 
CD9b T1 R2 acacacttatttcaccatct 
CD9b T2 F2 aaactaaacattttcttagt 
CD9b T2 R2 aattgaataataaaaggtga 
CD9b T1 F2 1.4.15 tatctatgctctttcccatgggacc 
CD9b T1 R2 1.4.15 ctcacaacaacacatcaagcctta 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.12 Genotyping PCR primers 
Table 2.13 Sequencing primers 
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2.2.1.2.2 Using restriction digest for genotyping 
Restriction digest using the enzyme Mbo II (NEB), was used on gDNA extracted from 
offspring from potential founder fish (F0s). The gDNA was extracted as described by 
Meeker et al. 2007 and the TALEN cut site amplified using the PCR primers CD9b T1 F1 
and CD9b T1 R1 or CD9b T2 F1 and CD9b T2 R1 (Table 2.12). The PCR reaction and 
thermal cycle are described below (Tables 2.14, 2.15). 3µL of the PCR reaction was 
checked for a single amplicon on a 1% agarose gel alongside a 100bp ladder. Once a 
single amplicon was obtained, 1µL Mbo II was added to the remaining 17µL PCR 
reaction and incubated at 37°C for 3 hours. 15µL of the reaction was then checked for 
digestion on a 3% agarose gel containing 2% high resolution agarose (Sigma) and 1% 
normal agarose, alongside a 100bp ladder. 
 
 
 
 
 
 
 
Thermal Cycle Temperature (°C) Time  
Initial Denaturation 94 2 minutes 
34 Cycles 94 20 seconds 
55 (variable) 20 seconds 
72 45 seconds  
Final Extension 72 3 minutes 
 
 
 
 
 
 
Component Volume (µL) 
ReddyMix (Sigma) 10 
100µM Forward Primer 0.1 
100µM Reverse Primer 0.1 
gDNA 1.5 
MQH2O 8.3 
Table 2.14  
PCR reaction for restriction digest 
Table 2.15 Restriction digest PCR reaction thermal cycle 
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2.2.1.3 Making injectable mRNA 
Transforming competent bacteria  
After defrosting NEB 10-beta competent E.Coli on ice, 2.5µL plasmid DNA was added to 
the cells and left for 30 minutes at room temperature. The cells were subsequently 
heat shocked at 40°C for 30 seconds then placed on ice for 5 minutes. 400µL SOC 
medium was added and the cells incubated with agitation for 1 hour at 37°C. The 
bacteria were then plated onto agar plates containing the relevant antibiotic and 
incubated overnight at 37°C.  
 
Plasmid Obtained Vector Resistance 
conferred 
Restriction 
enzyme (NEB) 
Mini or 
Midi Prep 
CXCR4b-
EGFP-globin 
E.Raz 
(Minina et al. 
2007) 
pSP64T Ampicillin 
(Sigma) 
Xba1 Mini 
CXCL12a-
Venus-
globin 
E.Raz 
(Minina et al. 
2007) 
pSP64T Ampicillin Xba1 Mini 
CD9b-T1-L ZGENEBIO 
Biotech INC. 
pZGB4L Kanamycin 
(Sigma) 
Not1 Midi 
CD9b-T1-R ZGENEBIO 
Biotech INC. 
pZGB4L Kanamycin Not1 Midi 
CD9b-T2-L ZGENEBIO 
Biotech INC. 
pZGB4L Kanamycin Not1 Midi 
CD9b-T2-R ZGENEBIO 
Biotech INC. 
pZGB4L Kanamycin Not1 Midi 
 
 
Amplification of plasmid DNA 
 QIAGEN Plasmid Mini- or Midi- Kits were used to amplify and purify the plasmid DNA, 
with the resulting DNA stored in TE buffer at -20°C before linearization.  The protocol 
followed was per the manufacturer’s instructions. Briefly, plasmid DNA was amplified 
by creating starter cultures of transformed bacteria in 14mL falcon tubes containing 
2mL LB and the relevant antibiotic (1µL/mL), which were then incubated for 8 hours at 
37°C (Table 2.15). Midi-prep kits then used a secondary culture step in which starter 
Table 2.15 Plasmids used to make injectable mRNA 
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cultures were diluted in LB and incubated overnight at 37°C. Bacterial cells were 
harvested by centrifugation, re-suspended and lysed using the kit buffers P1 and P2. 
DNA was precipitated using the buffer P3 and incubating on ice before separation from 
proteins and cell debris by centrifugation. DNA was cleaned further using a QIAGEN-
tip, which binds DNA and allowed residual contaminants to be washed away using the 
supplied buffer QC. DNA was eluted from the tips using the kit buffer QF before 
precipitating the DNA using isopropanol and centrifugation. Pellets were washed with 
70% ethanol and re-suspended in TE buffer. 
Linearization of plasmid DNA 
 The plasmids were then linearized using a relevant restriction digest as shown in 
Tables 2.15, 2.16, incubated at 37°C for 2 hours. Bovine Serum Albumin (BSA) was 
added to the reaction to help prevent loss of the restriction enzyme through adhesion 
to reaction tubes and pipette tips. 10µL of each digest and 1µL of each uncut plasmid 
was run on a 0.8% agarose gel for 45 minutes at 65V to check for complete digestion. 
 
 
 
 
 
 
Purification and extraction of DNA 
 The linearized DNA template was cleaned by adding 200μg/mL Proteinase K (Pro-K) 
(Sigma) and 0.5% SDS (sodium dodecyl sulfate) (Fluka) and incubating for 50 minutes 
at 50°C to remove any remaining proteins. A further 10 minute incubation at 95°C was 
used to de-activate the Pro K. The DNA template was then extracted and precipitated 
using phenol:chloroform:isoamyl alcohol (25:24:1) (phenol/chloroform) (Sigma) and 
ethanol using the following protocol.  
Reaction component Volume (µL)  
7µg  Plasmid variable 
Relevant buffer (NEB) 10 
Restriction enzyme (NEB) 3 
BSA (Sigma) 1 
MQH2O to 100 
Table 2.16 Restriction digest reaction 
for plasmid linearization 
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The DNA templates were transferred to 1.5mL Eppendorf tubes and equal volume of 
phenol/chloroform was added before centrifuging for 5-10 minutes at maximum 
speed. To fresh RNAse free tubes, an equal volume of chloroform (Sigma) was added. 
The aqueous phase from the centrifuged tubes was immediately transferred to the 
fresh chloroform containing tubes and centrifuged at max speed for 3 minutes. After 
centrifugation, the aqueous phase was transferred to new RNase free tubes. 1 in 10 
volume of sodium acetate and 110µL Isopropanol (Sigma) was added, before cooling 
for 30 minutes at -20°C to precipitate the DNA. After centrifugation at 10,000-20,000g 
at 4°C for 30 minutes, the pellets were washed with 70% EtOH and then air dried. The 
pellets were then re-suspended in nuclease free water and stored at -20°C. 
Transcribing mRNA for microinjection 
The DNA templates were transcribed into injectable mRNA using the mMESSAGE 
mMACHINE SP6 Transcription Kit (Ambion) and 1µg DNA per template. Residual 
nucleotides and proteins were removed and mRNA was precipitated by adding 30µL 
nuclease-free water and 30µL lithium chloride and cooling at -20°C for 30 minutes 
before centrifuging for 15 minutes at 20,000g at 4°C. The RNA pellets were then 
washed with 70% EtOH, air dried and re-suspended in 20µL nuclease-free water before 
storing at -80°C.  
 
2.2.1.4 Making cDNA 
To extract RNA, 1-10 embryos were placed in Eppendorf tubes containing 0.3mL TRI 
Reagent (Sigma) and homogenized. An additional 0.6mL TRI Reagent was added and 
the tubes agitated for 5 minutes on an orbital shaker.  If low numbers of embryos were 
used per tube (1-4 embryos), 5µL glycogen (20mg/ml Roche) was added as an inert co-
precipitant. 0.2mL chloroform was added, the tubes inverted to mix, then left at room 
temperature for 3 minutes before centrifuging at 12,000g, 4°C for 15 minutes to 
partition the RNA into the aqueous phase. 500µL Isopropanol was then added to 
500µL supernatant, the tubes inverted then left at room temperature for 10 minutes 
before centrifugation for 10 minutes at 12,000g at 4°C to precipitate the RNA. The RNA 
pellet was then washed once with 70% EtOH, and then re-suspended in nuclease-free 
water. 
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The RNA was then reverse transcribed to cDNA using the Applied Biosystems High 
Capacity RNA-to-cDNA kit and stored at -20°C. 
2.2.1.5 qRT-PCR  
qRT-PCR (quantitative reverse transcription-PCR) was conducted on single embryo 
cDNA using the Sigma S5193 kit and run on a Stratagene qPCR machine using MXPro 
software. Each reaction was set up as shown in Table 2.17 and followed the thermal 
cycle shown in Table 2.18. A reaction master-mix was created using the components 
shown in Table 2.17 and 15µL of the master-mix was aliquoted per well. To each well, 
5µL of 1:20 diluted cDNA was also added. When trialling the primers, to test for a 
single PCR product, a mix of diluted cDNAs was used but cDNA from individual 
embryos was used to look at the relevant expression of β-actin2, CD9b C-terminal RNA 
and CD9b N-terminal RNA in AB, CD9b -1/-1 and CD9b -8/-8 embryos . Four primer sets 
were trialled but only β-actin-2, CD9b C-term and CD9b N-term 1 primer pairs were 
used subsequently (Table 2.19).  
The fold expression of CD9b C-terminal RNA and CD9b N-terminal RNA in CD9b 
mutants was calculated by initially normalising the expression of CD9b C-terminal RNA 
and CD9b N-terminal RNA to the control gene, β-actin-2. Differences in fold expression 
between mutants and wildtype AB embryos were then calculated by normalising the 
mutant expression of the RNAs to the wildtype AB. 
The standard curves for the primer pairs were conducted on a mix of diluted AB cDNA. 
A serial dilution of the cDNA was carried out with 1, 1/4, 1/16, 1/64, 1/256 and 1/1024 
dilutions used. The last two dilutions didn’t appear to yield reliable results and so only 
the first four dilutions were analysed. 
 
 
 
 
 
Component Volume (µL) 
each 7.5µM Primer  1 
25mM MgCl2  2.8 
ROX Reference Dye 0.2 
SYBR Green Ready Mix (Jumpstart) 10 
1:20 cDNA 5 
Table 2.17 qPCR reaction  
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Thermal Cycle Temperature (°C) Time  
Initial Denaturation 95 3 minutes 
40 Cycles 95 15 seconds 
57  15 seconds 
72 20 seconds 
Dissociation  95 1 minute 
55 30 seconds 
95 30 seconds 
 
 
qPCR Primers Sequence (5’-3’) 
β-actin2 Forward ggacctgtatgccaacactg 
β-actin2 Reverse tgatctccttctgcatcctg 
CD9b C-term Forward gaacccgtgacatcgtgtaa 
CD9b C-term Reverse tacaacaggacaaccactcg 
CD9b N-term1 Forward aattctcaggtgctcagtctt 
CD9b N-term1 Reverse ttgatacactgaagtccacc 
CD9b N-term2 Forward aaggtcaattctcaggtgct 
CD9b N-term2 Reverse gcggccatggcttaaaaag 
 
 
 
 
 
 
 
 
 
 
Table 2.17 qPCR reaction  
Table 2.18 qPCR thermal cycle  
Table 2.19 qPCR primers  
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2.2.2 Zebrafish work and related methods 
2.2.2.1 Home Office regulation 
All experiments were carried out following the Home Office requirements for the use 
of animals in scientific research.  The majority of experiments were classed as 
unregulated procedures and carried out under the UK Home Office project license 
40/3459. Regulated procedures were conducted by colleagues under their UK Home 
Office personal project licenses. 
 
2.2.2.2 Maintenance of adult zebrafish 
Adult zebrafish were housed and bred in the UK Home Office approved Bateson centre 
aquaria at the University of Sheffield, which follow a regulated 14:10 hour light: dark 
cycle.  
 
2.2.2.3 Zebrafish strains 
Wildtype AB zebrafish were used as controls for all experiments, unless otherwise 
stated, and are maintained as breeding stocks in the aquaria. Heterozygous and 
Homozygous CD9b mutants (46delA or 42_49delCTTTATCT) were created from AB 
embryos and maintained on an AB background. Breeding stocks of CD9b mutants were 
maintained in the aquaria.  
Claudinb:GFP+/-;CD9b +/-8 adult females were produced from a Claudinb:GFP X CD9b -
8/-8 cross to produce embryos for the migration speed assay. This strain was not 
maintained after the migration speed assay experiments. 
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2.2.2.4 Pair mating 
Adult pairs were placed in clear, plastic breeding tanks containing aquarium water in 
the late afternoon, the day before embryos were required. The breeding tanks consist 
of two parts, a breeding chamber and a larger water holding tank. The breeding 
chamber sits inside the water holding tank and has a perforated base that allows eggs 
to fall into through the larger tank, preventing the eggs from being eaten by the adult 
fish. Overnight the two adults are separated by a clear plastic divider. This divider is 
removed the next morning after the lights have been switched on. Zebrafish are 
photoperiod breeders and so spawn after the lights are switched on (Legault 1958). 
Embryos were collected by transferring the breeding tank containing the adult fish to a 
new water holding tank, then the embryos are sifted out of the water of the original 
water holding tank. Embryos were collected every 20 minutes after divider removal 
when embryos of the same developmental stage were required or after 2.5 hours if 
embryos of the same stage were not required.  
 
2.2.2.5 IVF 
Fish were paired as described in the Pair Mate protocol, four days before the IVF 
procedure and then transferred back to their normal tanks. The fish were paired again, 
the afternoon before the IVF, but the dividers are not removed. The next morning fish 
of the same genotype are placed together in larger tanks, as zebrafish will not normally 
lay when grouped. Individual males and females were then anaesthetised in tricaine 
and patted dry before extraction of the gametes. Sperm was extracted from male fish 
using 10 µl capillaries (Hirschmann) and suction, whereas females were gently 
squeezed on the abdomen to release eggs. The sperm and eggs were mixed together 
and incubated for 30 seconds before adding 750 µl aquarium water to the eggs and 
incubating for a further 2 minutes. 9 ml of aquarium water was then added and the 
gametes incubated for 4 hours at 28°C. The numbers of fertilised and unfertilised eggs 
was then assessed. Dead eggs were immediately discarded after extraction from the 
females and so were not included in the analysis. 
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2.2.2.6 General embryo preparation 
Embryos were raised at 28°C in petri dishes containing E3 solution. E3 was changed 
daily and dead embryos removed. At the required time point, embryos were 
anaesthetised using tricaine, then fixed using 4 % PFA (Aldrich) in PBS. If the embryos 
remained in their chorions, the embryos were dechorionated using forceps before 
fixation. The fixed embryos were left in 4% PFA overnight at 4°C before being washed 
twice with PBST the following morning. Embryos were then put through a MeOH/PBS 
series using 30%, 60% and 100% MeOH before being stored in 100% MeOH (Sigma-
Aldrich) at -20°C.  
 
2.2.2.7 Survival curves and general phenotype assessment 
Embryos were left uninjected or injected with a morpholino or TALEN at various 
volumes during the 1- or 2- cell stage. Embryos were then placed in petri dishes 
containing E3 and transferred to a 28°C or 22°C incubator. No more than 60 embryos 
were placed in a single dish and embryos were evenly distributed between dishes. At 
the designated time points, up to five days post fertilisation (dpf), the number of 
surviving embryos was assessed and any dead embryos were removed. Survival of 
embryos was calculated as a percentage of the original number of embryos at 0dpf. To 
assess toxicity of MOs or TALENs, general embryo morphology was analysed and 
categorised by eye at the same designated time points using a dissecting microscope. 
 
2.2.2.8 Microinjection 
A Flaming/Brown micropipette puller was used to create micro-injection needles from 
borosilicate glass capillary tubes. Needles were filled with 3-4µL of injection material 
using 20µL microloader tips (Eppendorf) and the needle tip seal broken using forceps. 
The PV800 Pneumatic PicoPump, as part of the micro-injection jig, was set up to 
release the required amount of injection material by adjusting the air pressure and air 
expulsion time. To determine the amount (nL) of injection material ejected, injections 
were first carried out into mineral oil (Sigma) over a graticule (Pyser-SGI) to allow the 
bolus size to be measured. Bolus size correlates to the volume (nL) of injection 
material, allowing final concentration within the embryo to be calculated. For example, 
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injection of 0.5nL of 1mM injection material into a 1µL embryo will give a 0.5µM final 
concentration in the embryo (Table 2.20).  
 
 
 
 
 
 
 
Embryos were injected individually at the 1- or 2- cell stage with a stock concentration 
of injection material. When multiple concentrations were needed, a single stock 
solution was used at multiple volumes to create different final concentrations within 
the embryos, with the smallest volume injected first. To increase the final 
concentration, the bolus size was increased and re-measured before injecting the next 
group of embryos.   
 
2.2.2.9 Internalisation assay 
240pg CXCR4b-EGFP-globin and 384pg CXCL12a-Venus-globin mRNA was injected into 
individual blastocysts in 8-cell stage AB embryos, with either a single fluorescent 
construct per embryo or both constructs in separate blastocysts. The embryos were 
then incubated at 28°C before imaging at 6hpf. Embryos were imaged live using the 
Olympus Confocal microscope using 20X and 60X objectives, with the embryos held in 
3% methyl-cellulose between a glass slide and coverslip. CXCR4b-EGFP-globin was 
captured using excitation and emission wavelengths of 484/507 nanometers, whereas 
CXCL12a-Venus-globin used 515/528 nanometers. 
 
 
 
 
Table 2.20 Bolus size to volume conversion table 
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2.2.2.10 In situ hybridisation 
In situ hybridisation was carried out as described by Thisse & Thisse in 2008, with a few 
minor changes which are outlined subsequently. The protocol was carried out with 
embryos being treated in Eppendorf tubes for the entirety of the first two days, after 
which they were held in 12-well plates for staining before transferring back to 
Eppendorf tubes for storage.  
Day 1 
Embryos were taken through a reverse MeOH series, from 100% to 30%, before 
washing with PBST.  Embryos were digested with Pro-K (10µg/mL) using the timings 
described in Table 2.21, which are slightly different to those reported by Thisse & 
Thisse, although digestion time also depended on the freshness of the Pro-K aliquot. A 
water bath at 20°C was used during the digestion step to remove the effect of a 
variable room temperature on Pro-K digestion times. After re-fixing embryos in 4% PFA 
and washing with PBST, embryos were incubated with Hyb+ for 2 hours at 70°C. The 
Hyb+ then was replaced with 200µL Hyb+ containing 1-4µL RNA probe and left to 
hybridise overnight at 70°C.  
Day 2 
Salt washes were carried out initially at 70°C and then at room temperature to remove 
excess probe and non-specific hybridisation. After blocking for 3-4 hours with blocking 
buffer, embryos are incubated with anti-DIG-AP-Fab fragments (1:10000) (Roche) 
overnight at 4°C with agitation.  
Day 3 
Embryos were washed multiple times for 15-20 minutes in PBST to remove any 
unbound antibody before washing in staining buffer and incubating in staining solution 
containing NBT/BCIP (Sigma). Staining was monitored periodically using a dissecting 
microscope. After stopping the staining reaction with PBST 1mM EDTA, embryos were 
fixed with 4% PFA for 30 minutes at room temperature before conducting a MeOH 
series. Embryos were washed with 30% then 60% MeOH/PBS for 10 minutes before 
maintaining in 100% MeOH for up to 2 hours to remove excess non-specific staining. 
The MeOH series was then reversed and embryos washed twice with PBST for 5 
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minutes before washing with 50% glycerol. The embryos were then stored in 80% 
glycerol at room temperature in the dark. 
 
Stage Time (minutes)  
1-cell to 1 somite  0.5 
1-8 somites 1 
9-18 somites 3 
18-24 somites 10 
24 hours 15 
30 hours 22 
36-48 hours 30 
60 hours 40 
72 hours 50 
 
ISH probe synthesis 
Digoxigenin (DIG)-11-UTP (Roche) was used to create DIG-labelled antisense RNA 
probes for in situ hybridisation. The DNA templates for RNA ISH probes were produced 
predominantly using nested PCR; however the vasa probe was produced using a 
modified mini prep on transformed bacteria. Both protocols are described in further 
detail below. 
 
DNA template synthesis using a modified Mini Prep  
Vasa cDNA was provided by H.Knaut (NYU Medical Center and School of Medicine), as 
part of pBS+ cloning vector which conferred ampicillin resistance and contained 
surrounding M13 primer binding sites. The plasmid was transformed into NEB 10-beta 
competent E.Coli and left overnight. 
The next morning, bacterial cultures were transferred to 1.5mL Eppendorf tubes and 
centrifuged for 30 seconds at 14,000g. The resulting pellet was then treated with 
buffers from the Qiagen QIAprep Spin Miniprep Kit, using the following modified mini 
Table 2.21 Digestion times using 10mg/mL 
Pro-K 
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prep protocol. 200µl P1 buffer was added, to re-suspend the pellet, on ice. 200 µl P2 
buffer was then added and the Eppendorf inverted multiple times then left at room 
temperature for 5 minutes to lyse the cells. 200µl neutralising P3 buffer was then 
added, the tube inverted to mix, then centrifuged for 3 minutes at 14,000g. 600µl 
Isopropanol was placed in a fresh Eppendorf tube, to which the supernatant from the 
centrifuged tube was added and then placed at -20°C for 30 minutes. The tube was 
removed from the freezer and centrifuged for 30 minutes at 16,000g at 4°C to pellet 
the DNA. The supernatant was removed and the pellet washed gently with 700µl PE 
buffer. 50µl TE buffer was added to the dry pellet, mixed, and then left at room 
temperature for 5 minutes. 
After adding PB buffer to the mini prep at 5x the volume of DNA, the DNA was 
transferred to a QIAprep spin column (QIAGEN) and centrifuged for 15 seconds at 
14,000g. The pellet was washed twice using 500µl PE buffer and centrifuged for 15 
seconds at 14,000g. A further centrifugation of the column, without buffer, was carried 
out for 3 minutes at 14,000g before allowing the column to dry for 5 minutes. DNA was 
then eluted by adding 50µl EB, incubating for 3 minutes at room temperature, and 
centrifuging the DNA into a fresh Eppendorf for 2 minutes at 14,000g. 
The amount of cleaned DNA was determined using a spectrophotometer, 20ng of 
which was then used in a PCR reaction to create the DNA template. The PCR reaction is 
shown in Table 2.22 and the thermal cycle used was the same as shown in Table 2.10. 
The primers used are displayed in Table 2.24. 
  
 
 
 
 
 
 
 
Component Volume (µL) Concentration  
10x PCR Buffer 10 1x 
10mM NTPs 1 100 µM 
Taq polymerase 2 5 units 
25µM Forward Primer 1 0.25 µM 
25µM Reverse Primer 1 0.25 µM 
20 ng DNA variable - 
MQH2O to 85 - 
Table 2.22 PCR 
reaction for making a 
DNA template from 
plasmid DNA 
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DNA template synthesis using Nested PCR  
Nested PCR uses two PCR reactions to create a DNA template containing a T3/T7 
binding site from whole transcriptome cDNA. The first reaction amplifies the relevant 
section of cDNA and the second adds a T3/T7 binding site and further amplifies the 
cDNA. The first PCR reaction used the protocol in Table 2.9 and thermal cycle in Table 
2.10 with one difference, the denaturation step during the 35x cycles, was 45 seconds 
instead of 30 seconds. 1µL of the PCR product was then run on a 1% agarose gel to 
ensure amplification. The second PCR reaction used the same forward primer but a 
different reverse primer which targets upstream of the initial reverse primer and 
contains a T3 or T7 binding site (Table 2.24). The second PCR reaction used the same 
thermal cycle as the first but a slightly different PCR mix (Table 2.23). The PCR product, 
the DNA template, was then cleaned and transcribed as described below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Component Volume (µL) Concentration  
10x PCR Buffer 10 1x 
10mM NTPs 1 100 µM 
Taq polymerase 2 5 units 
25µM Forward Primer 1 0.25 µM 
25µM Reverse Primer 1 0.25 µM 
1st PCR product 1 Variable 
MQH2O 84 - 
Table 2.23 Second nested PCR reaction  
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Cleaning the DNA template 
400µL nuclease-free water was added to an Amicon 50K centrifugal filter unit along 
with the DNA template. The filter unit was then centrifuged at 14000g for 5 minutes. 
This wash was repeated twice more, adding 500µL nuclease-free water each time. The 
filter unit was then inverted in a new nuclease-free Eppendorf and spun at 1000g for 2 
minutes. 1µL of the product was then run on a 1% agarose gel to check for a single 
product of the anticipated size. 
DIG-NTP-RNA transcription of the DNA template to create an ISH probe 
The transcription reaction was set up on ice to the specifications shown in Table 2.25 
and then incubated for 2 hours at 37°C. 18µL nuclease-free water and 2µL RNAse-free 
DNAse (Roche) was added to the transcription mix before a further incubation for 30 
minutes at 37°C. Aldrich-Sigma spin filters were centrifuged empty for 2 minutes at 
750g, after which they were transferred to new nuclease-free Eppendorfs that contain 
14µL RNA-later (Sigma). The transcription mix was then added to the filters and 
centrifuged for 4 minutes at 750g. The resulting RNA was stored at -20°C, after 
Probe Primer name Sequence (5’-3’) 
Claudin b Claudinb Forward tttgctttttcgtaccgtag 
Claudin b Claudinb Reverse gaggctgtttcaaacgtggt 
Claudin b Claudinb Rev T3 ggatccattaaccctcactaaagggaatgagcctcaatgtccaacaa 
CD9a CD9a Forward ctgaagcatctttcgctcaca 
CD9a CD9a Reverse gttggcttttatttgagccatgt 
CD9a CD9a Rev T3 ggatccattaaccctcactaaagggaatgagccatgtgcaccaatgt 
CD9b CD9b Forward cttcgccacaagtgcctgat 
CD9b CD9b Reverse acatgttactttctctccaaactcc 
CD9b CD9b Rev T3 ggatccattaaccctcactaaagggaagttactttctctccaaactcccat 
Vasa pBS forward M13 gtaaaacgcggccagt 
Vasa pBS reverse M13 ggaaacagctatgaccatg 
Table 2.24 Primers for making ISH probes  
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checking for successful transcription by running 1µL of the RNA and complimentary 
DNA template on an agarose gel. 
Component Volume (µL) Supplier 
DNA to 1 µg variable - 
Nuclease-free water to 30  - 
Transcription buffer 3  NEB 
NTP-DIG-RNA  3  Roche 
RNAsin 1.5  Promega 
T3/T7 RNA polymerase  1.5  NEB 
 
 
2.2.2.11 Imaging embryos 
Embryos in 80% glycerol were transferred to glass slides using a glass pipette. Cover 
slips, with a drop of 80% glycerol, were placed over the embryo and maneuvered to 
position the embryo in the desired orientation. Plasticine between the coverslip and 
glass slide was used to hold the coverslip in the appropriate position.  Embryos were 
then imaged at various magnifications using a microscope mounted camera and 
imaging software (Table 2.2). The lateral views of the whole embryo or embryo tail 
were imaged using 5X and 10X objectives. Images of single neuromasts or primordia 
were imaged using 20X or 63X objectives. 
 
 
 
 
 
 
 
 
Table 2.25 Transcription reaction  
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2.2.2.12 Using To-Pro-1 Iodine to stain neuromasts  
Dechorionated 51 hpf embryos were placed, 10 embryos per well, in a 12-well plate 
containing E3 with 1µM To-Pro-1 (Invitrogen) and tricaine. The embryos were 
incubated in the dark for 15 minutes at 28°C and fluorescent staining of neuromasts 
was visualised using the YFP settings (515/531) on a Zeiss Zoom microscope. The 
embryos were then washed twice with E3 before imaging the embryos, using the Zeiss 
Zoom microscope, at 52hpf. The embryos were then fixed in 4% PFA at 52hpf for a 
subsequent ISH experiment. 
 
2.2.2.13 Developmental assays 
Staging and developmental assays were carried out as described by Kimmel et al. 1995, 
on live embryos. Three assays were used, embryo length, head-tail angle and otic 
vesicle length, which describes the number of otic vesicles which could be fitted 
between the otic vesicle and the eye.  
 
2.2.2.14 Migration speed assay 
The offspring from the cross between claudinb:GFP+/-;CD9b +/-8 adult females and 
CD9b -8/-8 adult males were initially sorted for claudinb:GFP. These embryos were 
then incubated at 28° until reaching 26 or 59 hpf. At these timepoints, the embryos 
were imaged using the Zeiss Zoom microscope before being returned to the incubator 
until 31 or 59hpf. At the later time points, the same embryos were imaged again and 
the primordium migration speed calculated using the distance travelled by the 
primordium during the incubation time. 
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2.2.3 Analysis  
2.2.3.1 PGC assays 
PGCs were firstly stained using a vasa in situ hybridisation and then PGC migration was 
analysed using two assays. Firstly, the distance between the most anterior and 
posterior PGCs was measured following the body axis. Secondly, the number of ectopic 
PGCs was also assessed. Ectopic PGCs were defined as being outside of the mean 
measurement between the most anterior and posterior PGCs in control embryos 
(Figure 2.1). Measurements were taken using Image J software and statistically 
analysed using Excel and GraphPad Prism. 
 
 
 
 
 
 
 
 
 
 
2.2.3.2 pLLP assays 
Neuromasts and the pLLP were stained prior to analysis using a claudin b in situ 
hybridisation. Five different assays were then used to analyse lateral line structure and 
primordium migration as shown in Figure 2.2. The measurement of trunk length was 
taken from the posterior side of the otic placode to the tail tip, following the body axis. 
Similarly, the total body length was measured following the body axis and ends at the 
tail tip but starts at the tip of the nose. The distance between the 1st and last 
neuromasts and between the 1st and 2nd neuromasts was measured then reported as a 
percentage of the total body or trunk length. Migration of the primordium was 
Figure 2.1 Assessment of ectopic PGCs 
(a) and the distance between the most 
anterior and posterior PGCs (b).  
(a) PGCs outside the mean control 
group cluster measurement (bracket) 
were considered ectopic 
(arrowheads). The mean control group 
cluster measurement bracket was 
placed over the main cluster for each 
embryo. 
(b) the distance between the most 
anterior and posterior PGCs was 
measured following the body axis 
(dashed line).  
a) 
 
b) 
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measured from the posterior side of the otic placode to the posterior side of the 
primordium and reported as a percentage of trunk length. A percentage of trunk or 
total body length was used to eliminate the variability of embryo size and remove the 
possibility that a difference seen was solely due to embryo size. The same software 
was used to analyse the pLLP as was used for PGC migration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
c) d) 
Figure 2.2 pLLP Assay measurements 
Representative images showing the measuring process for the pLLP assays. 
The trunk length (a) and total body length (b) were measured to the tail tip, starting 
from either the ear (a) or the nose (b). The distance between the 1st and 2nd 
neuromasts (c) or 1st and last neuromasts (d) was measured from the centre of the 
1st neuromast to the centre of the 2nd or last neuromast. Primordium migration (e) 
was measured from the otic placode to posterior primordium edge. e I) shows the 
unmeasured image for comparison. 
e) e I) 
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2.2.3.3 Statistics 
All statistical analyses were carried out using GraphPad Prism version 6 and Microsoft 
Excel, on data obtained using Image J/Fiji.   
Normality of data distribution was assessed by conducting a D’Agostino-Pearson 
omnibus K2 normality test on the experimental residuals and creating a histogram of 
residuals. Looking at the residuals allows normality to be assessed over the whole 
experiment and not just individual conditions as residuals report the difference 
between individual measurements and the condition group mean. 
Normality tests are very sensitive to outlier results which can lead to an inaccurate 
normality result and so the histogram was created and used to check this result. The 
histogram allows the shape and distribution of the data to be assessed by eye and 
compared to Gaussian distribution. The D’Agostino-Pearson omnibus K2 normality test 
was chosen over the Shapiro-Wilke normality test as the Shapiro-Wilke test works best 
when every value in a data set is unique but is less efficient when multiple values are 
the same, whereas the D’Agostino-Pearson omnibus K2 normality test is more 
versatile.  
For normally distributed data, parametric tests such as an Un-paired T-test or ANOVA 
with Dunnet’s multiple comparisons test were used. The ANOVA post-hoc tests, Sidak 
and Holms-Sidak multiple comparisons tests were used when more power was 
required. For non-normally distributed data non-parametric tests were used, most 
often Mann-Whitney U test or Kruskal-Wallis with Dunn’s multiple comparisons test. 
 
Percentages 
Percentages were first assessed for normal distribution and if found to be normally 
distributed were treated the same as all other parametric data. Percentage data that 
was found to be not normally distributed was transformed using the log10 
transformation for continuous data and the arcsine transformation for non-continuous 
count data.  
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Pooling data 
Before pooling data from experimental repeats, data of the same condition, e.g. 
control data, were compared for significant differences. If no significant differences 
were found, the data was pooled but if significant differences were found the 
experiments were not pooled and trends between experiments were studied.  
n numbers 
n numbers for all experiments, except pLL assays where n= number of lateral lines 
analysed, refer to individual embryos unless otherwise stated.  
 
2.2.3.4 Graphs 
Graphs are presented showing the mean ±SEM unless otherwise stated. Significance 
was calculated using GraphPad Prism with p<0.05 and indicated graphically using the 
notations described in Table 2.26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symbol P value 
NS (non-significant) ≥0.05 
* 0.01 to 0.05 
** 0.001 to 0.01 
*** 0.0001 to 0.01 
**** <0.0001 
Table 2.26 Statistical significance symbols 
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Chapter 3: CD9b Morpholinos 
3.1 Introduction 
Morpholino oligonucleotides (MOs) were used to investigate the effect of cd9b 
knockdown on PGC and pLLP migration. Morpholinos are synthetic nucleic acid analogs 
that can bind to specific complementary RNA sequences using Watson-Crick base 
pairing (Summerton and Weller 1997, Nasevicius and Ekker 2000) (Figure 3.1). 
Although MOs can bind to complementary nucleic acids, the MO structure is different 
to that of RNA. The differences are advantageous as MOs gain resistance to nuclease 
digestion and inhibition of non-specific protein interactions (Figure 3.1) (Summerton 
and Weller 1997, Ekker 2000, Corey and Abrams 2001). Injection of morpholinos into 
the yolk of 1-4 cell stage embryos can cause efficient and specific gene knockdown 
through embryonic development up to 50hpf (Nasevicius and Ekker 2000, Ekker 2000, 
Corey and Abrams 2001, Draper et al. 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5’ 
CD9b i2e3 
CD9b RNA 
RNA MO 
a) 
Figure 3.1 Diagram of the structure and binding of CD9b morpholinos 
Representative morpholino structure and its interaction with RNA (a). Two MOs were 
designed to bind cd9b RNA (b) (cd9b RNA diagram from ensemble.org). CD9b MO1 
was designed to bind to the 5’ UTR of cd9b RNA, causing a cd9b knockdown by 
inhibiting the progression of the ribosomal initiation complex and therefore 
preventing translation. CD9b i2e3 is a splice-site morpholino which binds to pre-mRNA 
and prevents splicing, causing aberrant protein production.  
3’ 
b) 
CD9b MO1 
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MOs have been used to successfully phenocopy a number of previously studied 
mutants, for example no-tail (T,brachyury homolog a), nacre (microphthalmia-
associated transcription factor a) and ace (fgf8a). However, it has been noted that 
many morphants showed unexpected additional phenotypes such as gnarled tails, 
elevated neural cell death or overall degeneration, which are often caused by off-
target activation of p53 (Nasevicius and Ekker 2000, Ekker 2000, Araki and Brand 2001, 
Draper et al. 2001, Ekker and Larson 2001, Sumanas and Larson 2002, Robu et al. 2007, 
Bedell et al. 2011).  Off-target effects are a relatively common occurrence with 
morpholinos, so a number of controls were used to help verify that any phenotypes 
seen were CD9b-knockdown specific. Firstly, uninjected embryos were raised and 
stained under the same conditions as injected embryos to ensure that phenotypes 
were not due to abnormal embryo batches. Secondly, a 5bp mismatch control which 
has previously been used by Trikic et al., was injected at the highest CD9b MO 
concentration to confirm that the morpholino  structure was not causing any toxicity 
at the concentrations used (Trikić et al. 2011). Thirdly, two different MOs were 
designed to target cd9b, one as a translation-site blocker (CD9b MO1) and the other as 
a splice-site inhibitor (CD9b i2e3). These MOs were injected independently to ensure 
that they produce the same phenotype (Figure 3.1b). Lastly, embryos were injected 
with a range of CD9b MO concentrations to verify that the phenotypes were not only 
present in embryos showing general morphological defects. (Sumanas and Larson 
2002, Eisen and Smith 2008, Bedell et al. 2011) 
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3.2 Results 
3.2.1 MO toxicity 
Injection of morpholinos at high concentrations can have a toxic effect on embryonic 
development and is often fatal. To ensure that the concentrations of the translation 
blocking CD9b morpholino, CD9b MO1, would not be completely lethal, 1-cell stage 
embryos were injected with different volumes of CD9b MO1 at a single concentration. 
This produced a range of final concentrations within the batch of embryos. The survival 
of the embryos with different final concentrations of CD9b MO1 was then recorded 
over 96hpf (Figure 3.2). Uninjected, pierced and ringer’s buffer injected embryos 
showed high viability with ~80-90% of the embryos surviving over four days. Pierced 
embryos, where the needle was inserted into the yolk but no liquid injected, were 
used to check whether the micro-injection technique was causing decreased survival. 
Ringer’s buffer was injected at the largest drop size used for the CD9b MO1 injections 
to control for any effects caused by the amount of liquid injected. Embryos injected 
with CD9b MO1, to give a final concentration of 0.5-2.0µM inside the embryo, showed 
a dramatic decrease in survival with only ~30-50% of the embryos surviving over 96hpf 
(Figure 3.2d). Injection of lower concentrations of CD9b MO1 resulted in a higher 
percentage of morphants surviving, ~50-80%, with one concentration even showing 
the same level of viability as the controls (Figure 3.2a-c). Similar results were seen in 
multiple experimental repeats and surprisingly the ringer’s buffer injected embryos 
always showed similar survival rates to CD9b MO1 0.2µM injected embryos (Figure 
3.2b-c). 
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a) 
d) 
Figure 3.2 Embryos injected with the translation blocker CD9b MO1 show decreased 
viability compared to the uninjected controls. 
Viability curve showing the survival of embryos, injected with CD9b MO1 0.1- 0.5µM 
(a-c) or 0.5-2.0µM (d) over 96 hpf. n= minimum 100 (a,c), and 60 (b,d) embryos for 
each condition. Two-Way ANOVA with Dunnett’s multiple comparisons test on 
untransformed (a-c) or log
10 
transformed data (d). p = <0.05. All graphs show data 
from individual experiments.  
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Amongst the surviving embryos, it was noted that a proportion of the CD9b MO1 
injected embryos showed abnormal developmental phenotypes (Figure 3.3a). The 
extent to which abnormal development affects CD9b MO1 injected embryos was 
assessed by evaluating embryos daily, over four days, for general phenotypes ranging 
from wildtype to mild, moderate and severe abnormal phenotypes (Figure 3.3-3.5). 
Phenotypes seen included pericardial or yolk oedema, a kinked, curly or shorter tail, 
wrinkled or decreased fin fold area, and decreased overall development (Figure 3.3a). 
Embryos were categorised as mild, moderate or severe depending on the number and 
severity of any abnormal phenotypes they had developed. While the majority of 
uninjected, pierced and ringer’s buffer injected embryos displayed wildtype 
phenotypes, a considerable percentage of CD9b MO1 injected embryos displayed 
abnormal phenotypes (Figures 3.3b-e, 3.4a-d, 3.5a-d). In embryos with lower final 
concentrations of CD9b MO1 (0.1-0.5µM), approximately 20% of the embryos showed 
abnormal phenotypes at 24hpf rising to 30-50% of embryos by 96hpf. The majority of 
the abnormal embryos only showed mild phenotypes, although the severity appears to 
increase with morpholino concentration and time (Figure 3.3b-e). Similar results were 
seen in the experimental repeat, although the range of phenotypes was more evenly 
distributed than seen in Figures 3.3b-e (Figure 3.4).  
Injecting higher concentrations of CD9b MO1, to give final concentrations of 0.5-
2.0µM, appears to recapitulate this result with a similar percentage of embryos 
showing abnormal phenotypes over the 96 hours; however the phenotypes seen were 
more severe (Figure 3.5). Higher concentrations of CD9b MO1 induced noticeably 
more moderate and severe phenotypes than lower concentrations, as well as a 
decrease in embryos showing wildtype phenotypes (Figures 3.3 – 3.5). 
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a I) a II) a III) 
Figure 3.3 Embryos injected with 0.1-0.5µM CD9b MO1 show abnormal phenotypes 
more often than control embryos. 
Representative images of the fixed embryos showing wildtype (a), mild (a I), moderate 
(a II) and severe (a III) phenotypes observed in 48hpf CD9b MO1 injected embryos. 
Abnormal phenotypes seen include pericardial oedema, kinked or curly tail, shorter 
tail, wrinkled or decreased fin fold, large yolk and decreased overall development. The 
lack of pigmentation is due to bleaching of the embryos post-fixation. 
Representative graphs of gross phenotypes shown by CD9b MO1 injected embryos at 
24 (b), 48(c), 72 (d) and 96 (e) hpf, where mild embryos showed one or  two minor 
defects, moderate showed multiple abnormalities, often including delayed overall 
development and severe displayed the most extreme phenotypes. n= minimum 100 
embryos for each condition. This figure shows data from a single experiment, see 
Figure 3.4 for experimental repeat. 
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Figure 3.4. Ringer’s buffer and CD9b MO1 injected embryos show increased 
frequencies of abnormal phenotypes at 24 (a), 48(b), 72 (c) and 96 (d) hpf. 
 The ringer’s buffer injected control embryos do show a decreased percentage of 
wildtype phenotypes compared with the other controls, however this may be due 
to micro-injection inexperience during this experiment as the experimental repeat 
(Figure 3.3) displays no such decrease. Phenotypes were categorised as described 
in Figure 3.3. n=minimum 60 embryos per condition 
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While the higher concentrations of CD9b MO1 do cause increased lethality and 
abnormal phenotypes, a percentage of the injected embryos were viable and showed 
wildtype phenotypes, especially at 24 and 48hpf (Figure 3.5). It was decided that 
concentrations of 0.5, 1.0 and 2.0µM CD9b MO1 would be used initially to investigate 
the effect of CD9b knockdown on PGC and pLLP migration (Figures 3.6 and 3.9). This 
decision was made based on the fact that morpholinos act in a knockdown capacity 
and if no phenotypes were seen using the lower concentrations it could be due to 
incomplete knockdown of CD9b.  
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Figure 3.5 Embryos injected with 0.5-2.0µM CD9b  MO1 show abnormal phenotypes 
more often than control embryos. 
Graphs of general phenotypes shown by CD9b MO1 injected embryos at 24 (a), 
48(b), 72 (c) and 96 (d) hpf. n=minimum 60 per condition. Phenotypes were 
categorised as described in Figure 3.3. Data from a single experiment. 
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3.2.2 PGC migration in CD9b morphants 
The effect of CD9b knockdown on PGC migration was investigated by injecting 
embryos to give final concentrations of 0.5, 1.0 or 2.0µM CD9b MO1 at the 1-cell 
stage, raising these to 30hpf before fixing and staining for the PGCs (Figure 3.6a). An 
antisense DIG-labelled RNA in situ hybridisation probe against vasa RNA was produced 
and used to stain the PGCs as vasa RNA is sequestered by PGCs (Braat et al. 1999).  
As well as uninjected controls, ringer’s buffer was injected to show any effects caused 
by the injection technique and a mismatch MO, which should not bind specifically to 
RNA, was injected to negate any effects the morpholino structure may have. Though 
PGC migration finishes at ~24hpf, embryos were fixed at 30hpf to ensure that any PGC 
phenotypes seen were not just due to general developmental delay in the CD9b 
morphants (Doitsidou et al. 2002). Whilst staining with the vasa probe was poor, PGCs 
could still be distinguished in the trunk although often not in the head.  With this in 
mind, PGCs were cautiously identified and the distance between the most anterior and 
posterior PGC was measured following the body axis (Figure 3.6b). This measurement 
was taken to quantify the observed phenotype of more widely spaced PGCs in CD9b 
morphants when compared to uninjected or mismatch MO embryos. Interestingly, a 
mutant with a CXCR4b-internalisation defect has been previously shown to have 
abnormal PGC migration, with PGCs overshooting their target region, causing a spread 
out phenotype (Minina et al. 2007). In CD9b morphants a small but significant increase 
in the mean distance between the most anterior and posterior PGC was seen 
compared to the uninjected (Figure 3.6b).  
To determine whether this significance was due to single PGCs migrating incorrectly or 
a mass disruption of PGC migration, the number of ectopic PGCs was also analysed. 
Germ cells were defined as ectopic if they were outside the mean uninjected PGC 
cluster size. The mean cluster size was taken as the mean distance between the most 
anterior and posterior PGC in the uninjected embryos for that experimental repeat. 
There was no significant difference in the number of ectopic PGCs in CD9b morphants 
and though there is a clear trend of embryos with increased numbers of ectopic PGCs 
in the CD9b morphants, the majority of embryos still had 0 or 1 ectopic PGCs. Wildtype 
embryos and injected embryos showing non-specific or off-target effects often have 
single ectopic PGCs (Weidinger et al. 1999, Goudarzi et al. 2013) (Figure 3.6c). This lack 
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of ectopic PGCs in CD9b morphants suggests the increase in spread of PGCs seen in 
Figure 3.6b may be due to a few individual PGCs migrating incorrectly and not due to a 
general spreading out of the germ cells.  
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Figure 3.6 30hpf embryos injected with 0.5-2.0µM CD9b MO1 show increased 
distance between the most anterior and posterior PGCs.  
Representative images of uninjected (a), Mismatch MO 2.0µM (a I), Ringer’s buffer 
2.0µM (a II), CD9b MO1 0.5µM (a III), CD9b MO1 1.0µM (a IV) and CD9b MO1 2.0µM 
(a V).  A significant increase in the mean distance between the most anterior and 
posterior PGC (b) but no significant increase in the number of ectopic PGC in CD9b 
MO1 injected embryos (c) was seen using a Kruskal-Wallis ANOVA with Dunn’s 
multiple comparisons test. n= minimum 7. P= <0.05. Pooled data of two experiments.  
a) 
a II) 
a III) 
a IV) 
a V) 
b) c) 
a I) 
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Thus, in CD9b morphants a small number of PGCs were failing to migrate correctly 
more frequently than in control embryos. However, it has been observed that PGCs 
can be easily perturbed in embryos that are developmentally abnormal (private 
communication, D. Gilmour, Heidelberg University, EMBL). While the more 
phenotypically normal embryos were fixed for the in situ hybridisation, between the 
decreased survival rate and low percentage of embryos showing wildtype phenotypes, 
embryos with mild or occasionally moderate abnormal phenotypes had to be used 
(Figure 3.2d and 3.5a). To evaluate whether CD9b knock down or abnormal embryo 
development was causing the significant increase in distance between the most 
anterior and posterior PGC in CD9b morphants, the experiment was repeated using 
lower concentrations of CD9b MO1 (0.1-0.5µM) (Figure 3.7). While the CD9b 
morphants appeared to show a slight spreading out of the germ cells, it appeared that 
the uninjected and mismatch MO injected embryos also showed this phenotype 
(Figure 3.7a). There was no significant difference in the distance between the most 
anterior and posterior PGCs or in the number of ectopic PGCs, although a small 
increase trend can be seen in both (Figures 3.7b-c). It was surprising that no significant 
difference was found for embryos with 0.5µM CD9b MO1 as this morpholino 
concentration had previously produced a significant phenotype, however, this may be 
due to differences in the uninjected control between the experiments (Figures 3.6b 
and 3.7b).  
To be certain that CD9b knockdown was not causing a significant effect on PGC 
migration a splice-blocking morpholino, CD9b i2e3, was injected into 1-cell stage 
embryos and the PGC  positions analysed at 30hpf (Figure 3.8). Initially it appeared 
that a concentration of 0.5µM CD9b i2e3 caused a PGC spreading out phenotype in 
30hpf embryos (Figure 3.8b I, Figure 3.8a IV), however this significance was not seen in 
two further experiments (Figure 3.8b, b II). Whilst the distance between the most 
anterior and posterior PGC could not be pooled due to differences in the uninjected 
populations, the number of ectopic PGCs from each experiment could be. Consistent 
with previous results, no significant difference was found in the number of ectopic 
PGCs (Figure 3.8c).  
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a) 
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a III) 
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c) 
Figure 3.7 No significant difference in PGC migration was observed in embryos 
injected with 0.1-0.5µM CD9b MO1 compared to uninjected controls.  
Representative images of 30hpf uninjected (a), Mismatch MO 2.0µM (a I), CD9b MO1 
0.1µM (a II), CD9b MO1 0.2µM (a III) and CD9b MO1 0.5µM (a IV).  No significant 
increase in the mean distance between the most anterior and posterior PGC (b) or in 
the number of ectopic PGC in CD9b MO1 injected embryos (c) was seen. Kruskal-
Wallis ANOVA with Dunn’s multiple comparisons test. n= minimum 10. P= <0.05. Data 
from a single experiment. 
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Figure 3.8 No significant difference in PGC migration was observed in CD9b i2e3 
injected and uninjected control embryos . 
Representative images of vasa RNA in situ hybridisation on 30hpf AB embryos which 
are (a) Uninjected or injected with (a I) Mismatch control morpholino 0.5μM, (a II) 
CD9b i2e3 0.1μM, (a III) CD9b i2e3 0.2μM or (a IV) CD9b i2e3 0.5μM. No significant 
difference in the distance between the most anterior and posterior PGC (b) or in the 
number of ectopic PGC (c). Kruskal-Wallis test with Dunn’s multiple comparison test. 
n= minimum 6 (b II), 10 (b, bI) or 26 (c) per condition. b)- b II) are graphs  of 
individual experimental repeat whereas  (c) shows the pooled data of three 
experiments. p=<0.05 
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3.2.3 pLLP migration in CD9b morphants 
As well as looking at PGC migration, the posterior lateral line was assessed in CD9b 
morphants. The protocol used was similar to the method used to investigate PGC 
migration except embryos were allowed to develop to 52hpf, though the pLLP should 
finish migration by ~42hpf, and the in situ hybridisation used a claudin b RNA probe as 
claudin b is expressed in the neuromasts and posterior lateral line primordium (Kimmel 
et al. 1995, Gompel et al. 2001, Haas and Gilmour 2006). Upon injection of CD9b MO1 
to give final concentrations of 0.5-2.0µM, it was immediately clear that CD9b 
morphants had significantly fewer neuromasts deposited and that spacing between 
the neuromasts was irregular (Figure 3.9a -b). After analysing the lateral line, a 
significant decrease in the percentage of total body length between the 1st and last 
deposited neuromasts was also found (Figure 3.9c). This suggested two hypotheses: i) 
the pLLP is migrating normally and the embryos are just developmentally delayed or ii) 
the pLLP is migrating abnormally and depositing less neuromasts. If hypothesis i) were 
correct, it would be expected that the spacing between the 1st and 2nd neuromasts 
would remain the same as in uninjected embryos. While there is no significant 
difference in the mean spacing between the 1st and 2nd neuromasts, there is an 
obvious increase in the variability of spacing between these neuromasts in CD9b 
morphants (Figure 3.9d). This is also clear in the representative images in Figure 3.9a, 
in particular 3.9a II, where the second neuromast is almost at the end of the tail. This 
variability suggests that hypothesis ii) may be correct. 
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a) a I) 
a II) 
a III) 
b) 
c) d) 
Figure 3.9 Injection of 0.5-2.0µM CD9b MO1 significantly decreases the number of 
neuromasts deposited by the  pLLP and affects their spacing. 
Representative images of ISH using a probe for claudin b RNA on 52hpf AB embryos 
that are uninjected (a) or injected with 0.5μM CD9b MO1 (a I), 1.0μM CD9b MO1 (a 
II) or 2.0 µM CD9b MO1 (a III). Neuromasts indicated by black arrowheads.  
There is a significant decrease in the number of neuromasts deposited (b) and the 
percentage of total body length between the 1
st
 and last neuromast (c) but no 
change in the mean percentage of total body length between the 1
st
 and 2
nd
 
neuromasts (d). ANOVA with Dunnet’s multiple comparisons test. n= minimum 6. 
p=<0.05. Data from a single experiment. 
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Whilst the lateral line phenotype appears to be strong and specific, the experiments 
were repeated using lower final concentrations of CD9b MO1 (0.1-0.5µM) to see if the 
phenotype was still present in embryos that showed fewer developmental 
abnormalities. CD9b morphants showed the same significant phenotype at the lower 
final concentrations as seen in embryos with the higher final concentrations of CD9b 
MO1 (Figure 3.9, 3.10). This was observed in two individual experimental repeats 
which have been pooled for Figure 3.10. Lower MO1 concentrations caused decreased 
neuromasts deposition, irregular spacing between neuromasts and less spacing 
between the first and last neuromasts (Figure 3.10). Although the CD9b morphants in 
Figures 3.9 and 3.10 appear slim in comparison to their uninjected counterparts, it 
does not seem likely that the lateral line phenotype is a consequence of the embryos 
general morphology. A further repeat of this experiment was carried out and the same 
lateral line phenotype was seen, even though the embryos appeared to have 
noticeably more wildtype morphology than the CD9b morphants in Figures 3.9 and 
3.10 (Figure 3.12a). This repeat was not pooled with the rest of the lateral line data as 
the experiment was carried out later on in the project and the CD9b MOs had to be re-
optimised as the concentrations of the MOs had increased during storage. 
A second MO, CD9b i2e3, was used to confirm that the lateral line phenotypes seen 
were not off target effects of CD9b MO1. The same lower concentrations (0.1-0.5µM) 
were used and embryos were raised and stained using the same protocol. CD9b i2e3 
morphants appeared to develop less general abnormalities (Figure 3.11a) and yet still 
showed a significant decrease in the number of neuromasts deposited in both 
experimental repeats (Figure 3.11b - b I). Only embryos with 0.5µM CD9b i2e3 showed 
a slight decrease in the percentage of body length between the first and last 
neuromast, indicating that the lack of neuromasts was not due to delayed primordium 
migration (Figure 3.11b - c). There was also irregular spacing seen between the 1st and 
2nd neuromast in CD9b i2e3 morphants and embryos with 0.2µM CD9b i2e3 showed a 
significant increase in the mean spacing between these neuromasts, a phenotype 
which was replicated for multiple concentrations of CD9b MO1 and CD9b i2e3 in 
Figure 3.12e.  
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Figure 3.10 Injection of 0.1-0.5µM CD9b 
MO1 causes abnormal pLL structure. 
Representative images of ISH using a 
probe for claudin b RNA on 52hpf AB 
embryos that are uninjected (a) or injected 
with 0.5μM Mismatch MO (a I), 0.1μM 
CD9b MO1 (a II), 0.2μM CD9b MO1 (a III) 
or 0.5 µM CD9b MO1 (a IV). There is a 
significant decrease in the number of 
neuromasts deposited (b) and the 
percentage of total body length between 
the 1
st
 and last neuromast (c) but no 
change in the mean percentage of  total 
body length between the 1
st
 and 2
nd
 
neuromasts (d). ANOVA with Dunnett’s 
multiple comparisons test. n= minimum 9 
(c,d) and minimum 12 (b). p=<0.05. Pooled 
data from two experiments. 
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Figure 3.11 Injection of 0.1-0.5µM CD9b i2e3 causes abnormal pLL structure. 
Representative images of claudin b in situ hybridisation on 52hpf AB embryos that are 
(a) Uninjected or injected with (a I) 0.5μM Mismatch MO, (a II) 0.1μM CD9b i2e3,   (a 
III) 0.2μM CD9b i2e3 or (a IV) 0.5µM CD9b i2e3.  
a IV) 
a) 
a I) 
a II) 
a III) 
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b I) 
Figure 3.11 Injection of 0.1-0.5µM CD9b i2e3 causes abnormal pLL structure 
continued.  
A Kruskal-wallis test with Dunn’s multiple comparisons test shows a significant 
decrease in the number of neuromasts deposited (b- b I). After log
10 
 transforming the 
data, an ANOVA with Dunnett’s multiple comparisons test found no difference in the 
percentage of total body length between the 1
st
 and last neuromasts (c) and limited 
significance in the percentage of total body length between the 1
st
 and 2
nd
 neuromasts 
(d). n= minimum 10 (b, b I), minimum 19 (c,d). b and b I show data from individual 
experiments, c-d show pooled data of two experiments. p=<0.05 
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The data shown in Figure 3.12 is from experiments conducted further on in the project 
during the re-optimisation of the CD9b MO concentrations for an alternative 
experiment, to make sure these concentrations produced the same phenotypes as 
seen previously. Embryos born to the same set of adult fish were injected with either 
CD9b MO1 or CD9b i2e3 during a single experiment and so any differences seen 
between the morpholinos will not be due to environmental or genetic background 
differences. Embryos injected with either CD9b MO1 or CD9b i2e3, but not the 
mismatch or uninjected embryos, showed a significant decrease in neuromasts 
deposited (Figure 3.12a, c). In embryos injected with CD9b i2e3, there was no 
difference in the percentage of trunk length between the 1st and last neuromast or in 
the percentage of trunk length between the ear and the last neuromast/primordium 
(Figure 3.12b, d). This suggests that primordium migration was not stalled and the 
deposition of the 1st and last neuromasts were in the expected positions, however, 
there are fewer neuromasts deposited within this space (Figure 3.12b-d). 
For embryos injected with CD9b MO1, there is a decrease in the percentage of trunk 
length between the 1st and last neuromasts. This could either be due to the 
primordium not migrating as far in the CD9b MO1 morphants or the 1st neuromast 
being deposited in a more posterior position (Figure 3.12d). The additional assay, 
displaying the percentage of trunk length between the ear and the last 
neuromast/primordium, shows that the primordium has migrated as far in embryos 
with 0.1µM CD9b MO1 as in uninjected embryos, suggesting the latter may be the case 
for these embryos.  Embryos with 0.2 or 0.4 µM CD9b MO1 show a decrease in the 
percentage of trunk length between the ear and primordium as well as a decrease in 
the percentage of trunk length between the 1st and last neuromasts. However, there is 
a larger decrease in the percentage of trunk length between the 1st and last 
neuromasts. This suggests that the 1st neuromast may have been deposited in a more 
posterior position and the primordium is stalling prematurely or migrating more slowly 
(Figure 3.12b, d). Irregular spacing was seen in all of the CD9b morphants with an 
obvious variation or increase in the percentage of trunk between the 1st and 2nd 
neuromasts (Figure 3.12e).  
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a) a I) 
a IV) 
a III) 
a II) a V) 
a VI) 
Figure 3.12 Injection of either  CD9b MO1 or  CD9b i2e3 causes abnormal pLL 
structure. 
Representative images of uninjected (a) embryos and embryos injected with 0.5µM 
Mismatch MO (a I), 0.1µM CD9b MO1 (a II), 0.2µM CD9b MO1 (a III), 0.4µM CD9b 
MO1 (a IV), 0.1µM CD9b i2e3 (a V), 0.2µM CD9b i2e3 (a VI) or 0.4µM CD9b i2e3 (a 
VII), stained for claudin b. 
a VII) 
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b) c) 
d) e) 
Figure 3.12 continued. Injection of either CD9b MO1  or CD9b i2e3  causes abnormal 
pLL structure.  
The percentage of trunk length between the ear and last neuromast/primordium 
remains the same in most of the CD9b morphants (b), however the number of 
neuromasts deposited in this space is significantly decreased (c). The percentage of 
trunk  length between the 1
st
 and last deposited neuromast is decreased in CD9b 
MO1 morphants but not CD9b i2e3 morphants (d) and the percentage of trunk 
length  between the 1
st
 and 2
nd
 neuromasts is highly variable in CD9b morphants but  
the mean is often significantly larger (e).  
The percentage of trunk length, defined as between the ear and tail tip, was used as 
the experiment was carried out after TALEN work where this measurement had been 
preferable. ANOVA with Dunnett’s multiple comparisons test was used for all data 
sets, although b,d and e were log
10
 transformed beforehand. n= minimum 12 lateral 
lines analysed per condition. p=<0.05. Data from a single experiment. 
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3.3 Discussion 
In this chapter morpholinos against cd9b were used to assess whether cd9b 
knockdown affected the CXCR4b-mediated processes of PGC and pLLP migration. 
While initial results suggested that CD9b may play a role in PGC migration, this 
significance was only seen with one morpholino, CD9b MO1, when injected at higher 
volumes and was seen in the only experiments where the controls showed no 
abnormally migrated PGCs (Figures 3.6-3.8). The lack of change in the number of 
ectopic PGCs seen in CD9b morphants supports the hypothesis that the significance 
seen in Figure 3.6b is due to single PGCs migrating abnormally and not due to a mass 
disruption of PGC migration. Together these results suggest that CD9b does not play a 
significant role in PGC migration.  
It appears more likely that CD9b plays a significant role in correct neuromast 
deposition by the pLLP. In CD9b morphants the pLL, while able to complete migration, 
always displayed decreased numbers of neuromasts in CD9b morphants. The 
neuromasts were consistently deposited in an irregular fashion, as displayed by the 
wide range of percentages of total body/trunk length between the 1st and 2nd 
neuromasts, often with an average overall increase in the spacing between these 
neuromasts. Many CD9b MO1 injected embryos also showed a decrease in the 
percentage of trunk between the first and last neuromasts, as well as a decrease in the 
percentage of trunk migrated by the primordium, suggesting that the pLLP has delayed 
or slower migration. This phenotype is only observed once in 0.5 µM CD9b i2e3 
injected embryos (Figure 3.11) which are also the only CD9b i2e3 morphants to show 
general morphological abnormalities. This decrease in the percentage of trunk 
between the first and last neuromasts is not repeated in 0.5 µM CD9b i2e3 injected 
embryos in Figure 3.12 that do not show general abnormalities.  One potential 
explanation for this difference could be that the delayed migration is an off-target 
effect of the general abnormalities seen in CD9b MO1 morphants and the morphants 
with 0.5µM CD9b i2e3 in Figure 3.11. The difference in the mechanisms of CD9b MO1 
and CD9b i2e3 action could be a second explanation for this phenotype difference. As 
a translation-blocker, CD9b MO1 prevents translation of both maternal and zygotic 
transcripts (Nasevicius and Ekker 2000). In contrast, CD9b i2e3 blocks a splice acceptor 
site which would be expected to cause a loss of function through exon deletion 
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(Draper et al. 2001, Morcos 2007). As maternal transcripts are already spliced, CD9b 
i2e3 only causes knockdown of zygotic transcripts. This could suggest that the 
decrease in the percentage of trunk between the first and last neuromasts and the 
decrease in the percentage of trunk migrated by the primordium seen in CD9b MO1 
could be due to loss of maternal cd9b RNA. However, the significant decrease in the 
percentage of trunk between the first and last neuromasts seen in CD9b i2e3 injected 
embryos in Figure 3.11 does not support this hypothesis.  Lastly, the efficiency of CD9b 
i2e3 knockdown of cd9b could also explain the different phenotypes. It would be 
expected that CD9b i2e3 would result in the deletion of exon 3, causing a loss of 
protein function. However, it is possible that either a partially or differentially 
functional protein was produced or a cryptic splice site was activated (Draper et al. 
2001, Morcos 2007). Either of these results would decrease the efficiency of CD9b 
knockdown and could explain the decreased severity in phenotypes seen with CD9b 
i2e3 compared to CD9b MO1. It appears unlikely; however, that a cryptic splice site 
would be activated as CD9b i2e3 is a splice acceptor site blocker not a splice donor site 
blocker. Splice acceptor sites are more complicated than splice donor sites and must 
be adjacent to a polypyrimidine tract therefore CD9b i2e3 is less likely to have revealed 
a cryptic splice acceptor site (Morcos 2007). This hypothesis could be investigated 
further by conducting RT-PCR on CD9b i2e3 injected embryos to characterise the 
outcomes of blocking the intron 2 – exon 3 splice site. Not only would this show 
whether exon 3 was deleted or whether a cryptic splice site was activated but it would 
also show the efficiency of the splice blocking due to the ratios of the different PCR 
products that the alternative splicing events would create.  
The decreased numbers of neuromasts and irregular spacing between them do appear 
to be specific to cd9b deficiency. These neuromast phenotypes were consistently seen 
in CD9b morphants, in embryos with and without general morphological 
abnormalities. They were reproduced in multiple experimental repeats and seen using 
both CD9b MO1 and CD9b i2e3 morpholinos which  bind to different sequences in 
cd9b. The lack of disrupted neuromast deposition in the uninjected, ringer’s buffer 
injected or mismatch MO injected embryos indicate that the phenotype is not due to 
the embryos used, injection technique or morpholino structure toxicity and so 
supports the hypothesis that these phenotypes are specific.  
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This recapitulates and expands on the work by Gallardo et al., 2010 which suggested a 
role for CD9b in the lateral line development. 
The specificity of the MO phenotypes could be investigated further using a number of 
different experiments, such as mRNA rescue or co-injection with a p53 MO. RT-PCR 
could also be used to assess the specificity of the phenotypes seen. The efficiency of 
CD9b i2e3 splice-blocking activity at a range of concentrations could be analysed by 
looking at the ratio of the normal to abnormally spliced PCR products. These 
efficiencies could then be compared to the general abnormalities and the pLL 
phenotypes seen in CD9b i2e3 morphants. If concentrations are found where the 
splice-blocking efficiency is high and the pLL phenotypes are observed but the general 
abnormalities are not, this would support the hypothesis that the pLL phenotypes are 
specific to cd9b knockdown. However, recapitulation of a MO phenotype in a mutant 
line is currently the gold standard. Therefore, I decided to create CD9b knock-out 
mutant lines to see if the phenotypes could be reproduced.  
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Chapter 4: CD9b deletion mutants 
4.1 Introduction 
TALENs (transcription activator like effector nucleases) are comprised of two different 
domains, a customisable DNA binding domain and a nuclease domain (Figure 4.1) 
(Miller et al. 2011, Zhang et al. 2011). The DNA binding domain is made from a 
modified TALE, Transcription Activator Like Effector protein, from the plant pathogen 
Xanthomonas (Boch et al. 2009, Miller et al. 2011, Zhang et al. 2011) . The DNA 
binding ability of TALE proteins comes from a central repeat domain where 
every repeat contains the same 34 amino acids, except for two hypervariable 
amino acids at positions 12/13. Each repeat corresponds to a single base in the 
target DNA and amino acids at positions 12/13 dictate which base the repeat 
binds to, for example a repeat with the amino acids N I at positions 12/13 will 
bind an adenine base (Figure 4.1) (Boch et al. 2009). Different combinations of 
these repeats allow sequence specific DNA binding domains to be created.  
After the discovery of the TALE repeat- DNA base code, Miller et al., 2011 
created TALENs. They found that modified TALEs could be coupled to the 
catalytic domain of the endonuclease FokI, which activates to create double 
strand DNA breaks (DSBs) upon dimerization. Two sequence specific TALE 
binding domains, each coupled to a FokI nuclease domain allowed Miller et al., 
2011 to specifically target and induce mutations in two human genes, NTF3 
and CCR5 (Figure 4.1). Mutations were induced through the error -prone 
endogenous repair of the TALEN-induced DSBs by non-homologous end joining 
(NHEJ). 
TALENs have since been used successfully in zebrafish embryos to produce 
mutations in many target genes (Huang et al. 2011, Sander et al. 2011, Dahlem 
et al. 2012, Moore et al. 2012, Cade et al. 2012) . Embryos injected with varying 
amounts of TALENs, from 4-600pg, showed higher mutation frequencies, lower 
toxicity rates and higher specificity than Zinc Finger Nucleases, which had been 
used previously to induce targeted mutations. The mutations induced were 
commonly small insertions and/or deletions (indels) of approximately 10bps, 
although mutations of a few hundred base pairs were also reported. These 
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indels often caused frameshifts and nonsense stop codons. (Huang et al. 2011, 
Sander et al. 2011, Dahlem et al. 2012, Moore et al. 2012, Cade et al. 2012)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two CD9b TALENs were designed by ZgeneBio using the program ‘ TEL Effector 
Nucleotide Targeter 2.0’. The TALENs were designed to target Exon 1, with TALEN 1 
predicted to cut in the 1st transmembrane domain and TALEN 2 in the EC1 (Figure 
4.1b). With these TALENs, pLLP and PGC migration was analysed in CD9b mosaic 
embryos as well as in CD9b homozygous mutants, which were created as described by 
Figure 4.2.  
b) 
Figure 4.1 Diagram of cd9b TALEN structure (a) and their predicted cut sites in CD9b 
(b).   
The cut sites in (b) are represented by amino acid number, their one letter code and 
nucleic acid sequence, from left to right respectively. The numbers on the diagram of 
CD9b in (b) show the amino acid number at that part of the structure. The di-
sulphide bonds between the conserved CCG motif and conserved cysteines are 
indicated by the dashed lines. EC1/2= Extracellular domain 1/2, aa= amino acid 
  
a) 
5’ 
3’ 5’ 
3’ 
FokI cut site 
N 
I 
N
G 
N
N 
H 
D 
5’ 3’ A    T    G    C 
gDNA 
DNA binding domain  FokI  
TALEN 2 cut site 
42    K     AAA 
41    T     ACT 
40    K     AAA 
39    A     GCT 
38    D    GAT 
37    F     TTC 
TALEN 1 cut site 
17      F     TTC    
16      I     ATC 
15      F     TTT 
14      L     CTC 
13      L     TTG 
aa   12 
       13 
gDNA 
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ID F0s X 
ID F0s by Mbo II restriction 
digest, or genotyping, of 
offspring looking for 
heterozygous cd9b mutants 
ID F1s 
WT Mosaic 
ID heterozygous F1s by 
genotyping fin clips 
In-cross F1s X 
ID homozygous F2s by 
genotyping fin clips 
Inject TALEN  
Figure 4.2 Diagram showing the production of homozygous mutants from TALEN 
injected embryos. 
Wildtype fish are shown as a black outline, heterozygous mutants display a 
coloured outline, different colours indicate different mutant alleles, and 
homozygous mutants are colour filled. Fish were raised for roughly 3 months before 
fin clips were taken or the fish were first crossed. ID = identify 
F0s are mosaic fish that have mutations in their germ cells and so have offspring 
that carry a mutation. 
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4.2 Results 
4.2.1 Assessment of TALEN toxicity 
Viability curves looking at the survival of embryos injected with a range of TALEN 
amounts, were initially created to find out how much TALEN mRNA to inject to create 
mosaic adults (Figures 4.3a,4.4a). Embryos injected with 400pg TALEN 1 showed 
decreased embryo survival over the first 24hpf. However, injection of 50 or 200pg of 
TALEN 1 did not induce decreased embryo survival compared to uninjected embryos 
(Figure 4.3a).  
The general morphology of the injected embryos was also assessed over the same time 
period as the viability curves. Again it appeared that only the embryos injected with 
400pg TALEN 1 showed any difference to the uninjected embryos, with an increased 
percentage of embryos displaying severe phenotypes at 24hpf (Figure 4.3b). 
Phenotypes seen in TALEN injected embryos included delayed development, smaller 
heads and kinked tails. Any phenotypes seen in TALEN 1 injected embryos appeared to 
be rescued over the next 48 hours, with the majority of embryos showing wildtype 
phenotype by 48 and 72hpf (Figures 4.3c,d). It was decided that using 400pg TALEN 1 
would be investigated further as the decrease in survival suggests that the TALEN is 
active but there is still a ~25% survival rate and the embryos appear to recover from 
any initial developmental delay (Figure 4.3). 
Survival and general phenotypes were also assessed in TALEN 2 injected embryos 
(Figure 4.4). Interestingly, TALEN 2 appeared more toxic than TALEN 1 with both 200 
and 400pg TALEN 2 inducing decreased survival (Figure 4.4a). This was also reflected in 
the general phenotypes seen, as both 200 and 400pg TALEN 2 caused an increase in 
the percentage of embryos with mild, moderate and severe phenotypes in comparison 
to uninjected embryos. Unlike TALEN 1 injected embryos, TALEN 2 injected embryos 
did not appear to recover as efficiently from the abnormal phenotypes seen at 24hpf 
with a percentage of TALEN 2 injected embryos still showing moderate and severe 
phenotypes at 72hpf (Figure 4.4b-d).  
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Figure 4.3 Embryos injected with 400pg TALEN 1 show decreased viability and an 
increase in abnormal phenotypes at 24hpf.   
Viability curve showing survival of TALEN 1 injected embryos over 72hpf (a). General 
abnormal phenotypes seen in TALEN 1 injected embryos at 24 (a), 48 (b) and 72 (c) 
hpf. Phenotypes defined as described in Chapter 3, Figure 3.3.  n= minimum 50 per 
condition. Data from single experiment. 
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Figure 4.4 Embryos injected with 200pg or 400pg of TALEN 2 show decreased 
viability and an increase in abnormal phenotypes oer 72hpf. 
 
Viability curve showing survival of TALEN 2 injected embryos over 72hpf (a). General 
abnormal phenotypes seen in TALEN 2 injected embryos at 24 (a), 48 (b) and 72 (c) 
hpf. Phenotypes defined as described in Chapter 3, Figure 3.3.  n= minimum 39 per 
condition. Data from single experiment. 
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4.2.2 Creating cd9b mosaic zebrafish 
As 400pg of TALEN 1 and TALEN 2 had a ~25% survival rate and showed predominantly 
wildtype embryos by 72hpf, embryos injected with TALEN 1 or TALEN 2 were 
genotyped at 72hpf to assess whether the TALENs were inducing mosaicism. Whilst 
the uninjected embryos showed homozygous wildtype sequence around the TALEN 1 
cut site, embryos injected with 400pg TALEN 1 showed clear mosaicism around the 
TALEN cut site (Figure 4.5).  
 
 
 
 
 
 
 
 
TALEN 2 injected embryos did not show any mosaicism around the TALEN cut site and 
appeared no different to the uninjected embryos (Figure 4.6). None of the 14 TALEN 2 
injected embryos assessed showed mosaicism, suggesting that the lack of mosaicism is 
not due to selecting an unaffected embryo by chance.  
 
 
 
 
 
 
 
a) 
b) 
Figure 4.5 Injection of 400pg cd9b TALEN 1 at the 1-cell stage causes mosaicism in the 
genomic sequence of cd9b in 72hpf embryos. 
Uninjected (a) embryos show the wild-type cd9b sequence whereas TALEN 1 (b) 
injected embryos show large amounts of mosaicism around the cut site (dashed box).  
n= 4 per genotype. Data from a single experiment. 
a) 
b) 
Figure 4.6 Injection of 400pg cd9b TALEN 2 at the 1-cell stagedoes not cause 
mosaicism in the genomic sequence of cd9b in 72hpf embryos. 
Uninjected (a) and TALEN 2 injected (b) embryos show the wild-type cd9b sequence 
around the cut site (dashed box), suggesting that TALEN 2 is not inducing double-
strand breaks in cd9b.  n= 8 (a), 14 (b). Data from two experiments. 
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As TALEN 2 does not appear to causing mosaicism in the predicted site, 400pg TALEN 1 
was injected into 1-cell stage AB embryos to create mosaic adult F0s. While the 
embryos were being raised to adulthood, which takes roughly 3 months, mosaic TALEN 
injected embryos were examined for PGC and pLLP phenotypes. Though a PGC 
phenotype was not expected, due to the absence of a phenotype in CD9b morphants, 
PGC migration was assessed in TALEN 1 injected embryos. As expected, TALEN 1 
injected embryos did not show any PGC phenotypes, neither the distance between the 
most anterior and posterior PGCs or the number of ectopic PGCs were significantly 
different (Figure 4.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Injection of cd9b TALEN 1  does not cause abnormal PGC migration. 
Vasa in situ hybridisation on 30 hpf AB embryos (a) uninjected or injected with (a I) 
200pg cd9b TALEN 1, (a II) 400pg cd9b TALEN 1. No significant difference in the 
distance between most anterior and posterior PGC in cd9b TALEN 1 injected embryos 
(b) or in the number of ectopic PGC (c), was seen using a Kruskal-Wallis with Dunn’s 
multiple comparisons test. n=10 per condition. p=<0.05. Data from a single 
experiment. 
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PGC migration was also assessed in TALEN 2 injected embryos. As TALEN 2 does not 
appear to cause mosaicism at its cut site, it was thought that TALEN 2 injection could 
be used as a control for the TALEN construct. Surprisingly, TALEN 2 injected embryos 
show a small but significant increase in both the distance between the most anterior 
and posterior PGCs and the number of ectopic PGCs (Figure 4.8). While it could be that 
TALEN 2 is cutting elsewhere in cd9b or a different gene, it should be noted that TALEN 
2 injection caused a large percentage of the embryos to show general abnormal 
phenotypes and a PGC phenotype was only seen in CD9b morphants which also 
showed abnormal morphologies (Figure 4.4 and Chapter 3, Figures 3.4-3.5). This could 
support the hypothesis that the significance seen here is not caused by CD9b 
knockdown but is rather a consequence of the general abnormal phenotypes induced 
by TALEN 2 toxicity.  
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Figure 4.8  Injection of cd9b TALEN 2  does cause abnormal PGC migration. 
Vasa in situ hybridisation on 30 hpf embryos (a) uninjected or injected with (a I) 
200pg cd9b TALEN 2, (a II) 400pg cd9b TALEN 2. A small significant difference can be 
seen in the distance between the most anterior and posterior PGCs (b) and the 
number of ectopic PGCs (c) using ANOVA with Dunnett’s multiple comparisons test. 
n= minimum 10 per condition. p=<0.05. Data from a single experiment. 
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The effect of TALEN 1 injection on lateral line migration was also analysed (Figure 4.9). 
A decrease in the number of neuromasts and irregular spacing was expected as this 
would replicate the phenotypes seen in CD9b morphants. A significant decrease in the 
number of neuromasts was seen in embryos injected with 400pg TALEN 1, however, 
the mean number of neuromasts in these embryos is still within the normal range of 7-
8 neuromasts deposited in wildtype embryos (Gompel et al. 2001) (Figure 4.9b). A 
decrease in the percentage of total body length between the 1st and last neuromasts 
was also seen with 400pg TALEN 1, which could suggest that the primordium had not 
completed migration or that  the 1st neuromast was deposited in a slightly more 
posterior position to normal (Figure 4.9c). The increase in variation in the percentage 
of total body length between the 1st and 2nd neuromasts may support the latter 
hypothesis, as it suggests irregular neuromast spacing in TALEN 1 injected embryos 
(Figure 4.9d). The observations that TALEN 1 injected embryos do not show any 
obvious developmental delay and their recovery from any general abnormal 
phenotypes by 48hpf also supports this hypothesis (Figures 4.3c, 4.9a).  
Embryos injected with TALEN 2 were also assessed for lateral line phenotypes (Figure 
4. 10). No significant difference in the number of deposited neuromasts or in the 
percentage of total body length between the 1st and 2nd neuromasts was seen but 
there was a significant decrease in the percentage of total body length between the 1st 
and last neuromasts in embryos injected with 400pg TALEN 2 (Figure 4.10b-d). 
Embryos injected with 400pg TALEN 2 had primordia that were noticeably delayed and 
showed general morphological defects, which could explain the decrease in the 
percentage of total body length between the 1st and last neuromasts. 
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Figure 4.9 Injection of 400pg cd9b TALEN 
1 causes a small but significant effect on 
thepLL structure. claudin b in situ 
hybridisation on 52hpf AB embryos 
uninjected (a) or injected with 200pg 
cd9b TALEN 1 (a I), 400pg cd9b TALEN 1 
(a II).  
A small but significant decrease in the 
number of neuromasts deposited (b) and 
the percentage of total body length 
between the 1
st
 and last neuromast (c) in 
embryos injected with 400pg TALEN 1. 
While there is no significant difference in 
the mean spacing between the 1
st
 and 
2
nd
 neuromast (d), there is a significant 
difference in the standard deviation 
between the groups, indicating irregular 
spacing as seen with CD9b MOs 
(Bartlett’s test, p = 0.0050). n= 10 per 
column, ANOVA with Dunnett’s multiple 
comparisons test. p=<0.05. Data from 
single experiment. 
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Figure 4.10  Injection of 200pg or 400pg 
cd9b TALEN 2 does not affect pLL 
structure. 
claudin b in situ hybridisation on 52hpf 
embryos (a) uninjected or injected with 
(a I) 200pg cd9b TALEN 2, (a II)400pg 
cd9b TALEN 2. A significant difference 
can be seen in the percentage of total 
body length between the 1
st
 and last 
neuromast (c) but not in the percentage 
of total body length between the 1
st
 and 
2
nd
 neuromasts (d) or the number of 
neuromasts (b). ANOVA with Dunnett’s 
multiple comparisons test. n= minimum 
6 per column. p=<0.05. Data from a 
single experiment. 
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4.2.3 Creating CD9b homozygous mutants 
After raising the TALEN 1 injected embryos to maturity, F0s that successfully 
transmitted CD9b mutations through the germ line were identified (Figure 4.2). These 
F0s were out-crossed with AB fish and the resulting F1 offspring were raised. The 
offspring contained a mixture of wildtype and CD9b heterozygous mutants, depending 
on whether the germ cell had originally been mutated in the mosaic parent. 
Heterozygous F1s were identified by genotyping fin clips and five mutant alleles were 
identified (Figure 4.11). Four of these alleles induce nonsense stop codons and result in 
a frameshift. Initially, F1s were randomly in-crossed to create compound 
heterozygotes. These embryos showed no PGC phenotype and only a slight pLLP 
phenotype where there was a small but significant increase in the percentage of trunk 
length between the 1st and 2nd neuromasts (Figures 4.12, 4.13). The percentage of 
trunk length was used instead of the percentage body as the embryonic heads were 
removed prior to ISH for genotyping.  
 
 
 
 
 
 
 
 
 
 
 
 
 
CD9b  
CD9b -8bp,  42_49delCTTTATCT 
CD9b -1bp(T),  45delT  
CD9b -1bp(A),  46delA  
CD9b -4bp, 44_48delTTAT  
CD9b -12bp, 39_50delGCTCTTTATCTT 
Figure 4.11 Most cd9b deletion alleles identified were predicted to cause frameshifts 
and nonsense stop codons. Predicted open reading frames (red), potential start sites 
(blue) and stop codons (bold) for the 5 alleles found in cd9b heterozygous mutants 
(F1s) are shown. Nucleotide mutations are given after their assigned name. Predictions 
made using ExPASy (Artimo et al. 2012). 
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Figure 4.12. CD9b compound heterozygotes (-1 T/-8) appear to have no PGC 
migration defects. 
vasa in situ hybridisation on 30hpf  CD9b -1/-8 (a I) or wt sibling (a) embryos. No 
significant difference in the distance between the most anterior and posterior PGCs 
(b) or in the number of ectopic PGCs (c) is seen in CD9b compound heterozygotes. n= 
minimum 6 per condition. Unpaired T test (a) and Mann-Whitney U test (b). p=<0.05 
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Figure 4.13.The  pLL in CD9b compound heterozygotes shows slight  neuromast 
spacing differences. 
claudin b in situ hybridisation on 52hpf CD9b -1T/-8 (a I) or wt siblings (a). No 
significant difference was found in the number of neuromasts deposited (b) or the 
percentage of trunk length between 1
st
 and last neuromast (d and e). However, a small 
significant increase in the percentage of trunk length between the 1
st
 and 2
nd
 
neuromasts (c) was seen. Unpaired T test, p=<0.05. n = minimum 6 per genotype. (d) 
and (e) are two experiments that could not be pooled due to significantly different 
controls. (b) and (c) show the pooled data of two experiments. 
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To create a CD9b homozygous mutant line with a single mutant allele, F1s with the 
42_49delCTTTATCT mutation, hereafter called CD9b -8, were in-crossed and the 
resulting offspring were raised to adulthood (Figure 4.2). This allele was used as it had 
the largest deletion and caused the earliest nonsense stop codon (Figure 4.11). 
Homozygous CD9b -8/-8 adults were identified by genotyping fin clips taken from the 
adult offspring from the F1 in-cross. CD9b knockout was then confirmed in the 
homozygous mutant line using a cd9b ISH on 36hpf AB and CD9b -8/-8 embryos (Figure 
4.14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) b) 
a I) b I) 
Figure 4.14 CD9b -8/-8 embryos show dramatically reduced cd9b RNA compared to 
AB embryos. 
Representative images of a cd9b in situ hybridisation  on 36hpf AB (a) and CD9b -8/-
8 homozygous embryos (b). a I) and b I) show the staining in the posterior lateral 
line primordium. Scale bar 50µM (a I) and 100µM (b I). n= minimum 3 imaged but 
10 observed per genotype. Images and observations from a single experiment. 
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Figure 4.15 The expected percentages of 
wt siblings, heterozygous and 
homozygous mutant embryos were 
observed in three heterozygous F1 in-
crosses. Embryos were fixed at 30 or 
52hpf before genotyping for use in 
further experiments. Mean genotype 
ratios from three experimental repeats. 
n= minimum 28 embryos per experiment 
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4.2.4 CD9b homozygous mutants 
While the CD9b -8/-8 homozygous mutant line was being raised, CD9b +/-8 adults 
were in-crossed to generate CD9b -8/-8 progeny. Embryos from these in-crosses were 
fixed at either 30 or 52hpf, then genotyped. The genotype ratios were assessed to 
investigate the early viability of CD9b homozygous mutants and to find homozygous 
mutants for later experiments. The expected ratio of wt, heterozygous and 
homozygous mutants was seen each time, showing that the CD9b homozygous 
mutants are viable during the first 50 hours of embryonic development (Figure 4.15).  
4.2.4.1 PGC migration in CD9b homozygous mutants 
While no PGC phenotype is expected in CD9b mutants, due to the majority of CD9b 
morphants not showing a significant phenotype, PGC migration was analysed to 
ensure that CD9b deficiency does not cause a PGC phenotype. As expected, no 
significant difference in the distance between the most anterior and posterior PGC, 
was found (Figure 4.16). 
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Figure 4.16 PGC migration is not affected in CD9b homozygous mutants.  
vasa ISH on 30hpf WT (a) and CD9b -8/-8 (a I) embryos. There is no significant 
difference in the distance between the most anterior and posterior PGC (b) as shown 
by a Mann-Whitney U test. n= minimum 13. p=<0.05. Pooled data from two 
experiments. 
a ) a I) 
b) 
117 
 
4.2.4.2 pLL phenotypes in CD9b homozygous mutants 
Due to the phenotypes seen in CD9b morphants, it was expected that a lateral line 
phenotype would be seen in CD9b mutants with a decreased number of neuromasts 
deposited and irregular spacing between them. Initially, it appeared that the opposite 
phenotype might be occurring, with an additional neuromast being deposited (Figure 
4.17b). A closer inspection of the additional structure seen in CD9b -8/-8 embryos 
suggested that the structure may actually be a secondary primordium and not an 
additional neuromast (Figure 4.17 b I-II).  
 
 
 
 
 
 
 
 
 
 
To confirm whether the structure was a neuromast or not, embryos were first 
incubated with To-Pro-1 and imaged (Figure 4.18 a I, III, b I, III). To-Pro-1 is a cell 
impermeable fluorescent nucleic acid stain that is able to enter neuromast cells but 
not primordium cells. The same embryos were then put through a claudin b in situ 
hybridisation to highlight both neuromast and primordia structures. If the structure 
was an additional neuromast, it would be seen with both To-Pro-1 and claudin b in 
situ, however if the structure was the secondary primordium it would only be seen 
after the ISH. Figure 4.18 shows that the additional structure is only visible in the 
claudin b in situ and therefore was actually Prim II, a secondary posterior lateral line 
primordium that migrates along the horizontal myoseptum depositing additional 
b I) b II) 
b) a) 
Figure 4.17 CD9b -8/-8 embryos may show an additional neuromast. 
claudin b ISH on 52hpf WT siblings (a) and CD9b -8/-8 (b) embryos. An additional 
neuromast-like structure was seen in CD9b -8/-8 embryos (b, redbox/ b II). However,  
b II shows a more elongated structure than the circular neuromast shown in b I)/black 
box. Scale bar 50µM. n= minimum 8 per genotype. Images from a single experiment. 
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neuromasts after the primary posterior lateral line primordium (Prim I) has completed 
migration (Ledent 2002, Sapede et al. 2002, Nuñez et al. 2009). 
 
  
a) 
a I) 
a II) 
a III) 
b) 
b I) 
b II) 
b III) 
Figure 4.18 The ‘ additional neuromast’ is Prim II.  
Neuromasts in AB (a) and CD9b -8/-8 (b) 52hpf embryos were stained with To-Pro-1 (a 
I,b I) before using a claudin b in situ hybridisation (a,b) to highlight both Prim II and the 
neuromasts.  a II), b II) and a III), bIII) show relevant close ups of the red boxes in a), aI), 
b) and b I). Comparison of a II) to a III) and b II) to b III) clearly show that the ‘extra 
neuromast’ seen in a) and b) is absent in a I) and b I) (red boxes), suggesting the 
structure is Prim II. Scale bars are 100µM (a II, b II). n= 8 per genotype. Images from a 
single experiment. 
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Having shown that the ‘additional neuromast’ was actually Prim II, the CD9b -8/-8 
embryos were re-assessed for lateral line phenotypes. As the heads of the embryos 
had been removed for genotyping prior to the ISH, distances were calculated as a 
percentage of trunk length. Trunk length was measured from the otic vesicle to the tail 
tip.  
 No significant difference was found in the number of neuromasts, the percentage of 
trunk length between the 1st and last neuromasts or the percentage of trunk length 
between the 1st and 2nd neuromasts (Figure 4.19a-c). This is summarised by the mean 
neuromast positions as shown in Figure 4.19d. 
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Figure 4.19 CD9b mutants show normal primary posterior lateral line structure.  
There is no significant difference in the number of neuromasts at 52hpf (a), the 
percentage of trunk length between the 1
st
 and last neuromasts (b) or in the 
percentage of trunk length between the 1
st
 and 2
nd
 neuromasts (c). No difference in 
the mean position of each neuromast, between the ear (0) and tail tip (100), is seen 
between CD9b mutants and WT siblings using an ANOVA with Sidak’s multiple 
comparisons test (d). The percentage of trunk length was used as the heads were 
removed prior to the ISH for genotyping. Significance was determined using an 
unpaired T-test, on log
10
 transformed data for (c) and untransformed data for (a) and 
(b) . n= minimum 8, p=<0.05. Data from a single experiment. 
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4.2.4.3 Prim II migration in CD9b homozygous mutants 
With the position of Prim II initially causing confusion in the CD9b -8/-8 mutants, I 
decided to look at the position of Prim II in both the mutants and WT siblings. To do 
this, the distance migrated by Prim II was measured from the otic vesicle as a 
percentage of trunk length. Initially it appeared that Prim II had migrated further in 
mutant embryos than the wt siblings by 52hpf (Figure 4.20a). However, when the 
position of Prim II was assessed in the embryos from Figure 4.18, it appeared that the 
position of Prim II was significantly more posterior than in the AB embryos (Figure 
4.20b). One of the differences between the two experiments was the genealogy of the 
embryos; the embryos in Figure 4.20a are from CD9b +/-8 parents whereas the mutant 
embryos from Figure 4.20b are from CD9b -8/-8 parents with AB WT controls. 
 
 
 
 
 
 
 
 
 
4.2.4.4 Prim I migration and early pLL phenotypes in CD9b homozygous 
mutants 
Due to the similarities between the primary (Prim I) and secondary (Prim II) posterior 
lateral line primordiums, the observed changes in Prim II migration may also suggest a 
role for CD9b in Prim I migration (Ledent 2002, Sapede et al. 2002, Nuñez et al. 2009, 
Sarrazin et al. 2010). Migration of Prim I as well as lateral line structure was assessed at 
36hpf. Structure was analysed because although the primary posterior lateral line 
shows no structural abnormalities in CD9b mutants at 52hpf, it is possible that CD9b 
a) b) 
Figure 4.20 CD9b homozygous mutant embryos show an increase in trunk migrated 
by Prim II when compared to WT siblings (a), but a decrease in migration when 
compared to AB embryos (b) at 52hpf. Unpaired T test (a, b), on untransformed (a) 
or log
10
 transformed data for (b). n= minimum 8 per genotype. p=<0.05. Data from 
two experiments. 
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mutants show a lateral line phenotype earlier in development and have recovered by 
52hpf (Figure 4.19).  
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Figure 4.21 CD9b mutants show delayed Prim I migration and increased spacing 
between deposited neuromasts at 36hpf.  
claudin b ISH on AB (a) and CD9b -8/-8 (a I) embryos showed a decrease in the number 
of neuromasts deposited by 36hpf (b), and an increase in the  percentage of trunk 
length between the 1
st
 and 2
nd
 neuromasts (d). While there was no difference in the 
percentage of trunk length between the 1
st
 and last neuromasts (c), there was a 
decrease in the percentage of trunk length migrated by Prim I from the otic vesicle (e). 
The mean neuromast positions can be seen in (f).  Mann-Whitney U test (b) and 
Unpaired T tests (c-f), with Holm-Sidak correction for multiple comparisons in (f). n= 
minimum 10 per genotype. p=<0.05. Data from a single experiment. 
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By 36hpf, CD9b -8/-8 mutants have deposited significantly fewer neuromasts and show 
a significant increase in the percentage of trunk between the 1st and 2nd neuromasts 
but no difference in the percentage of trunk between the 1st and last neuromast. This 
shows that within the same neuromast deposition space less neuromasts have been 
deposited in CD9b mutants (Figure 4.21 a-c,f). This phenotype is summarised in Figure 
4.21f where the mean positions of deposited neuromasts are shown. The 2nd and 3rd 
neuromasts have been deposited in significantly more posterior positions in the CD9b 
mutants. Delayed Prim I migration is also seen in Figure 4.21e, where the percentage 
of trunk length between the otic vesicle and primordium tip is measured. Interestingly, 
the CD9b-8/-8 embryos used were the offspring of CD9b homozygous mutants and so 
the delayed Prim I migration mirrors the delayed Prim II migration seen in CD9b -8/-8 
embryos from homozygous mutant parents (Figures 4.20b, 4.21e).  
4.2.4.5 Does genealogy affect primordium migration in CD9b homozygous 
mutants? 
To see whether the pattern of delay or increase in migration of Prim I and Prim II could 
be seen at both 36 and 52hpf, CD9b +/-8 adults were in-crossed and the resulting wt 
siblings and homozygous mutant embryos analysed at 36hpf. Unfortunately, the otic 
vesicles were cut off during the genotyping of the embryos and so only the number of 
neuromasts deposited by Prim I at 36hpf could be analysed, whereas migration was 
assessed for Prim II. As is evident in Figure 4.22, it appears that there is a pattern to 
the data when experiments are separated according to the parents’ genotypes. It 
appears that CD9b -8/-8 embryos from homozygous parents show delayed migration 
of Prim I and Prim II whereas CD9b -8/-8 embryos from heterozygous parents show an 
increase in Prim I and Prim II migration (Figure 4.22). The delay seen in embryos from 
homozygous parents is also apparent at later stages of development, with embryos at 
72 and 96hpf also showing delayed Prim II migration (Figure 4.23). 
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Figure 4.22  The migration of Prim I and Prim II appear to be affected differently in CD9b 
mutant embryos depending on their parents. 
The number of neuromasts deposited by Prim I by 36 hpf seems to be increased in 
CD9b -8/-8 embryos from heterozygous parents (a) but decreased in embryos from 
homozygous parents (b). This difference is replicated at 52hpf, looking at the 
percentage of trunk length migrated by Prim II in 52hpf embryos from heterozygous 
parents (c) or homozygous parents (d). Mann-Whitney U test (b), unpaired T test (a,c) 
and unpaired T test on log
10
 transformed data (d). n= minimum 14 (a), 10 (b), 8 (c,d) 
p=<0.05. Data from four individual experiments. 
Figure 4.23 The delay in Prim II migration is also seen at 72 (a) and 96 (b) hpf in 
embryos from CD9b homozygous mutant parents. Unpaired T test on n= minimum 10 
(a) and 9 (b) p=<0.05. Data from a single experiment. 
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Figure 4.24 Developmental assays showed no significant difference in development 
between AB and CD9b -8/-8 embryos from AB and CD9b -8/-8 parents.  
Embryo length (a), Head-Tail Angle (b) and Otic vesicle length (c) were measured at 
24 (I), 48 (II)and 72 (III) hpf. All the assays had non-significant results. Otic vesicle 
length is defined as the number of otic vesicle that could fit in the distance between 
the eye and the ear. Unpaired T-test, significance calculated on log
10
 transformed 
data for c II. n= 10 per genotype. p=<0.05. Data from a single experiment. 
a I) 
a II) a III) 
b I) b II) b III) 
c III) c II) c I) 
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The opposing phenotypes seen could be due to an overall developmental delay in the 
embryos from homozygous parents, which could then be masking any true lateral line 
phenotype.  CD9b may be required during early development for efficient 
development and so the delay seen may not be specific to the lateral line. To 
determine whether this hypothesis was true, embryos from AB and CD9b -8/-8 adults 
were analysed using three different staging assays from Kimmel et al., 1995 at three 
different time points. No significant difference was found in any of the three assays: 
embryo length, head-tail angle or the otic-vesicle length at 24, 48 or 72hpf (Figure 
4.24). This suggests that the delay phenotype seen in the lateral line is not due to 
general developmental delay and therefore may be specific to the lateral line. 
Upon closer inspection of the pattern seen in Figure 4.22, it appears that there is a 
difference between the wildtype controls with the AB embryos showing higher results 
than WT siblings. To look into this, AB embryos from an AB in-cross and wildtype 
embryos from a CD9b +/-8 (female) x AB (male) cross were fixed at 36hpf and a claudin 
b in situ hybridisation carried out to assess the percentage of trunk length migrated by 
Prim I.  No significant difference was seen in the percentage of trunk migrated or the 
number of neuromasts deposited by 36hpf between the two controls (Figure 4.25). 
This suggests that the difference seen in Figure 4.22 between the controls may be due 
to environmental differences between experiments or background genetic differences 
from using different tanks of ABs. 
 
 
 
 
 
 
 
 
Figure 4.25 No difference in the percentage of trunk length migrated by Prim I (a) or 
in the number of neuromasts deposited (b) by 36hpf is seen between AB and WT 
siblings. n= minimum 6. Unpaired T test. p=<0.05. Data from a single experiment. 
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Whilst no hypothesis had been formed as to why embryos from heterozygous and 
homozygous parents would show opposite phenotypes, the phenotypes appeared to 
be significant and specific. The difference in position of Prim I and Prim II at 36 and 
52hpf could either be due to a change in the onset of migration, a change in the speed 
of migration or a combination of the two. The speed of Prim I and Prim II migration 
was assessed using the claudinb:GFP line which had been crossed with CD9b -8/-8 
adults to produce a line of double heterozygous fish (claudinb:GFP +/-, CD9b +/-). 
These fish were then crossed with CD9b -8/-8 fish and the claudinb:GFP+ embryos 
from the resulting offspring were selected. These embryos were then imaged at 26 and 
31hpf for Prim I and 52 and 59hpf for Prim II. claudinb:GFP embryos were used as a 
control and the claudinb:GFP,cd9b-8/-8 embryos were identified after imaging by 
genotyping. As is evident from Figure 4.26 there was no difference in the speed of 
migration of Prim I or Prim II in the CD9b -8/-8 embryos.  This could suggest that the 
onset of migration is affected but not the speed of migration. 
 
 
 
 
 
 
 
A second CD9b knock out line was developed using F1s with the 46delA mutation, 
hereafter called CD9b -1, which causes a frameshift and an early stop codon (Figure 
4.11). CD9b knockout was confirmed by cd9b in situ hybridisation (Figure 4.27). 
claudinb in situ hybridisation experiments were carried out on 36 and 52hpf embryos 
to see if the migration phenotypes seen in CD9b-8/-8 embryos were replicated in a 
different CD9b mutant allele. Figure 4.28 shows there was no significant difference in 
the position of either Prim I or Prim II at 36 and 52hpf in the CD9b -1/-1 embryos which 
is surprising given the significance seen in Figure 4.22. 
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Figure 4.26  Migration speed of Prim I, or Prim II, is not affected in CD9b -8/-8 embryos.  
Speed of Prim I migration (a) and Prim II migration (b), between 26 - 31hpf and 52-59hpf 
respectively, was calculated for WT and CD9b -8/-8 embryos. No significant difference 
seen using an unpaired T test for either Prim I or Prim II migration speed. n= minimum 
7, p=<0.05. Data from two experiments looking at either Prim I or Prim II. 
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Figure 4.27 Expression of cd9b is reduced in 36hpfCD9b -8/-8 (b) and CD9b -1/-1 (c) 
homozygous mutants compared to AB embryos(a),. CD9b expression assessed using in 
situ hybridisation with a cd9b RNA probe.  CD9b can be seen in the neuromasts and 
primordium of the posterior lateral line in WT embryos (black arrows, a), but is absent 
in CD9b mutants (b,c). n= minimum 3 imaged, 10 observed per genotype. Data from a 
single experiment.  
a)  
b)  c)  
Prim I 
Prim II 
Heterozygous parents Homozygous parents 
a)  
d)  c)  
b)  
Figure 4.28 The migration phenotypes are not replicated in CD9b -1/-1 mutants.  
There is no significant difference in the percentage of trunk length migrated by 36hpf 
by Prim I in CD9b -1/-1 embryos from heterozygous (a) or homozygous (b) parents. 
There is also no difference in the percentage of trunk length migrated by Prim II by 
52hpf in CD9b -1/-1 embryos from hetro- (c) or homo-zygous (d) parents. Unpaired T 
test on normal (d) or log
10
 transformed data (a-c). n= minimum 10 (a), 20 (b), 13 (c), 
25 (d). p=<0.05. Data taken from four experiments. 
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Due to the lack of migration phenotype seen in CD9b -1/-1 embryos, I decided to 
repeat the claudinb in situ hybridisation experiments on 36 and 52hpf CD9b -8/-8 
embryos from both heterozygous and homozygous parents. Each experiment was 
performed in triplicate but only the migration assay looking at Prim I migration in 
36hpf embryos from heterozygous parents could be pooled and so the other 
conditions were analysed by looking for trends between the individual experiments 
(Figure 4.29). Representative graphs are shown for Figures 4.29b-d, for the 
experimental repeats see Figures 4.20, 4.21e and 4.30. 
 As shown in Figure 4.29e, the pattern starts to break down when the experimental 
repeats are taken into account. No significant difference was seen in the migration of 
Prim I in CD9b -8/-8 from heterozygous parents, both when looking at the pooled data 
and the individual experiments (Figure 4.29a,e). A significant decrease in Prim I 
migration at 36hpf was consistently seen in CD9b -8/-8 embryos from homozygous 
parents, suggesting that this phenotype may be specific and the developing embryos 
may need maternal CD9b for correct Prim I migration (Figure 4.29b,e). For Prim II 
migration, the data was much more varied (Figure 4.29e). In 52hpf CD9b -8/-8 embryos 
from heterozygous parents, each experiment gave a different result with significant 
increase, decrease and no significant difference seen (Figure 4.29e). Due to the 
opposing results, I concluded that the significant difference initially seen is most likely 
an artefact resulting from the variability of Prim II migration. I reached the same 
conclusion when looking at 52hpf CD9b -8/-8 embryos from homozygous parents as 
the significant decrease in migration was only observed in the initial experiment and 
not repeated (Figure 4.29e). 
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Prim I 
Prim II 
Heterozygous parents Homozygous parents 
Figure 4.29 The migration pattern is not replicated in further experiments.  
The percentage of trunk migrated by Prim I by 36hpf only appears to be affected in 
embryos from homozygous parents (b) and not heterozygous parents (a). No 
significant difference is seen in the migration of Prim II by 52hpf in embryos from 
homozygous parents (d) and heterozygous parents (c). e) shows the outcome of each 
experimental repeat, with increase in migration in CD9b mutants displayed as a green 
arrow, a decrease as a red arrow and ns shows no significant difference. 
Unpaired T test, n= minimum 14 (a,c,d), 20 (b). (a) shows pooled data of 3 
experiments but the three repeats of b-d can’t be pooled so a representative graph is 
shown, see Figures 4.20a,b,  4.21e and 4.30 for the experimental repeats of b-d. 
p=<0.05 
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Heterozygous parents Homozygous parents 
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Figure 4.30 The migration pattern is not replicated in further experiments, 
experimental repeats of Figure 4.29.  
The percentage of trunk migrated by Prim I by 36hpf appears to be consistently 
decreased in embryos from homozygous parents (a). No significant difference is seen 
in the migration of Prim II by 52hpf in embryos from homozygous parents (c) but a 
small decrease was seen in embryos from heterozygous parents (c) in this repeat. 
Unpaired T test, n= minimum 16 (b), 20 (a), 25 (c). p=<0.05 
Prim I 
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hpf Homozygous parents 
72  NS NS 
96  NS NS 
Figure 4.31 The delay in Prim II migration at 72 (a) and 96 (b) hpf in not observed in 
further experimental repeats.  
Graphs of individual experiments showing the percentage trunk migrated by Prim II at 
72 (a, a I) or 96 (b, b I) hpf. Unpaired T test on log
10 
transformed data (a, a I) and 
untransformed data (b, b I).n = 20. See Figure 4.23 for experimental repeats. c) shows 
the outcome of each experimental repeat, with increase in migration in CD9b mutants 
displayed as a green arrow, a decrease as a red arrow and ns shows no significant 
difference. p=<0.05 
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As well as the pattern seen in Figure 4.22 breaking down, the delay in Prim II migration 
seen at 72 and 96hpf previously also breaks down when the experiments are repeated. 
Only one of the three experiments showed a delay in Prim II migration, again 
suggesting that the initial delay seen is not a true CD9b deficiency phenotype (Figure 
4.31).  
The variability in percentage of trunk length migrated by Prim I and Prim II in both 
wildtype and mutant embryos suggests that any overall effect seen is not solely due to 
the CD9b mutation but could be due to a number of background environmental 
differences. One of these differences could be temperature fluctuations between 
experiments, which has been shown to affect penetrance in many other mutant lines  
(Johnson and Weston 1995, Dick et al. 2000, Poss et al. 2002, Parichy et al. 2003, Pei et 
al. 2007, Lin et al. 2013). Embryos are incubated at 28°C in a communal incubator, 
which is subject to temperature fluctuations depending on how often and for how long 
the incubator door is opened. The room temperature also changes throughout the 
year and so the extent to which the temperature changes will also depend on the 
room temperature during the experiment.  To assess whether temperature 
fluctuations were affecting the migration of Prim I, AB and CD9b -8/-8 embryos were 
placed at 22°C for 72hpf, by which time they had developed to around stage Prim-25. 
Figures 4.32a and b show there is a decrease in the percentage of trunk migrated, 
however if this change is compared to the decrease seen in embryos from the same 
batch that were placed at 28°C until Prim-25, it is clear that the lower temperature is 
not exacerbating the delay (Figure 4.32). Whilst there appears to be no difference in 
the migration of Prim I in embryos incubated at 22°C compared to 28°C, there was a 
striking number of obvious abnormalities seen in the CD9b KO mutants kept at 22°C, 
which is explored later in Chapter 5 (Figure 4.32a). 
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Figure 4.32  The variability in migration does not appear to be due to temperature 
sensitivity. 
CD9b -8/-8 embryos (a I) raised at 22°C for 72hpf (to stage Prim-25) , stained for 
claudin b, show a decrease  in the percentage trunk migrated by Prim I (b) compared 
to AB embryos (a). However, there is no difference in percentage trunk migrated by 
Prim I in stage matched embryos raised at 28°C (c) indicating the temperature is not 
causing or exacerbating the difference. Unpaired T test (b) and ANOVA with Sidak’s 
multiple comparison test, which gave increased power (c), were both performed on 
log
10
 transformed data. n= minimum 10 p=<0.05. Data from a single experiment. 
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4.2.4.6 Is CXCR4b trafficking affected in CD9b homozygous mutants? 
The original hypothesis of this project predicted that CD9b may play a role in 
regulating the signalling of CXCR4b. Leung et al. reported in 2011 that CD9 was up-
regulated by CXCR4 and promoted CXCR4-mediated migration of HSCs. If CD9b played 
a similar role in the pLL, it would be expected that a pLL phenotype would have been 
observed in CD9b mutants. However, CXCR4 signalling has also been reported to be 
regulated by a tetraspanin through trafficking of CXCR4 (Yoshida et al. 2008).  It has 
been suggested that we may not have expected to see a lateral line phenotype even if 
CD9b is regulating CXCR4b trafficking. Unpublished data looking at a mutant with a 
CXCR4b-internalisation defect showed no lateral line phenotype (personal 
communication, Dr. D. Gilmour, European Molecular Biology Laboratory Heidelburg). 
To investigate whether CD9b was required for CXCR4b internalisation, an 
internalisation assay was developed (Figure 4.33). CXCR4b-EGFP and CXCL12a-Venus 
constructs were provided by Prof. E.Raz, University of Mϋnster (Minina et al. 2007), 
mRNA produced and injected individually into single blastocysts at the 8-cell stage in 
separate AB embryos (Figure 4.33a-b). Expression of both CXCR4b-EGFP and CXCL12a-
venus were as expected, with CXCR4b expressed on the cell membrane and the ligand 
CXCL12a dispersing from CXCL12a-producing cells (Figure 4.33a-b) (Minina et al. 2007). 
The constructs were then injected into individual blastocysts in single 8-cell stage AB 
embryos, incubated for 3-4 hours and imaged, to see if the CXCR4b-EGFP and CXCL12a-
Venus would co-localise and internalise, replicating endogenous CXCR4b and CXCL12a 
(Figure 4.33c) (Tarasova et al. 1998). As shown in Figure 4.33c, the CXCR4b-EGFP and 
CXCL12a-Venus can be seen co-localised in intracellular puncta, suggesting that the 
ligand bound the receptor, inducing internalisation and re-localisation for degradation.  
 The internalisation assay was then used on both AB and CD9b -8/-8 embryos to assess 
CXCR4b internalisation in CD9b deficient cells. Puncta were seen in both AB and CD9b -
8/-8 embryos with CXCR4b-EGFP and CXCL12a-Venus co-localising inside the cells 
(Figure 4.34). This shows that CXCR4b is able to internalise in CD9b -8/-8 embryos, 
however, it does not rule out CD9b playing a role in CXCR4b internalisation in the 
lateral line. Tetraspanins are well known for their redundancy and a lack of phenotype 
could be explained by this (Hemler 2005, 2008, Hassuna et al. 2009). It may also be 
that CD9b only aids CXCR4b internalisation in certain tissues such as the lateral line, 
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which would not be seen at such an early embryonic stage. Whilst CD9b may aid 
CXCR4b internalisation in the lateral line, there is no positive data to support 
continuing this investigation.  
  
a) a‘) a I) 
b I) 
c IV) 
b) b‘) 
c) 
c I) 
c II) c II’) c III) 
Figure 4.33 The CXCR4b-EGFP and CXCL12a-Venus co-localise and internalise like 
wildtype CXCR4b and CXCL12a. 
Individual injections of CXCR4b-EGFP (a) and CXCL12a-Venus (b) into single blastocysts 
at the 8-cell stage (a I, b I) shows the membrane localisation of CXCR4b and the 
dispersion of CXCL12a. Co-injection of CXCR4b-EGFP and CXCL12a-Venus at 8-cell 
stage (c) displays co-localisation inside the cell. Magnification of the white box is 
shown in c I-III), with both channels shown in c I), CXCR4b only in c II) and CXCL12a 
only in c III).  n= 3 (a), 2 (b), 5 (c) images, minimum 3 embryos observed per condition. 
Data from a single experiment. 
c III’) 
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Figure 4.34 Co-localisation of CXCR4b and CXCL12a in intracellular puncta can be 
seen in both WT (a) and CD9b -8/-8 (b) embryos. 
AB (a) and CD9b -8/-8 embryos (b) injected with CXCR4b-EGFP (a I, b I) and CXCL12a-
Venus (a II, b II) in different blastocysts at the 8-cell stage and imaged 3-4 hours later. 
Scale bars 25µM. n= 2(a), 5(b) images, minimum 3 embryos observed. Data from a 
single experiment. 
a) 
b II) 
b I) 
b) 
a I) 
a II) 
a I) 
a II) 
b I) 
b II) 
a) 
b I) 
a I) 
b) 
Figure 4.35 AB and CD9b -8/-8 embryos show no clear difference in cd9a RNA staining 
in the pLLP. 
cd9a in situ hybridisation in 36hpf AB (a) and CD9b -8/-8 (b) embryos. a I) and b I) 
show the staining in the posterior lateral line primordium. Scale bars 50µM. n= 3(a), 
4(b) images, minimum 10 embryos observed per genotype. Data from a single 
experiment. 
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4.2.4.7 Why do CD9b morphants and mutants display different pLL 
phenotypes? 
At the beginning of this project the gold standard for reverse genetics was the creation 
of a mutant line. However, a recent paper by Rossi et al., 2015 showed that mutations 
in egfl7and vegfaa induced redundancy whereas knock-down technologies did not. In 
light of this, a cd9a in situ hybridisation was carried out on 36hpf AB and CD9b -8/-8 
embryos to look for an upregulation of expression of the cd9b paralog, cd9a, in the 
lateral line primordium (Figure 4.35). cd9a was shown to be expressed in both AB and 
CD9b -8/-8 embryos with no obvious difference between the two, suggesting that cd9a 
expression is not noticeably upregulated (Figure 4.35). This was unexpected as cd9a 
has not previously been shown to be expressed in the lateral line in wildtype embryos, 
however, the expression was reproduced in multiple experiments.  
Rossi et al.,2015 also demonstrated that injecting morpholinos into mutants, of the 
same target gene, can help to describe why phenotypes were seen with morphants but 
not mutants. Injecting CD9b MOs into CD9b mutants and seeing no phenotype would 
rule out the possibility that the CD9b MO phenotypes were caused by off-target 
effects, it would also show that the mutants are complete knock-outs and have no 
residual WT protein. AB, CD9b -8/-8 and CD9b -1/-1 embryos were left uninjected or 
injected with CD9b MO1, CD9b i2e3 or Mismatch MO at the 1-cell stage to give a final 
concentration of 0.1µM after which lateral line phenotypes were assessed by claudin b 
in situ hybridisation at 52hpf (Figure 4.36). AB embryos injected with CD9b MO1 or 
CD9b i2e3 replicated the phenotypes seen previously, showing decreased numbers of 
neuromasts deposited and irregular spacing between neuromasts, with CD9b MO1 
causing a stronger phenotype.  No difference in the percentage of trunk length 
migrated by Prim I or the percentage of trunk length between the 1st and last 
neuromasts was seen in AB embryos injected with CD9b i2e3, however, a significant 
decrease was seen in CD9b MO1 injected embryos (Figure 4.36). This suggests that 
Prim I may not have completed migration in the AB CD9b MO1 morphants, whereas it 
had in CD9b i2e3 morphants. 
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a III) a II) 
a I) a) 
b III) b II) 
b) b I) 
c III) 
c II) 
c) c I) 
Figure 4.36 CD9b MO1 but not CD9b i2e3 causes abnormal pLL structure in CD9b 
mutant embryos. 
Representative images of a claudin b in situ hybridisation on 52hpf AB (a), CD9b -
8/-8 (b) and CD9b -1/-1 (c) embryos. Embryos were left uninjected (a,b,c) or 
injected with 0.1µM Mismatch MO (I), CD9b MO1 (II) or CD9b i2e3 (III). 
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a) 
d) 
b) 
c) 
Figure 4.36 continued.CD9b MO1 but not CD9b i2e3 causes abnormal pLL structure 
in CD9b mutant embryos. 
52hpf AB (blue), CD9b -8/-8 (orange) and CD9b -1/-1 (green) embryos were left 
uninjected or injected with 0.1µM Mismatch MO, CD9b MO1 or CD9b i2e3. Lateral 
line phenotypes were assessed using four assays: percentage of trunk length 
migrated by Prim I (a), percentage of trunk length between the 1
st
 and last 
neuromast (b), percentage of trunk length between 1
st
 and 2
nd
 neuromasts (c) and 
the number of neuromasts deposited (d). Significance was analysed using an ANOVA 
with Sidak’s multiple comparison test on log
10
 transformed data (a-c) or a Kruskal-
Wallis test with Dunn’s multiple comparisons test (d). n= 20 except for CD9b -1/-1 
uninjected where n=6 and CD9b -1/-1 i2e3 where n=12. Many CD9b -1/-1 embryos 
died or were severely developmentally delayed and so were not analysed. Injected 
embryos were compared against the uninjected group of the same genotype. 
p=<0.05. Data from a single experiment. 
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CD9b -1/-1 and CD9b -8/-8 embryos injected with CD9b i2e3 showed no significant 
difference, compared to uninjected, in any of the assays indicating that no lateral line 
phenotypes were caused by this MO. CD9b MO1, however, did appear to cause a 
lateral line phenotype with less neuromasts deposited and varied spacing between the 
1st and 2nd neuromasts. This induced phenotype in the CD9b mutants appears milder 
than the one seen in AB embryos injected with CD9b MO1 (Figure 4.36). 
 The lack of lateral line phenotypes in CD9b mutants injected with CD9b i2e3 suggests 
that the lateral line phenotypes seen in CD9b morphants are not due to general off-
target effects or morpholino toxicity. If this were the case, it would be expected that 
both MOs would induce a phenotype in the CD9b mutants. The presence of lateral line 
phenotypes in CD9b MO1 injected CD9b mutants could suggest that CD9b MO1 is 
knocking down a secondary target, which could explain the more severe phenotypes 
seen with CD9b MO1. Alternatively it could suggest that there is residual functioning 
protein in the CD9b mutants.  
BLAST (Basic local alignment search tool) was used to look for potential secondary 
targets of CD9b MO1 (Figure 4.37a). The only complete match was to cd9b as expected 
and all the potential secondary targets were predicted sequences, of which none were 
tetraspanins (Figure 4.37a). This suggests that CD9b MO1 is only binding cd9b. 
 
 
 
 
 
 
 
 
 
a) 
b) 
Figure 4.37 CD9b MO1 appears to only bind and affect cd9b (a) but CD9b i2e3 may not 
affect cd9b in the CD9b mutants. 
CD9b MO1 appears to only bind cd9b (a), and not cd9a, according to BLAST. All other 
alignments with high query cover were just predicted sequences and no other 
tetraspanins were included in the list. It appears that only CD9b MO1, and not CD9b 
i2e3, may affect the two CD9b mutants as the mutations induce non-sense stop 
codons before the splice site affected by CD9b i2e3 (b). 
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Looking at the target sites for CD9b i2e3 and CD9b MO1 in cd9b, it became apparent 
that CD9b i2e3 binds after the nonsense stop codons induced in the CD9b mutants 
(Figure 4.37b). This could suggest that CD9b i2e3 may not have any additional effect on 
knocking down cd9b, whereas CD9b MO1 binds at the 5’UTR which would prevent 
translation of any mutant RNA not degraded by nonsense mediated decay (Figure 
4.37b). The two mutants have cut sites in the first cd9b exon, which induced 
frameshifts; however the N-terminus and the beginning of the first transmembrane 
domain remain wildtype (Figure 4.1,4.11). It has been shown by multiple groups that 
the N- and C- termini of tetraspanins can play an important role in their function, for 
example the N-terminus of CD63 is required for its correct localisation and partner 
protein trafficking function (Yoshida et al. 2008). Taken together this could suggest 
that the N-terminal of CD9b is needed for CD9b to function correctly in the lateral line, 
with the CD9b N-terminus present in CD9b mutants but knocked down when using 
CD9b MO1. 
To investigate whether the CD9b N-terminus RNA is present in CD9b mutants or 
degraded by nonsense mediated decay, qPCR was used to assess the levels of CD9b N- 
and C-terminals relativet to a reference gene, β-actin2 (Tang et al. 2007).  Three primer 
pairs were designed to bind cd9b, with two targeting the 5’UTR and N-terminus and 
one targeting the 3’UTR and C-terminus. The primers for the control gene, β-actin2 
were provided by Dr. P.Hua, University of Oxford. Primer pairs were initially tested on 
a cDNA mixture containing AB, CD9b -1/-1 and CD9b -8/-8 cDNA and dissociation 
curves studied to ensure that a single product was being produced by each primer pair, 
shown by the production of a single peak on the dissociation curve (Figure 4.38). I 
decided to use primers for β-actin2, CD9b C-terminus and CD9b N-terminus 1 but not 
CD9b N-terminus 2 as the primary N-terminus pair produced a cleaner dissociation 
peak. 
These primers were then used for qPCR on cDNA from six single AB, CD9b -1/-1 or 
CD9b -8/-8 embryos. qPCR is highly sensitive to pipetting errors and so three technical 
repeats were conducted to highlight any abnormal results, which were later identified 
and removed blind before analysing the results. The results from CD9b C- or N- 
terminal primers were first normalised to β-actin2 expression results. The relative 
expression of CD9b N- and C- terminal RNA in CD9b mutants, compared to wildtype, 
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was then calculated. Figure 4.39a shows a significant decrease in the expression of 
CD9b C-terminal RNA in both CD9b mutants. The decrease is within the expected range 
for nonsense mediated decay (NMD), with 40-70% reductions due to NMD having 
been reported previously (Baker et al. 2006, Luan et al. 2015, Roman-Sanchez et al. 
2015). Interestingly, CD9b N-terminus RNA does not show the same result. CD9b -1/-1 
mutants appear to have no significant difference in the expression of CD9b N-terminal 
RNA, whereas CD9b -8/-8 mutants do show a significant decrease with approximately 
half the expression level compared to AB embryos (Figure 4.39b). Due to the 
differences in primer efficiencies, as shown by the standard curves in Figure 4.40, the 
CD9b C-terminal and CD9b N-terminal expression levels cannot be directly compared 
to each other. However, this qPCR has shown that CD9b N-terminal RNA is still present 
in CD9b mutants. If the N-terminus of CD9b does play a role in CD9b function in the 
lateral line, it would explain why a migration delay was seen in CD9b -8/-8 embryos 
from homozygous parents but not CD9b -1/-1 embryos and why CD9b MO1 causes an 
abnormal lateral line phenotype but CD9b i2e3 does not in CD9b mutants.  
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Figure 4.38 The qPCR primer pairs produce a single product. 
Dissociation curves of β-actin 2 (a) and CD9b primer pairs: CD9b C-terminus (b), CD9b 
N-terminus 1 (c) and CD9b N-terminus 2 (d). n= 4 technical repeats  
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Figure 4.39 Expression of CD9b (a) C-Terminal  but not  (b) N-Terminal RNA is 
significantly reduced in both  CD9b mutants compared to AB embryos.  
qPCR on single 36hpf embryo cDNA using 6 biological samples and three technical 
repeats for each condition. Abnormal results, due to pipetting errors, were 
removed. Unpaired T-test with Holm-Sidak’s multiple comparisons correction, 
p=<0.05. n= minimum 15 (a) and 11 (b) data points per genotype 
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Figure 4.40 Primer pairs cannot be directly compared as primer efficiencies are not 
within 10-15% of each other. 
Standard curves of β-actin 2 (a), CD9b C-terminal (b) and CD9b N-terminal (c). Primer 
efficiencies were 70.4 % (a), 125.0 % (b) and 159.67% (c) as calculated by MxPro. n=3 
technical repeats 
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4.3 Discussion 
Having created and studied two CD9b mutant lines for PGC and pLLP migratory 
defects, it has been shown that while the PGCs phenocopy the PGCs in CD9b 
morphants, the pLL does not. Homozygous CD9b mutants show no difference in the 
clustering of PGCs to wildtype controls, a phenotype which is seen in all of the CD9b 
morphants except embryos injected with the highest amounts of CD9b MO1(0.5-
2.0µM) (Figure 4.16, Figure 3.6). These morphants also displayed increased 
morpholino toxicity, resulting in general morphological abnormalities (Figure 3.5). 
Interestingly this is mirrored by the CD9b mosaic embryos that were injected with 
either TALEN 1, which caused fewer morphological abnormalities, or TALEN 2, which 
caused greater amounts of morphological abnormalities (Figures 4.3-4.4). Only the 
TALEN 2 injected embryos showed a PGC phenotype, with increased distance between 
the most anterior and posterior PGC and increased numbers of ectopic PGCs (Figures 
4.7-4.8). This supports the hypothesis that the significance seen in CD9b MO1 0.5-
2.0µM morphants is due to general toxicity causing abnormal PGC migration and not a 
specific phenotype due to CD9b deficiency. The fact that TALEN 2 does not cut CD9b at 
the predicted site, unlike TALEN 1, may also suggest that any PGC phenotypes seen are 
due to general toxicity, however, the possibility of TALEN 2 causing DSBs elsewhere in 
cd9b or another gene cannot be ruled out.  
While CD9b morphants did not show a consistent PGC phenotype, a consistent pLL 
phenotype was seen. CD9b morphants showed a decreased number of neuromasts 
deposited, irregular spacing between neuromasts and often a delay or stalling in 
primordium migration (Figures 3.10-3.12). Surprisingly, this phenotype is not 
recapitulated in CD9b homozygous mutants (Figure 4.19). This lack of phenotype could 
be due to a number of reasons. Firstly, the phenotype seen in CD9b morphants could 
be due to off target effects of the morpholinos and not due to CD9b knockdown. 
Secondly, the CD9b morphant phenotypes may be specific but tetraspanin redundancy 
could rescue the phenotype in CD9b mutants. Finally, the CD9b mutants could have 
some residual function. 
It seems unlikely that the phenotypes seen in CD9b morphants are solely due to 
morpholino toxicity, as the same phenotype was seen with two independent 
morpholinos and at a range of concentrations. If the phenotypes were due to MO 
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toxicity, one would expect the lateral line phenotype to disappear with the general 
morphological defects seen in the embryos with higher concentrations of MO.  This 
does not appear to be the case as the disrupted lateral line is present in embryos that 
do not show MO toxicity (Figures 3.11, 3.12). It would also be expected that injecting 
either of the CD9b MOs into CD9b mutants would cause lateral line phenotypes, if the 
cause was purely MO toxicity, however only CD9b MO1 and not CD9b i2e3 caused a 
phenotype (Figure 4.36).  
Tetraspanins are well known for their redundancy within the tetraspanin family and 
mouse knockouts of single tetraspanins often appear healthy and viable with mild 
phenotypes, whereas double tetraspanin knockout mice often show increased 
numbers and severity of phenotypes (Knobeloch et al. 2000, Takeda et al. 2003, 2008, 
Wright et al. 2004, Hemler 2005, 2008, Hassuna et al. 2009, Gartlan et al. 2010). In 
zebrafish, this redundancy tendency may be amplified due to the occurrence of a fish-
specific whole genome duplication in teleost fish. This means that many tetraspanins, 
for which there is one mammalian ortholog, have two paralogs in zebrafish (Meyer and 
Van de Peer 2005, Brunet et al. 2006, Garcia-España et al. 2008, Huang et al. 2010, 
Howe et al. 2013b). This is true for CD9, as mammals have a single CD9 whereas 
zebrafish have CD9a and CD9b.  Initially it appeared that cd9a and cd9b were 
expressed in different tissues (Figure 1.7). However, this research has shown cd9a to 
also be expressed in the pLL. Whilst both cd9a and cd9b seem to be expressed in the 
pLL, CD9a does not appear to be upregulated in this organ in CD9b mutants (Figure 
4.35). A CD9a mutant line has been developed using CRISPRs by another member of 
the lab, which is currently being studied for lateral line phenotypes. A double CD9a, 
CD9b mutant line is also in development using the CD9a CRISPR and my CD9b TALEN, 
which will be analysed for lateral line phenotypes in the future. However, the ISH data 
in Figure 3.35 suggests that redundancy is not the cause of the lack of phenotype seen 
in the CD9b mutants. If redundancy was rescuing the phenotype, no phenotype would 
be expected upon injection of CD9b MOs into CD9b mutants; however this was not the 
case (Figure 4.36). 
CD9b in situ hybridisation experiments on CD9b -8/-8 and CD9b -1/-1 embryos showed 
no noticeable cd9b RNA and so it was expected that the mutant RNA was being 
degraded by nonsense mediated decay, resulting in a CD9b knockout (Figures 
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4.14,4.27).  It was therefore unexpected to find that CD9b MO1 caused a lateral line 
phenotype in CD9b mutants. One hypothesis for this phenomenon was the presence of 
functioning CD9b protein in the CD9b mutants (Figure 4.36, 4.37). As CD9b -8/-8 and 
CD9b -1/-1 embryos have a frameshift causing mutation in Exon 1 of CD9b, only the N-
terminus remains wildtype (Figure 4.11). It has been shown in a number of 
tetraspanins that the N- and C- termini are required for their correct function (Zhang et 
al. 2001, Stipp et al. 2003, Shoham et al. 2006, Wang et al. 2011a, Lapalombella et al. 
2012). qPCR to investigate the relevant expression of the N- and C- termini of cd9b in 
CD9b mutants showed that while the C-terminal has decreased expression in both 
mutants, the N-terminal is only significantly decreased in CD9b -8/-8 but not CD9b -1/-
1 (Figure 4.39). This fits with the observation that CD9b -8/-8 mutants from 
homozygous parents show a delayed Prim I migration but the equivalent CD9b -1/-1 
embryos do not (Figures 4.28,4.29). This suggests that the N-terminal of maternal 
CD9b may be needed during early embryogenesis for correct migration of Prim I. It also 
supports the hypothesis that neuromast deposition may be influenced by the N-
terminus of CD9b. While the relative expression of the cd9b N-terminal is significantly 
reduced in CD9b -8/-8 embryos, the levels are only 50% of wildtype which may be 
enough for normal function of the lateral line.  
If, as hypothesised, the N-terminus is enough for and required for correct CD9b 
function in the lateral line and the CD9b morphant phenotypes are specific, the 
mechanism of CD9b function will need to be explored. One hypothesised mechanism 
was that CD9b could interact with and cycle CXCR4b; however, a CXCR4b 
internalisation mutant has since been shown to have no lateral line phenotype 
(personal communication, D. Gilmour, European Molecular Biology Laboratory 
Heidelburg). Recent papers have described an alternative mechanism in cell culture 
where CD9 is upregulated by CXCL12 signalling, which in turn causes the upregulation 
of RAC 1, polymerisation of actin and production of long actin protrusions which are 
used for CXCR4-mediated migration (Leung et al. 2011, Brzoska et al. 2015, Arnaud et 
al. 2015). However, this signalling pathway appears to be likely regulated by the C-
terminus of CD9b (Arnaud et al. 2015).  
A second model suggests that the N-terminus of CD9b may have signalling activity 
which could regulate the survival of lateral line cells. This model revolves around the 
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tyrosine residue in the N-terminus of CD9b. This tyrosine residue is part of the 
sequence IKYLLFI, which is similar to the sequence IKYFLFV in the N-terminus of human 
CD37 (Figure 4.41a). In CD37 this sequence is reported to be an immune tyrosine-
based inhibitory motif (ITIM) -like domain. ITIM domains consist of a conserved 
sequence (S/I/V/LxYxxI/V/L, where x denotes any amino acid) within the cytoplasmic 
domains of many immune system inhibitory receptors. It was shown that although 
CD37 has an additional residue between the tyrosine and isoleucine /valine/leucine, 
the domain acts like other ITIM domains. The ITIM-like domain was tyrosine 
phosphorylated by Src-family kinases, which allowed association with and activation of 
a number of proteins including SHP1, LYN, SYK and PI3Kγ. The recruitment and 
activation of proteins such as SHP1 and LYN by the ITIM-like domain was shown to 
regulate apoptosis in B-cells (Lapalombella et al. 2012).  
It appears that CD9 and Src-family kinases might regulate each other. As well as Src-
family kinases phosphorylating ITIM domains, multiple Src-family kinases are regulated 
by CD9. Yamazaki et al. 2011 showed that expression of four members of the Src-
family was regulated by the presence or absence of CD9 in human B-cells and that the 
Src protein was inactivated upon CD9 knockdown. This suggests there may be a 
feedback loop between CD9 and Src-family kinases, which may have implications for 
lateral line primordium migration and neuromast deposition.  
It was recently shown that the Src-family kinase inhibitors Emodin, SU6656 and RBI 
caused delayed lateral line primordium migration in zebrafish embryos. A phenotype 
which was replicated with injection of CRISPRs targeting src or tks5a, a downstream 
target of src, indicating the involvement of the Src pathway in regulation of Prim I 
migration (Gallardo et al. 2015). It was also noted that embryos injected with src or 
tks5a CRISPRs showed a decreased primordium size, a phenotype which is reminiscent 
of decreased proliferation or increased apoptosis in the primordium.  
Correct regulation of apoptosis and proliferation in Prim I is required for correct 
neuromast deposition with increase of the former and decrease of the latter resulting 
in decreased numbers of neuromasts deposited even though Prim I has reached the 
end of the tail (Aman et al. 2011, Valdivia et al. 2011). Cell survival in the primordium 
could be regulated by the ITIM-like domain in CD9b. In B-cells the protein SHP1 which 
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is activated by the ITIM-like domain in CD37 has been shown to downregulate Akt, and 
was suggested to downregulate MAPK, phosphorylation which then negatively 
regulates cell survival (Lapalombella et al. 2012). The Akt and MAPK pathways have 
also been shown to be regulated by CD9 in megakaryocytes  (Desterke et al. 2015). In 
the same study, CD9 was shown to positively regulate CXCR4-mediated migration of 
megakaryocytes as well as CXCR4 and CXCL12 expression (Desterke et al. 2015). 
 It could be hypothesised that the IKYLLFIF sequence in the CD9b N-terminus is an 
ITIM-like domain, interacting with and regulating Src-family kinases, which in turn are 
activating CD9b to allow docking of proteins such as SHP1. This in turn could allow 
CD9b to regulate cell survival in the primordium by regulating Akt and MAPK signalling 
pathways (Figure 4.41b).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
Figure 4.41 Model of the potential signalling properties of the CD9b N-
terminus.Clustal multiple sequence alignment of Zebrafish CD9b with Human and 
Zebrafish CD37 using MUSCLE (Multiple Sequence Comparison by Log-Expectation) 
(a). Residue colour indicates residue physicochemical properties: red – small 
hydrophobic, magenta-basic, green- hydroxyl, sulfhydryl, amine or G, blue- acidic. 
Conserved residues are noted by *, strongly similar residues scoring >0.5 and weakly 
similar residues scoring <0.5 in the Gonnet PAM 250 matrix are noted by : and . 
respectively.  
The proposed feedback loop between CD9b and Src-family kinases (b). This could 
regulate the activation of Src-family kinases as well as CD9b partner proteins such as 
SH1, LYN, PI3K and SYK (b). In turn this could help to regulate the migration and 
neuromast deposition of the lateral line by regulating primordium size through Akt 
and MAPK signalling. Dotted lines indicate hypothesised activities. 
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Chapter 5: 
CD9b mutants raised at 22°C 
5.1 Introduction 
The tail phenotypes seen in CD9b -8/-8 embryos raised at 22°C were unexpected as 
CD9b is not specifically expressed in the tail during development (Figure 4.32, Table 
1.4). Interestingly, a number of different chemical toxins are reported to induce a 
similar morphological phenotype, often including a shortened, kinked or curly tail with 
abnormal fin fold development (Samson and Shenker 2000, Saslowsky et al. 2010, 
Bakos et al. 2013, Yuan et al. 2014, Ahmad et al. 2015). Kinked and curly tails are also 
seen in a zebrafish hyperammonemia model (Feldman et al. 2014). As processing of 
toxins, including ammonia, is carried out by the kidneys this could suggest that CD9b 
may have a role in kidney function. In support of this, CD9b is strongly expressed in the 
pronephros during zebrafish development (Figures 4.14, 4.27, Table 1.4), and the 
mammalian homolog of CD9b, CD9, has been shown to be expressed in human, 
mouse, rat and canine kidney cells (Kaprielian et al. 1995, Sheikh-Hamad et al. 1996, 
2000, Sincock et al. 1997, Yanez-Mo et al. 2001, Kuroda et al. 2001, Blumenthal et al. 
2015). CD9 has been shown to play a role in the stress responses of kidney cells, where 
it is upregulated or increases survival when kidney cells are placed under osmotic, 
oxidative or mechanical stress (Sheikh-Hamad et al. 1996, 2000, Takemura et al. 1999, 
Blumenthal et al. 2015). Together this could suggest a hypothesis that CD9b in 
zebrafish is upregulated in the pronephros when under stress to allow the organ to 
function efficiently. Without this upregulation in the CD9b mutants the removal of 
bodily toxins, such as ammonia, could become impaired and lead to the tail 
phenotypes seen. 
5.2 Results 
Given that zebrafish are normally raised at 28°C, decreasing the incubator temperature 
to 22°C causes a temperature stress on the developing embryos. When raised at 22°C a 
large percentage of CD9b -8/-8 embryos showed dramatically shorter, kinked or curled 
tails, whereas their AB counterparts showed no abnormalities (Figure 5.1c). These 
phenotypes were observable by eye, as seen in Figure 5.1a-5.1b II, however some of 
the mutants looked normal overall. Embryos were categorised as having no obvious 
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phenotype or a mild, moderate or severe tail phenotype.  Mild embryos were defined 
as having one trunk defect, moderate embryos showed two and severe showed the 
most extreme versions of these phenotypes. Although many CD9b mutants showed no 
obvious phenotype, upon measuring the trunk length of the embryos it became clear 
that the mutants had significantly shorter trunks than the ABs (Figure 5.1c-d). This 
decrease in trunk length at 22°C is only seen in CD9b -8/-8 embryos; AB embryos 
appear unaffected by the different raising temperatures (Figure 5.1e).  
 
 
 
 
 
 
 
  
Figure 5.1 CD9b -8/-8 embryos (b), but not AB (a) embryos, show abnormal tail 
phenotypes when incubated at 22°C until reaching Prim-25 stage. 
 The embryos are stained for claudin b expression via in situ hybridisation. The wildtype 
AB embryos show a normal phenotype with no obvious defects (a). Some of the CD9b -
8/-8 embryos also showed no obvious phenotype (b), although some showed shorter 
kinked or tightly curled tails (b I and b II). The percentage of embryos showing tail 
phenotypes is shown in (c). CD9b -8/-8 embryos show significantly shorter trunks when 
incubated at 22°C compared to AB embryos under the same conditions (d). This 
decrease in trunk length is only seen in CD9b -8/-8 embryos at 22°C whereas AB trunk 
lengths are the same at both 28°C and 22°C (e). All embryos were from the same AB or 
CD9b -8/-8 batch. An unpaired T test was used to analyse (d) and an ANOVA with Sidak’s 
multiple comparisons test was used for (e). Sidak’s test was used as it has increased 
power and corrects for multiple comparisons. n= minimum 10. p=<0.05. Data from a 
single experiment. 
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As many embryos died during development when raised at 22°, the experiment was 
repeated to assess whether the abnormal phenotypes seen were a result of selection 
bias through high embryo death in the previous batch. A larger number of AB and 
CD9b -8/-8 embryos were placed at 22°C for 72hpf then assessed by eye for obvious 
phenotypes, fixed and a randomly chosen subset imaged and measured (Figure 5.2). As 
seen in Figure 5.2a-5.2c, a range of tail phenotypes were observed again, including 
shorter, kinked or curled tails but also uneven or underdeveloped fin folds. Any fin fold 
phenotypes seen previously in Figure 5.1 would have been dismissed as potentially 
resulting from the use of proteinase K to digest the embryos during the in situ 
hybridisation. Whilst a large number of the CD9b -8/-8 embryos were labelled as no 
obvious phenotype, measurements showed that the tails were significantly shorter 
and the fin folds significantly smaller in the mutants (Figure 5.2d-5.2e). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) 
b) 
b I) 
b II) 
b III) 
Figure 5.2 CD9b -8/-8 embryos (b), but not AB (a) embryos, show abnormal tail and 
finfold phenotypes when incubated at 22°C for 72hpf. 
 A range of phenotypes was seen in CD9b -8/-8 embryos from no obvious (b), mild (b I), 
moderate (b II) and severe (b III). Phenotypes were defined in the same way as Figure 
5.1, except fin fold phenotypes were included in this repeat. A number of CD9b -8/-8 
embryos show obvious trunk phenotypes (c), however the embryos that show no 
obvious phenotypes by eye have shorter trunks (d) and smaller fin fold areas (e). Fin 
folds outlined in a),b) in black. n= minimum 215 (c), 15(d,e). Mann-Whitney U test (d) 
and Unpaired T test (e). ****p<0.0001. Data from a single experiment. 
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To investigate whether the phenotypes also occurred in a different CD9b mutant allele, 
the experiment was repeated but CD9b -1/-1 embryos were also raised at 22°C for 
72hpf. While a large percentage of CD9b -8/-8 and CD9b -1/-1 embryos did show tail 
phenotypes, surprisingly so did the AB embryos (Figure 5.3a). The significant difference 
seen previously in trunk length and fin fold area between AB and CD9b mutant 
embryos was not replicated (Figures 5.3b-5.3c). A final repeat confirmed that this loss 
of significance was not an isolated event (Figure 5.4).  
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Figure 5.3 Further experimental repeats show AB embryos developing abnormal tail 
phenotypes as well as CD9b mutants when raised at 22°C. 
The percentage of CD9b mutant embryos showing tail phenotypes  is greatly increased 
in this repeat, however, many AB embryos also showed obvious tail phenotypes (a). n= 
minimum 60. 
The change in AB tail phenotypes is also mirrored in the loss of significant difference in 
trunk length (b) and fin fold area (c). Significance was assessed using an ANOVA with 
Dunnett’s multiple comparisons test.  n= minimum 14. Data from a single experiment. 
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A large percentage of AB embryos showed tail phenotypes in two of four independent 
experiments. The data from these experiments cannot be pooled and so the means of 
individual experiments were compared for trunk length and fin fold area (Figure 5.5). 
The variation in experimental means suggest that the significance differences seen in 
Figures 5.1 and 5.2 were an artefact of the variable nature of embryo development at 
22°C, and the lack of phenotypes shown by AB embryos occurred by chance. 
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Figure 5.4. AB embryos develop abnormal tail phenotypes as well as CD9b mutants 
when raised at 22°C. 
A large percentage of AB embryos display tail phenotypes, whereas less are seen in 
CD9b -8/-8 embryos, suggesting that the phenotypes seen are not due to CD9b 
deficiency (a). n= minimum 100 
No significant difference is found in trunk length (b) and fin fold area (c). Significance 
was assessed using an unpaired T test (b) and a Mann-Whitney U test (c).  n= 
minimum 10.  
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Figure 5.5 Large variation between the means of each experimental repeat suggests the 
initial significance difference in trunk length (a) and fin fold area (b) was an artefact. 
As the data cannot be pooled, the means from each experiment have been compared. A 
large variation can be seen between the experiments, suggesting that the significance 
initially seen was an artefact and not a true phenotype of CD9b deficiency. Mann-
Whitney U tests between AB and CD9b -8/-8 embryos show no significant difference 
between the means. A Mann- Whitney U test was used as only one data  point was 
reported for CD9b -1/-1 and ANOVAs need >1 data point per column. The lack of CD9b -
1/-1 repeats is due to a lack of fertilised eggs being laid by CD9b -1/-1 adult pairs. 
n=minimum 1 experiment mean 
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Figure 5.6 Tail phenotypes are found in embryos of all genotypes from CD9b +/-8 in-
cross.  
Embryos from CD9b +/-8 parents were raised at 22°C and embryos that developed tail 
phenotypes were genotyped (a). A chi-squared test showed the resulting number of 
embryos in each genotype did not differ significantly from Mendelian inheritance 
ratios (P=0.0832). The number of embryos observed by genotyping and expected by 
Mendelian inheritance is shown in (b). n= 32 embryos. Data from a single experiment. 
a) b) 
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Though AB embryos showed abnormal tail phenotypes in two of four repeats, CD9b 
mutant embryos showed abnormal phenotypes in all four. To determine whether 
CD9b deficiency was increasing the number of embryos with tail phenotypes, CD9b +/-
8 adults were paired and the resulting embryos collected the next day. The embryos 
were raised at 22°C for 72hpf before being assessed for tail phenotypes. Any embryos 
with abnormal tails or fin folds were then genotyped. If CD9b deficiency was increasing 
the occurrence of abnormal tail development, it would be expected that a large 
number of the embryos genotyped would be CD9b homozygous mutants and few 
would be wild type siblings. This appears not to be the case. An almost equal number 
of homozygous mutants and wildtype siblings were found in the genotyped embryos, 
with the number of embryos found in each genotype not significantly different to the 
number of embryos expected by Mendelian inheritance laws (Figure 5.6). This suggests 
any differences seen were not due to CD9b deficiency. 
5.3 Discussion 
While it is clear that CD9b deficiency in embryos raised at 22°C, instead of 28°C, does 
not promote abnormal tail development, it is still possible that CD9b could play a role 
in the zebrafish pronephros. CD9 has been shown to be expressed in kidney cells of a 
wide range of organisms and has been implicated in promoting survival during cellular 
stress by regulating signalling and augmenting both cell-cell and cell-matrix 
attachments through interactions with β1-integrin and heparin-binding epidermal 
growth factor-like (HB-EGF) (Sheikh-Hamad et al. 1996, 2000, Takemura et al. 1999). 
Expression of CD9 in podocytes has also been shown to stimulate protrusion formation 
and increase migration speed during wound healing (Blumenthal et al. 2015). It would 
be interesting to see if any similar roles are found for CD9b in future research. 
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Chapter 6:  
CD9b mutants and fertility 
6.1 Introduction 
In 1999, it was shown that CD9 is expressed on the cell membrane of murine oocytes 
and ovulated eggs. An anti-CD9 mAb, JF9, was shown to inhibit sperm- egg binding and 
fusion in vitro (Chen et al. 1999). A role for CD9 in fertilisation was confirmed with the 
generation of CD9 deficient mice (Kaji et al. 2000, Le Naour et al. 2000, Miyado et al. 
2000). While CD9 deficient mice grew to adulthood with no obvious abnormalities, 
female CD9b -/- mice had severely reduced fertility with litter sizes <2% of wildtype 
(Miyado et al. 2000). It was observed that mating behaviour, number of oocytes 
ovulated, ovary morphology and sperm-egg binding were normal, however, the sperm 
and egg fusion was almost completely inhibited in CD9 -/- females (Kaji et al. 2000, Le 
Naour et al. 2000, Miyado et al. 2000).  
 CD9, as a member of the tetraspanin family, is well known for its ability to interact 
with other members of the tetraspanin family and multiple membrane surface 
proteins. In doing so, tetraspanins can act as ‘molecular facilitators’ for cellular 
processes (Rubinstein et al. 1996b, Maecker et al. 1997). It was therefore suggested 
that CD9 may organise partner proteins on the egg membrane to generate fusion 
competent sites (Zhu et al. 2002, Ziyyat et al. 2006, Jégou et al. 2011). Many potential 
CD9 partners, such as integrin-α6β1, have been shown to be non-essential for gamete 
fusion although recently the egg membrane protein Juno has been shown to be 
required for fertilisation (Miller 2000, He et al. 2003, Bianchi et al. 2014). 
It was also proposed that CD9 could act as a direct receptor for a sperm membrane 
protein, as binding of the ligand PSG17 (pregnancy-specific-glycoprotein-17) to CD9 on 
the egg membrane can prevent sperm fusion. Although PSG17 is not a sperm protein, 
this suggests the binding site is needed for sperm-egg fusion (Ellerman et al. 2003). The 
sperm protein, Izumo, is required for gamete fusion but it’s egg receptor is Juno not 
CD9 (Inoue et al. 2005, 2011, 2013, Satouh et al. 2012, Bianchi et al. 2014). It appears 
that CD9 may partner with Juno and regulate the binding of Izumo/Juno, after which 
Izumo dimerises and is passed to an alternative unknown egg receptor for tight 
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adhesion of the membranes (Chalbi et al. 2014, Inoue et al. 2015). Although CD9 is not 
required for Izumo/Juno binding, CD9 is required for correct formation and distribution 
of microvilli on the egg membrane (Kaji et al. 2000, Runge et al. 2007, Zyłkiewicz et al. 
2010). Incorrect egg membrane structure in CD9 -/- eggs may account for the 
differences in Izumo/Juno binding kinetics (Runge et al. 2007, Chalbi et al. 2014). 
While the majority of research on CD9 in fertility has focussed on female fertility, there 
is evidence suggesting that CD9 may play a role in male fertility also. CD9 has been 
shown to be expressed on spermatogonial stem cells and throughout the majority of 
spermatogenesis in mice (Kanatsu-Shinohara et al. 2004, Kierszenbaum et al. 2006, Ito 
et al. 2010).Like Izumo, CD9 is an inner acrosomal membrane associated protein in 
mature sperm and only becomes exposed after the acrosome reaction which occurs 
upon binding the zona pellucida (Ito et al. 2010, Inoue et al. 2011, Barraud-Lange et al. 
2012). Whilst a role for CD9 in mature sperm has yet to be proposed, a role for CD9 in 
spermatogonial stem cells can be inferred from recent papers. Spermatogonial stem 
cells (SSCs) are located in specific niches in the testis that release the chemoattractant 
CXCL12, which is needed for both homing and maintenance of SSCs (Kanatsu-
Shinohara et al. 2012, Yang et al. 2013, Westernströer et al. 2014). In order to access 
these niches, spermatogonial stem cells have to cross the blood-testes barrier. This 
transmigration requires the activation of Rac1 on the stem cells (Takashima et al. 
2011). Recent publications have shown that CXCL12 upregulates CD9 and CD9 
subsequently promotes Rac1 activation and actin polymerisation (Leung et al. 2011, 
Brzoska et al. 2015, Arnaud et al. 2015). It could be that a similar mechanism is present 
in spermatogonial stem cells. 
To my knowledge there has been no research into a possible role for CD9a or CD9b in 
zebrafish sperm-egg fusion or spermatogenesis. 
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6.2 Results 
In the CD9 knockout mouse, the main phenotype is a severe decrease in the number of 
pups born due to decreased sperm – egg fusion (Kaji et al., 2000; Le Naour et al., 2000; 
Miyado et al., 2000). We decided to check whether the total number of eggs laid per 
CD9b -8/-8 and CD9b -1/-1 pair, as well as the number of fertilised, dead and 
unfertilised eggs, was the same as those laid by their WT counterparts (Figure 6.1). AB, 
CD9b -1/-1 and CD9b -8/-8 in-cross pairs were set up in pair mating tanks and the total 
number of eggs laid per pair were collected and assessed the next morning (Figure 
6.1a).  Having only 5/6 pairs of CD9b -1/-1 and CD9b -8/-8 mutants, the experiment 
was repeated on multiple occasions to increase the reliability of the conclusions as 
laying behaviour varies largely between experiments. CD9b mutant pairs have a 
significantly decreased number of eggs per clutch, 31.36 ± 18.16 eggs and 38.97± 7.975 
eggs compared to 170.3±18.16 (mean ± SEM) eggs from AB pairs. It is also apparent 
that CD9b mutant pairs often lay no eggs at all (Figure 6.1a). 
The total clutch size assessed in Figure 6.1a included fertilised, dead and unfertilised 
eggs laid by each pair. The number of each egg type produced per pair that laid can be 
seen in Figures 6.1b-d. A significant decrease in the number of eggs fertilised per CD9b 
mutant pair (Figure 6.1b) mirrors the decrease seen in overall clutch size. This 
mirroring is not seen in the number of dead (Figure 6.1c) or unfertilised (Figure 6.1d) 
eggs. Due to significant differences between experimental repeats, the data for the 
number of dead eggs laid per pair cannot be pooled and so a representative 
experiment is shown in Figure 6.1c. An increase in the number of dead eggs laid by 
CD9b mutants can be seen in Figure 6.1c, however the number of pairs observed is low 
for CD9b -1/-1 as only pairs that laid any eggs were included. Whilst CD9b mutant pairs 
did not lay dead eggs in every experimental repeat (Figure 6.2), there was a trend of 
CD9b mutant pairs laying dead eggs with increased frequency, as shown in Figure 6.1c. 
The number of unfertilised eggs per CD9b mutant pair, in contrast to both fertilised 
and dead eggs, does not appear to change in comparison to AB pairs (Figure 6.1d). 
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Figure 6.1 CD9b mutant pairs lay smaller clutches of eggs.  
A significant decrease in the total number of eggs laid per pair, including fertilised, 
dead and unfertilised eggs, is seen with CD9b mutant pairs (a). The number of 
fertilised eggs laid per pair is also significantly decreased (b); however the numbers 
of dead (c) and unfertilised (d) eggs are increased or unchanged respectively. a),b) 
and d) represent pooled data from 4 -5 experimental repeats but c) is a 
representative experimental repeat as the data could not be pooled (for the repeats 
see Figure 6.2). Whilst the data for the number of dead eggs could not be pooled, 
the percentage of pairs that laid dead eggs was assessed to give an overview of the 
repeats (c I). Chi-squared analysis of (c I) shows a significant difference between the 
groups (p=<0.0001). All experiments, except (c I) were analysed using a Kruskal-
Wallis test with Dunn’s multiple comparisons test where p=<0.05. n=minimum 25 
pairs (a), minimum 12 pairs  (b), minimum 2 pairs (c) and minimum 10 pairs per 
genotype (c I) and (d). Only pairs that laid any eggs were included in b-d.  
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Figure 6.2 CD9b mutant pairs lay dead eggs more often than AB pairs. 
Experimental repeats (a-d) looking at the number of dead eggs laid per pair , all 
analysed using Kruskal-Wallis with Dunn’s multiple comparisons test. Only pairs that 
laid were included in the data collection and CD9b mutant pairs often laid no eggs, 
leading to the low n numbers. n= minimum 2 pairs 
a) 
d) 
b) 
c) 
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If clutch size was the only laying phenotype seen from CD9b mutant pairs, it would be 
expected that the number of fertilised, dead and unfertilised eggs would also 
decrease. Figure 6.1 shows that while this is the case for the number of fertilised eggs, 
it is not true for the numbers of dead and unfertilised eggs. We therefore decided to 
look at the percentage of fertilised, dead and unfertilised eggs per clutch to see if the 
ratio of egg phenotypes within CD9b mutant clutches is affected (Figure 6.3). 
CD9b mutant pairs have a significantly lower percentage of fertilised eggs per clutch 
24.14 ±11.17 and 61.52±8.76 percent of eggs fertilised in comparison to AB clutches 
that have 96.54 ±0.89 percent of eggs fertilised (Figure 6.3a).  It can therefore be 
inferred that CD9b mutants have a significant increase in the percentage of dead and 
unfertilised eggs per clutch. It can be seen in Figure 6.3b that both dead and 
unfertilised eggs appear to increase individually, with the percentage of dead eggs 
most dramatic with CD9b -1/-1 pairs. 
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Figure 6.3 CD9b mutant pairs have a lower percentage of fertilised eggs per clutch.  
The percentage of fertilised eggs is significantly decreased in clutches from CD9b 
mutant pairs (a). n= minimum 10 pairs per genotype, with only pairs that laid 
counted, from four repeats. An ANOVA with Dunnett’s multiple comparisons test was 
performed after removal of definitive outliers (3 outliers, ROUT, q=0.1) to give 
normally distributed data. p=<0.05 
Given the significant decrease in fertilised eggs seen in (a), it can be inferred that 
there is a significant increase in the percentage of dead and unfertilised eggs per 
clutch from CD9b mutants. This increase is apparent in (b), where the average 
breakdown of clutches from wildtype and CD9b mutant pairs is shown.  
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While migration of PGCs to the embryonic gonadal ridge in CD9b mutants has been 
shown to be normal in a previous chapter, CD9b mutants may have fewer PGCs which 
could then result in a reduced clutch size. To investigate this, an ISH was carried out on 
32hpf AB, CD9b -1/-1 and CD9b -8/-8 embryos using a vasa RNA ISH probe to stain the 
PGCs (Figure 6.4b-6.4b II). The number of PGCs per embryo was counted and no 
significant difference found between AB and CD9b mutant embryos (Figure 6.4a).   
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Figure 6.4 Number of PGCs per embryo at 32hpf is comparable between AB and CD9b 
mutant embryos.  
There is no significant difference in the number of PGCs in AB and CD9b mutant 
embryos at 32hpf (a). This was shown using an ANOVA with Dunnett’s multiple 
comparisons test on n= minimum 10 embryos per genotype. p=<0.05. Data from a 
single experiment.  
b-b II show representative images of 32hpf AB (b), CD9b -1/-1 (b I) and CD9b -8/-8 (b 
II) embryos stained to show vasa RNA in PGCs using ISH. Both sides of each embryo 
were imaged to assess the number of PGCs per embryos. 
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 The decrease in clutch size and decrease in percentage of eggs fertilised per clutch 
from CD9b mutant pairs are significant and interesting phenotypes, however, there are 
a number of factors that could be contributing to these results. Behavioural and 
physiological factors such as age, breeding interval and size can affect egg production 
(Eaton and Farley 1974, Niimi and LaHam 1974, Skinner and Watt 2007, Paull et al. 
2008, Uusi-Heikkilä et al. 2010, Filby et al. 2010, Nasiadka and Clark 2012). Due to the 
use of communal AB stocks, the same tank of ABs was not used every time. This means 
there may be background genetic variations between the AB controls but all ABs used 
had been born in the same month and so negates any age effects. The CD9b mutants 
were born within two months of the ABs. The communal AB stocks may be less 
stressed than the mutants as they have an enforced breeding interval of two weeks 
between pairings, unlike the CD9b mutants which can be paired every week. This 
stress was controlled for by trying to limit CD9b mutant pairings to every two weeks 
and ensuring that the mutants, if paired in consecutive weeks, were then given two 
weeks rest before pairing again. Size differences were managed by pairing fish of 
similar sizes. Ideally, ABs and CD9b mutants would have been raised and bred under 
identical conditions to control for these variables, however, this was not viable at the 
time. 
IVF was used to investigate whether the clutch size and fertilisation phenotypes were 
still significant after elimination of many of the behavioural and physiological factors in 
zebrafish spawning. AB, CD9b -1/-1 and CD9b -8/-8 in-cross pairs were set up in pair 
mating tanks overnight with eggs and sperm collected manually the next morning by 
gently squeezing anaesthetised fish. Eggs and sperm from the same genotype were 
then mixed and activated to induce fertilisation. Eggs were assessed for fertilisation 
two hours after the IVF procedure. This experiment focuses only on fertilised and 
unfertilised eggs as any dead eggs were immediately disposed of during the IVF. Of the 
females that laid suitable eggs, there is a significant decrease in the number of eggs 
per clutch from CD9b mutant females 37.33± 4.177 and 50.00±16.14 eggs on average 
compared to AB with 146.7±22.84 eggs (Figure 6.5a). Not only is the clutch size smaller 
from CD9b mutant pairs, but the percentage of eggs fertilised is also decreased (Figure 
6.5b). The number of eggs fertilised and unfertilised per pair can be seen in Figure 
6.5bI, with individual pairs aligned vertically.  
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Due to the challenging nature of the IVF protocol, it was expected that not every fish 
would yield gametes for extraction; however, it appeared that sperm extraction was 
occurring less frequently from CD9b mutant males (Figure 6.6a and 6.6aI). Preliminary 
observations from the aquarium staff also suggests that the CD9b males also yielded a 
lower volume of sperm than AB males, although due to the time constraints on the IVF 
protocol, sperm volume could not be accurately measured.   
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Figure 6.5 Clutches produced by IV,F from CD9b mutant pairs, have a decreased 
clutch size and lower percentage of eggs fertilised per clutch.  
The number of eggs is significantly decreased in clutches from CD9b mutant pairs 
(a). Of the eggs laid, a significantly lower percentage were fertilised by CD9b mutant 
males (b). Dead eggs were immediately discarded during the IVF protocol and 
therefore (a) and (b) represent only fertilised and unfertilised eggs. The number of 
fertilised and unfertilised eggs is shown in b I), with individual pairs aligned vertically. 
n= minimum 3 pairs. ANOVA with Holm-Sidak multiple comparisons test was carried 
out on the original data from (a) and on arcsine transformed data in (b). The Holm-
Sidak post-hoc test was chosen as it has more power than Dunnett’s multiple 
comparisons test. p=<0.05. Data from a single experiment. 
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Female CD9b mutants show no such difference in gamete extraction, with females 
from each genotype yielding eggs ~ 50% of the time (Figure 6.6b and 6.6bI). This may 
be a result of some of the AB fish laying prior to the IVF, whilst being held as a group in 
a large tank. This group laying is unusual and the males/females were separated as 
soon as the laying was observed. However, this could mean that some of the female 
ABs that did not yield eggs during the IVF could have already laid their ovulated eggs. 
The IVF experiments were repeated, however, due to high mortality rates of the 
procedure the experiment had to be terminated prematurely and the data could not 
be used. 
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Figure 6.6 Sperm, but not oocytes, were extracted with a lower frequency from CD9b 
mutants. A decrease in the percentage of males from which sperm can be extracted is 
seen with CD9b mutant males (a, a I). This trend is not seen with female CD9b 
mutants; it appears that eggs can be extracted from female CD9b mutants as 
frequently as AB females (b, bI). n= minimum 4 males or 9 females per genotype. Data 
from a single experiment.  
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We decided to assess whether the phenotypes seen in CD9b mutant clutches were due 
to cumulative effects from both parents or due to a single gender as seen in the CD9b 
KO mice. Multiple pairs were set up including AB, CD9b -1/-1 and CD9b -8/-8 in-crosses 
as in previous experiments, as well as CD9b -1/-1 and CD9b -8/-8 out-crosses with AB 
for example CD9b -1/-1 female X AB male. The pairs were left in pair-mating tanks 
overnight and the eggs collected the following morning.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7 Clutch size can be rescued by substitution of either CD9b mutant partner  
but the decrease in the percentage of fertilised eggs can only be rescued by 
substitution of the CD9b mutant male for an AB male.  
Clutch size can be rescued by substitution of a CD9b mutant partner, male (m) or 
female (f), with an AB (a). A Kruskal-Wallis test with Dunn’s multiple comparisons 
test was carried out on the pooled data of three experimental repeats. n= minimum 
12 pairs per cross. The percentage of fertilised eggs o only returns to wildtype levels 
upon substitution of a CD9b mutant male with an AB male (b). An ANOVA with 
Dunnett’s multiple comparisons test was carried out on arcsine transformed data 
pooled from three experiments. The average percentage of fertilised, dead and 
unfertilised eggs per clutch is shown in (c). n= minimum 10 pairs per cross for (b) and 
(c), except CD9b -1/-1 x CD9b -1/-1 where only 4 of 12 pairs laid. p=<0.05 
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Clutch size can be partially or fully rescued by replacement of a CD9b mutant partner 
with an AB (Figure 6.7a).  A significant decrease in clutch size, in comparison to AB 
clutches, is seen in clutches from CD9b -1/-1 and CD9b -8/-8 in-crosses; however this is 
not the case when an AB, either male or female, is paired with a CD9b mutant.  
The percentage of eggs fertilised can also be rescued to wildtype levels, although only 
through substitution of a CD9b mutant male for an AB male (Figure 6.7b). This suggests 
that CD9b deficiency in females does not affect the ability of the eggs to be fertilised 
but CD9b deficiency in males dramatically reduces the males’ ability to fertilise both 
wildtype and CD9b mutant eggs.  
The mean percentage of fertilised, dead and unfertilised eggs can be seen in Figure 
6.7c. It appears that a decrease in fertilised eggs comes with a dramatic increase in 
unfertilised eggs but the percentage of dead eggs does not vary hugely. This supports 
the hypothesis that CD9b mutant males cannot efficiently fertilise eggs, rather than 
the decrease in fertilised eggs being due to an increase in dead eggs (Figure 6.7c). 
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6.3 Discussion 
In this chapter, it has been shown that CD9b -/- zebrafish pairs lay decreased clutch 
sizes and CD9b -/- males have severely reduced fertility. While the reduced number of 
fertilised eggs seen in Figure 6.1b is akin to the reduced fertility seen in CD9b -/- mice, 
the decreased clutch size is surprising as CD9b -/- mice show no ovulation defects (Le 
Naour et al. 2000, Miyado et al. 2000). Due to the previous investigation of PGCs in 
CD9b mutants, an immediate thought was to look for a decrease in the number of 
PGCs in CD9b mutants; however, it appears that both production and migration of 
PGCs is unchanged in CD9b mutants (Figure 6.4 and Figure 4.16). While this doesn’t 
eliminate the possibility of impaired gametogenesis in later development, it does rule 
out a causative role for PGCs in both migration and numbers. 
IVF was used to elucidate whether factors such as courting behaviour, adult size and 
mate choice were causing the decrease in clutch size. The reduction in clutch size seen 
in Figure 6.5a indicates that this is not the case.  The protocol used for the IVF does not 
however eliminate any potential anatomical differences, between CD9b mutant 
females and AB females in their reproductive system, that could impede egg laying. 
This possible explanation for the decrease in clutch size seems unlikely though as CD9b 
mutant females paired with AB males in Figure 6.7 showed no significant difference in 
the number of eggs laid. This shows that the CD9b mutant females have the ability to 
ovulate and lay large numbers of eggs. 
The decrease in clutch size seen from CD9b mutant pairs could be explained by the 
requirement of reproductive pheromones for successful zebrafish breeding (Van den 
Hurk and Lambert 1983, Lambert et al. 1986, van den Hurk et al. 1987). Zebrafish 
females only ovulate when in the presence of male zebrafish during the breeding 
process (Hisaoka and Firlit 1962, Eaton and Farley 1974, Lambert et al. 1986). Females 
are stimulated to ovulate overnight by steroid glucuronides, produced by the Leydig 
cells in the testis of male zebrafish, which are released into the water (Hisaoka and 
Firlit 1962, Eaton and Farley 1974, Lambert et al. 1986, van den Hurk et al. 1987, van 
den Hurk and Resink 1992, Gerlach 2006). During and after ovulation female zebrafish 
also produce steroid glucuronides, such as oestradiol-17β-glucuronide and 
testosterone-glucuronide, that are secreted from the ovaries to attract the males and 
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initiate courtship behaviour in the males which facilitates egg laying  (Van den Hurk 
and Lambert 1983, Lambert et al. 1986, Kang et al. 2013) (Figure 6.8a).    
 During the IVF protocol, CD9b -1/-1, CD9b -8/-8 and AB in-cross pairs were left 
together overnight, therefore the females of each genotype were only exposed to 
pheromones from a male of the same genotype. The eggs were extracted manually the 
following morning. Using manual extraction removed any potential differences in 
courtship behaviour that could affect the number of eggs laid and the percentage of 
eggs fertilised. The reported decrease in clutch size after IVF suggests that ovulation is 
not being induced to the same extent in CD9b mutant females as in AB females. 
Decreased ovulation could be due to defective steroid glucuronide production by the 
males or recognition by the female CD9b mutants. If ovulation inducement was the 
sole cause of the decreased clutch size, then it would be expected that the phenotype 
would be rescued in Figure 6.7a with substitution of either the CD9b mutant male with 
an AB or the CD9b mutant female with an AB. Surprisingly the phenotype was rescued 
no matter which mutant partner was substituted with an AB (Figure 6.7a). Whilst it 
could be possible that both production of and response to male pheromones are 
defective, it would be expected that no rescue would be seen at all. However, it is 
more probable that the courtship inducing pheromones are also affected, either in the 
production of by the females or response to by the males. This would then explain 
why, although the CD9b mutant x AB pair clutch size is not significantly different to AB 
x AB pairs, the rescue of the phenotype appears partial and the numbers of eggs laid 
per pair are mostly lower than the AB x AB pairs (Figure 6.7a).   
As well as a decreased clutch size, a decrease in the number and percentage of eggs 
fertilised was seen from CD9b mutant pairs (Figures 6.1 and 6.3).  Although the 
impaired fertilisation is more aligned with the phenotype seen in CD9b -/- mice, it 
appears that the requirement for CD9b lies with male zebrafish, in contrast to CD9b-/- 
mice where CD9 is required for female fertility (Kaji et al. 2000, Le Naour et al. 2000, 
Miyado et al. 2000)(Figure 6.7b-c). The reduced fertilisation seen using IVF suggests 
that the defect seen in Figure 6.3 is not due to an absolute absence of sperm 
production, sperm release or sperm motility (Figure 6.5b).  However, a reduced 
quantity or quality of sperm, due to a need for CD9b during spermatogenesis, could be 
causing the decreased male fertility seen. A decrease in the percentage of males from 
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which sperm could be extracted was shown in Figures 6.6a and 6.6aI and the 
mammalian homolog of CD9b, CD9, has been shown to be expressed throughout the 
majority of murine spermatogenesis (Kanatsu-Shinohara et al. 2004, Kierszenbaum et 
al. 2006, Ito et al. 2010) Interestingly, it appears that the steroid glucuronides that 
have been suggested to act as reproductive pheromones in zebrafish, such as 
oestradiol-17β-glucuronide and 17α,20β-dihydroxy-4-pregnen-3-one-glucuronide, can 
induce and regulate zebrafish spermatogenesis in their de-glucuronidated state (Van 
den Hurk and Lambert 1983, Lambert et al. 1986, van den Hurk et al. 1987, van den 
Hurk and Resink 1992, Miura and Miura 2003, Chen et al. 2010, 2013). A requirement 
of CD9b for efficient production of the steroids used as reproductive pheromones and 
spermatogenesis inducers would explain both the decreased clutch size and decreased 
percentage of eggs fertilized. This may also account for the results seen in Figure 6.7 
where partial rescue of clutch size occurs by AB substitution of either partner but 
complete rescue of fertilization only occurs through substituting a mutant male for an 
AB male (Figure 6.8). 
It could be that CD9b is needed for efficient recognition of these steroids, however, 
this is less likely as reproductive pheromones are detected in their glucuronidated 
state by olfaction whereas spermatogenesis occurs in the testis and requires de-
glucuronidated steroids indicating that two different receptors are probably required 
(Van den Hurk and Lambert 1983, van den Hurk et al. 1987). 
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d) 
Figure 6.8 Model of potential outcomes from reduced production of reproductive 
steroids in CD9b mutants 
Steroid glucuronides (blue arrows) are produced and released by both male and 
female zebrafish to induce ovulation and courtship respectively. This in turn leads to 
eggs being laid by the females and fertilised by the males. Fertilisation requires 
efficient spermatogenesis, which is under the control of the same steroids but de-
glucuronidated (blue curly arrow), to produce mature sperm. In AB pairs this results 
in many fertilised eggs (a). In CD9b mutant pairs (b) it is hypothesised that less 
steroid glucuronides are produced leading to less ovulation and less courtship 
resulting in fewer eggs laid. Less sperm would also be predicted as fewer steroids 
would be produced to induce spermatogenesis, resulting in a lower percentage of 
eggs fertilised. The models for CD9b mutant x AB outcrosses are shown in (c) and (d). 
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Chapter 7: Discussion and future work                             
7.1 Summary of results 
Treatment of embryos with CD9b MOs resulted in decreased neuromast deposition 
and irregular spacing between neuromasts in the embryonic posterior lateral line.  
Homozygous CD9b mutants did not show the same phenotype, with the embryonic 
posterior lateral line appearing phenotypically normal. However, preliminary data 
suggested that this may be due to residual functionality of the remaining wild-type N-
terminal portion of CD9b in homozygous mutants.  
It appeared initially that CD9b homozygous mutants developed tail defects when 
raised at the lower temperature of 22°C, further experiments demonstrated that this is 
not the case and the observed defects were probably due to chance.  
As with CD9-/- mice, CD9b homozygous mutant zebrafish showed fertility defects. 
CD9b mutant pairs laid fewer eggs and of the eggs laid, fewer were fertilised. The 
decrease in egg numbers can be rescued by exchanging either CD9b homozygous 
mutant partner, male or female, for a wildtype partner. However, the fertilisation 
defect was only rescued when the CD9b mutant male was exchanged for a wildtype 
male, suggesting the fertility defect is due to the male not the female partner.  
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7.2 Chapter 3: CD9b morphants 
In this chapter, I characterised the effect of CD9b MO injection on two CXCR4b-
mediated migratory processes: PGC and pLLP migration. Initially it seemed that the 
migration of PGCs was affect by CD9b knockdown. However this phenotype was not 
reproduced with a second CD9b morpholino and was only observed in embryos 
injected with the highest amounts of morpholino, many of which also appeared to be 
suffering from morpholino toxicity. Therefore I concluded that CD9b knockdown did 
not cause specific PGC migratory defects.  
Unlike PGCs, the pLLP migration and neuromast deposition was consistently affected 
by CD9b morpholino injection. Fewer neuromasts were deposited in CD9b morphants 
and spacing between deposited neuromasts was irregular but often with an overall 
increase in the distance between. This work re-capitulated and then expanded on the 
results reported by Gallardo et al. 2010 in their brief proof-of-principle experiment. 
These authors reported a new method to assess tissue specific gene expression, during 
which they found high levels of cd9b mRNA in the lateral line primordium cells. To 
validate their method, they used a morpholino to knock-down cd9b and showed some 
images of cd9b morphants with a reduced number of neuromasts. By using two CD9b 
morpholinos, with different target sequences, at a range of concentrations and 
analysing the neuromast deposition phenotypes, this phenotype has been quantified, 
validated and characterised. 
Due to the consistent observation of the neuromast deposition phenotype in this 
work, with multiple morpholino concentrations,  two individual morpholinos, and the 
previous report by Gallardo et al., it appears likely that this phenotype is specific to 
cd9b knockdown.  
The gold standard for confirming the specificity of the observed phenotype was, at the 
time, to determine if the phenotype is re-capitulated in deletion mutants. 
Unfortunately, the CD9b mutant lines I created did not replicate the phenotypes seen 
in CD9b morphants. This may be due to compensation by other genes. Rossi et al. 2015 
recently reported that compensatory genes and proteins are upregulated in egfl7 and 
vegfaa mutants but not in the corresponding morphants. This resulted in severe 
vasculature phenotypes in egfl7 morphants but normal phenotypes in egfl7 mutants. 
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Alternatively, it could suggest that CD9b retained some residual function in the CD9b 
mutant lines which is then lost upon CD9b MO1 injection. 
In light of this, it would be better to confirm the specificity of the neuromast 
deposition phenotypes using mRNA rescue and so future work would include 
attempting to rescue the phenotypes using morpholino-resistant cd9b mRNA.  
 
7.3 Chapter 4: CD9b mutants 
Like CD9b morphants, CD9b deletion mutants showed no differences in PGC migration 
and so it was concluded that CD9b does not play a role in PGC migration. 
CD9b homozygous mutants also showed no posterior lateral line defects. Only CD9b -
8/-8 embryos from homozygous parents showed a consistent delay in Prim I migration, 
which was not replicated in CD9b -1/-1 embryos.  This difference between CD9b 
mutant and morphant phenotypes was investigated by injecting CD9b morpholinos 
into homozygous mutants. If the morphant phenotype was due to an off-target effect, 
both morpholinos would produce neuromast phenotypes. If the mutant was rescued 
by redundancy then morpholino injection wouldn’t produce any phenotype. However, 
only the start-site morpholino and not the splice-site morpholino produced the 
neuromast phenotype in CD9b mutant embryos. Knocking down translation of the 
mutant cd9b mRNA resulted in the abnormal neuromast phenotype seen in CD9b 
morphants. This suggested that the mutant CD9b protein in CD9b -1/-1 and CD9b -8/-8 
embryos had a residual function which may be rescuing the mutants. As the mutation 
site is near the 5’ of the gene, only the N-terminus of CD9b remains wildtype in CD9b -
1/-1 and CD9b -8/-8 mutants. In the CD9b mutants, it would be expected that the 
mutation in cd9b would activate non-sense mediated decay, resulting in a knock-out of 
gene function. However, qPCR showed that the expression of 5’ cd9b mRNA was not 
decreased in CD9b -1/-1 embryos and only 49% decreased in CD9b -8/-8 embryos. In 
contrast, both CD9b -1/-1 and CD9b -8/-8 embryos showed significant decreases in the 
expression of 3’ cd9b mRNA. This preliminary data suggests that the N-terminus of 
cd9b is not cleared in CD9b mutants and has some residual function which is masking 
the phenotype seen in CD9b morphants. This function could occur through regulation 
of CXCR4b signalling.  
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Interaction and trafficking of CXCR4b by the tetraspanin CD63 has been shown to 
occur through the N-linked glycans of CD63 (Yoshida et al. 2008, 2009). In CD9 the only 
N-linked glycan is located in the EC1, after the mutation site, and therefore if CD9 
played a role in CXCR4b internalisation it would be expected that trafficking 
differences would be observed in the CD9b mutants (Boucheix et al. 1991). However, 
internalisation of CXCR4b appears unaffected in the CD9b homozygous mutants.  
Recent papers have described a mechanism where CXCL12-CXCR4 signalling up-
regulates CD9 expression. CD9 in turn increases the ability of cells to migrate (Leung et 
al. 2011, Brzoska et al. 2015, Arnaud et al. 2015). In lymphoblastic leukemia, this 
occurs through CD9 enhancing RAC1 activation which promotes the formation of actin-
rich lamellipodia for migration (Arnaud et al. 2015). However, this mechanism of CD9 
promoting CXCR4-mediated migration has been reported to be facilitated through the 
C-terminus of CD9 and not the N-terminus (Arnaud et al. 2015). As the N-terminus is 
the only wildtype portion of CD9b remaining in the CD9b mutants, it appears unlikely 
that this mechanism is facilitating the residual function in CD9b mutants. 
A recent report by Desterke et al. 2015 has shown that CD9 positively regulates CXCR4 
and CXCL12 expression in megakaryocytes as well as CXCR4-mediated migration. It was 
also reported that CD9 regulated Akt and MAPK phosphorylation. These pathways 
have been reported to be regulated in a similar manner by an ITIM-like domain in 
CD37, which allows CD37 to regulate cell survival (Lapalombella et al. 2012). 
Interestingly, CD9b appears to also have an ITIM-like domain in its N-terminus. This 
suggests that the N-terminus of CD9b may still have signalling ability in the CD9b 
mutants. 
To investigate whether CD9b in the CD9b mutants has retained some functionality, 
future work would include attempting to rescue CD9b morphants with morpholino-
resistant mRNA which replicates the mRNA produced in CD9b mutants as well as 
investigating the possible ITIM-like domain in the N-terminus. To do this, the 
phosphorylation of the N-terminal tyrosine residue and association with proteins such 
as SHP1 would need to be analysed. Mutation of the tyrosine residue within the ITIM-
like domain and assessment of Akt and MAPK phosphorylation would also help to 
confirm whether CD9b is regulating these pathways in a similar manner to CD37. 
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7.4 Chapter 5: CD9b mutants raised at 22°C 
Initial experiments showed differences in tail development between wildtype and 
CD9b homozygous mutants raised at 22°C. Further experiments did not recapitulate 
this observed difference as wildtype embryos also had abnormal tail development and 
statistical tests showed no difference in tail length or fin fold area between CD9b 
mutant and wildtype embryos.   
Whilst the initial observation and hypothesis for this chapter was proven invalid, it 
would still be interesting to investigate the function of CD9b in the developing 
pronephros. As shown in Figure 1.7 and Table 1.4, cd9b is highly expressed in the 
embryonic pronephros and in other models has been shown to be important in the 
stress response of kidney cells (Sheikh-Hamad et al. 1996, 2000, Takemura et al. 1999, 
Blumenthal et al. 2015). The CD9b mutants could be assessed for pronephros function, 
cell adhesion and cell survival under similar stress conditions.   
 
7.5 Chapter 6: CD9b mutants and fertility 
Fertility of CD9b -/- zebrafish was assessed for both the number of eggs laid and the 
percentage of eggs fertilised. It was found that CD9b -/- zebrafish pairs laid decreased 
numbers of eggs and CD9b -/- males had severely reduced fertility.  
Fertility was assessed because CD9 -/- female mice have a severe fertility defect, 
where few pups were born due to defective sperm-egg fusion (Kaji et al. 2000, Le 
Naour et al. 2000, Miyado et al. 2000). CD9-/- mice appeared to produce normal 
numbers of eggs in contrast to CD9b-/- zebrafish which laid significantly fewer eggs 
than wildtype fish (Le Naour et al. 2000, Miyado et al. 2000). It was surprising that the 
fertilisation defect appears to reside in the CD9b -/- male partner not the female, 
unlike CD9-/- mice (Kaji et al. 2000, Le Naour et al. 2000, Miyado et al. 2000). However, 
CD9 has also been reported to be expressed in male mice throughout spermatogenesis 
and in mature sperm during fertilisation (Kanatsu-Shinohara et al. 2004, Ito et al. 
2010).  
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In out-cross experiments, where one mutant partner was substituted for a wildtype 
partner, it was shown that substitution of either partner rescued the numbers of eggs 
laid but only the substitution of the male partner increased fertility. This apparent 
ability of both the male and female partner to affect the ovulation of the female might 
be explained by the mechanism of zebrafish breeding. Female zebrafish are induced to 
ovulate by steroid glucuronides produced by male zebrafish, which are released into 
the water. Courtship behaviour in males, to promote egg laying, is then induced by 
steroid glucuronides produced by the female (Eaton and Farley 1974, Van den Hurk 
and Lambert 1983, Lambert et al. 1986, van den Hurk et al. 1987, van den Hurk and 
Resink 1992). Interestingly, some of these steroids have also been reported to regulate 
spermatogenesis (Miura and Miura 2003, Chen et al. 2010, 2013). A role for CD9b in 
the production of these steroids would explain both of the fertility phenotypes seen in 
CD9b -/- pairs as well as the results of the out-cross experiments.  
Steroid extraction from zebrafish holding water or rescue experiments using ovarian or 
testes homogenates from wildtype fish could be used to test whether CD9b -/- fish 
have deficient production, release or recognition of steroid glucuronides. To assess 
whether the fertility defect in male CD9b -/- fish is due to defective spermatogenesis, 
sperm count and quality could be assessed as well as conducting histological 
examinations of spermatogenesis in the testis. 
 
7.6 Conclusions 
 CD9b does not play a role in PGC migration. 
 CD9b plays a role in neuromast deposition in the pLL and the 5’ of CD9b may be 
important for this function.  
 CD9b deficiency does not result in abnormal tail development when embryos 
are raised at 22°C. 
 CD9b functions in fertility, affecting both clutch size and egg fertilisation. 
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